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Summary: 
Signalling pathways downstream of the transforming growth factor ß 
(TGF-ß) family of cytokines, including the bone morphogenetic protein 
(BMP), play crucial roles during development and in adult tissue homeostasis 
in vertebrates. Aberrant TGF-ß and BMP signalling is associated with many 
human disorders including cancer. TGF-ß and BMP cytokines signal through 
the activation of type I receptor kinases, which then phosphorylate SMAD 
transcription factors (1/5/8 in the BMP pathway and 2/3 in the TGF-ß 
pathway). In the canonical pathway, this triggers the association of these 
SMADs with SMAD4 and their translocationto the nucleus, where they 
regulate the expression of target genes. TGF-ß and BMP can also control 
cellular responses independently of SMAD4, although how these are 
achieved is poorly understood. Although the fundamental steps in the TGF-ß 
pathway are established, gaps remain in our understanding of the context-
specific regulation of the pathway. 
In the first part of my thesis, I report the discovery and characterisation 
of FAM83G/PAWS1 as a novel interactor of SMAD1. I demonstrate that 
FAM83G/PAWS1 forms a complex with SMAD1 in a SMAD4-independent 
manner. Furthermore, BMP induces the phosphorylation of FAM83G/PAWS1 
through BMPR1A, which is essential for the BMP dependent expression of 
SMAD4-independent BMP-target genes NEDD9 and ASNS. This uncovers 
FAM83G/PAWS1 as the first non-SMAD substrate for BMPR1A and a novel 
player in the BMP pathway. Furthermore, FAM83G/PAWS1 expression in 
Xenopus laevis embryos induces a complete duplication of axis phenotype, 
XI 
suggesting putative regulatory roles in the BMP and Wnt signalling. I also 
demonstrate that FAM83G/PAWS1 regulates the expression of over 800 
genes independent of BMP-stimulation suggesting wider roles for 
FAM83G/PAWS1 beyond the BMP pathway. 
In the second part of my thesis, I analyse the specificities and 
potencies of the most frequently used small molecule inhibitors of the TGF-ß 
and BMP pathways. Small molecule inhibitors of type 1 receptor kinases 
have been extensively used to assess the physiological roles of TGF-ß and 
BMP signalling in cells and organisms. While all of these inhibitors have been 
reported as selective inhibitors of specific ALKs, extensive specificity tests 
against a wide array of protein kinases have not been performed. In this 
thesis, I report on the specificities and potencies of the small molecule 
inhibitors of the TGF-ß (SB-431542, SB-505124, LY-364947 and A-83-01) 
and BMP (Dorsomorphin and LDN-193189) signalling pathways against a 
panel of kinases covering approximately one fourth of the human kinome. On 
the whole, the inhibitors of the TGF-ß pathway appeared to be more selective 
to their targets than the inhibitors of the BMP pathway. Based on the derived 
specificity and potency profiles, I recommend SB-505124 as the most 
suitable molecule for use as an inhibitor of the TGF-ß pathway. 
Dorsomorphin is not suitable for use as an inhibitor of the BMP pathway. 
LDN-193189 is a very potent inhibitor of the BMP pathway but at 
concentrations used to inhibit ALKs 2&3, it also potently inhibits a number of 
other protein kinases. Hence, its use as a selective BMP-pathway inhibitor 
has to be considered with caution. These results highlight the need for 
XII 
caution when using any small molecule inhibitors as tools for assessing the 
physiological roles for BMP and TGF-ß signalling. 
Publications: 
Vogt, J., Dingwell, K., Herhaus, L., Macartney, T., Smith, J. & Sapkota, 
G. 2013. Protein Associated With SMAD1 (PAWS1/FAM83G) is a substrate 
for type I BMP receptors and modulates BMP signalling. In preparation 
Vogt, J., Traynor, R. & Sapkota, G. 2011. The specificities of small 
molecule inhibitors of the TGFß and BMP pathways. Cell Signal, 23, 1831-
42. 
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1 Introduction 
1.1 TGF-ß Ligands 
In humans, the transforming growth factor-ß (TGF-ß) family of 
cytokines consists of at least 33 different ligands. These play crucial roles in 
a large range of cellular processes, including cell proliferation, differentiation, 
apoptosis, immune response, and extracellular matrix organisation as well as 
development (Derynck and Miyazono, 2007, Shi and Massague, 2003, 
Massague, 2008, Akhurst and Hata, 2012). The TGF-ß family of cytokines 
can be divided into two sub-families: the TGF-ß sub-family comprising 
TGFß1, 2, and 3, Activin and Nodal on one hand and the bone morphogenic 
protein (BMP) sub-family comprising BMPs, growth and differentiation factors 
(GDFs) and anti-Müllerian hormone (AMH) on the other. The subdivision of 
the ligands is based on the difference displayed by the ligands in receptor 
binding and specific SMAD protein activation (Shi and Massague, 2003). The 
expression pattern of the different ligands is often tissue and context 
dependent. While most TGF-ß and BMP ligands are expressed in and impact 
many cells and tissues, others such as AMH is only expressed during 
development for a relatively short period of time (Massague, 2008). 
TGF-ß and BMP cytokines are expressed as precursor proteins in 
cells. These pro-cytokines are subsequently cleaved by specific proprotein 
convertases belonging to the subtilisin-like proprotein convertase (SPC) 
family in order to generate active cytokines (Dubois et al., 1995, Nachtigal 
and Ingraham, 1996, Constam and Robertson, 1999). Endopeptidase 
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cleavage results in the production of active C-terminal mature protein. These 
active TGF-ß/BMP molecules subsequently form either homo or hetero 
dimers with other members of their cytokine subfamily. The processed 
ligands are then secreted to the extra cellular matrix (ECM) (Cui et al., 1998, 
Annes et al., 2003). These ligand dimers are stabilised by hydrophobic 
interactions and disulphide bonds between conserved cysteine residues 
(Griffith et al., 1996, Scheufler et al., 1999, Sun and Davies, 1995). Initiation 
of the intracellular signalling pathway starts with the binding of the excreted 
ligand dimers to the extracellular domains of their cognate transmembrane 
cell receptor pairs. 
1.2 TGF-ß membrane receptors and pathway initiation 
TGF-ß cell membrane receptors are transmembrane proteins that are 
divided into three different groups: Type I, type II and type III receptors (Shi 
and Massague, 2003). Type I and II receptors are serine/threonine protein 
kinases. Type III receptors function as co-receptors by enhancing the binding 
of the TGF-ß ligands to the type I and type II receptors but do not possess 
serine/threonine protein kinase activity (Shi and Massague, 2003).  
There are five type II receptors (ActR-IIA, ActR-IIB, BMPR-II, AMHR-II 
and TGFßR-II) and seven type I receptors (also known as Activin-receptor-
Like-Kinases: ALKs 1–7) in humans (Manning et al., 2002). These are 
classified according to their affinity for selective TGF-ß ligands. As the TGF-ß 
ligand dimers bind to two type I and II receptors; the activated receptor 
complex comprises two type I and two type II receptors bound to a specific 
ligand dimer (Shi and Massague, 2003). Ligand binding induces a 
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conformational change in the complex that enables type II receptor kinases 
to phosphorylate type I receptor kinases at the cytoplasmic GS domain. This 
activates the type I receptor kinases. The phosphorylation and activation of 
the type I receptor kinase enables the binding of receptor regulated (R)-
SMAD proteins (SMADs 1,2,3,5 and 8) and subsequently leads to the 
phosphorylation of R-SMADs at their C-terminal SXS motif by the type I 
receptor kinase (Kim et al., 2008, Wright et al., 2009, Shi and Massague, 
2003, Wrana et al., 1994). 
The BMP signalling pathway can be inhibited at the ligand-receptor-
binding initiation step by proteins that bind to the secreted ligands. These 
ligand traps, such as CHORDIN and NOGGIN, bind to their corresponding 
BMP ligands and thereby inhibit the BMP ligand from binding to the receptors 
(McMahon et al., 1998, Piccolo et al., 1996). CHORDIN has been reported to 
predominantly bind BMP-2 and BMP-4, whereas NOGGIN, has been 
reported to bind BMP-4 and BMP-7, thus demonstrating that ligand traps can 
selectively bind and regulate the activity of specific BMP cytokines at the 
extracellular level (Groppe et al., 2002, Larrain et al., 2000). CHORDIN and 
NOGGIN are prominent inhibitiors of BMP signalling during embryogenesis 
(De Robertis and Kuroda, 2004). Furthermore, BMP signalling can also be 
inhibited by the pseudo-receptor BAMBI (Onichtchouk et al., 1999). BAMBI 
displays a homology to the BMP type I receptor kinase extracellular domain, 
which allows binding to BMP cytokines but no SMAD protein activation 
occurs (Onichtchouk et al., 1999). Activin ligand traps, such as 
FOLLISTATIN, also function in a similar manner and regulate the activity of 
these ligands (Massague and Chen, 2000). 
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1.3 SMAD proteins 
SMAD proteins are the intracellular mediators of the BMP and TGF-ß 
signalling pathways. The SMAD proteins are the human homologs of SMA 
(Caenorhabditis elegans) and MAD (Drosophila melanogaster) (Raftery et al., 
1995, Sekelsky et al., 1995, Savage et al., 1996). In humans there are eight 
different SMAD proteins, some of which also express splice variants. These 
are classified in three distinct groups according to their functions in cells: R-
SMADs (SMADs 1, 2, 3, 5 and 8), co-SMAD4 and inhibitory SMADs (I-
SMADs 6 and 7). Subsequent to the receptor complex activation, the R-
SMADs are phosphorylated at the two Serines at the extreme C-terminal 
SXS motif (also known as tail-phosphorylation) as described above. Unless 
stated otherwise, phosphorylation of SMAD proteins in this thesis refers to 
tail-phosphorylation of R-SMADs. R-SMAD proteins can be further sub-
divided into two groups based on the specific ligands that induce their 
phosphorylation: BMP ligands induce the phosphorylation of SMADs 1, 5 and 
8 (BMP R-SMADs), whereas TGF-ß ligands induce the phosphorylation of 
SMADs 2 and 3 (TGF-ß R-SMADs) (Shi and Massague, 2003, Hinck, 2012). 
However, it has also been reported that in certain cell types TGF-ß ligands 
can induce the phosphorylation of BMP R-SMADs (Goumans et al., 2003, 
Daly et al., 2008). 
Once phosphorylated, R-SMADs bind and build a heterotrimeric 
complex with the co-SMAD4, comprising SMAD4 and two R-SMADs. This 
complex formation is a key feature for both BMP and TGF-ß activated 
signalling and occurs with all R-SMADs (Wang et al., 2013, ten Dijke and Hill, 
2004). The phosphorylation of R-SMADs induces their translocation to the 
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nucleus (Chen and Xu, 2011). Although R-SMADs have been reported to 
shuttle back and forth from the nucleus through their nuclear import and 
export domains in the presence or absence of ligands (Hill, 2009), their 
ligand-induced nuclear localisation and association with SMAD4 is essential 
for regulation of transcription of hundreds of canonical target genes (Shi and 
Massague, 2003, Ross and Hill, 2008, Wang et al., 2013). When SMAD4 
expression is absent or it is mutated, TGF-ß and BMP ligands no longer 
induce the expression of canonical target genes but can still induce the 
transcription of some genes (Levy and Hill, 2005, Deng et al., 2009). In this 
case, the signalling pathways are usually referred to as non-canonical (or 
SMAD4-independent) TGF-ß or BMP signalling (see below section 1.5). 
1.3.1 Structure of SMAD proteins 
R-SMAD proteins consist of two highly conserved domains: MAD 
homology domain 1 (MH1) at the N-terminus and MAD homology domain 2 
(MH2) at the C-terminus. The main feature of the MH1 domain in SMADs 1, 
3, 4, 5 and 8 is its ability to bind DNA. While SMAD2 just lacks a critical short 
sequence for DNA binding (Dennler et al., 1999), the I-SMADs 6 and 7 have 
much shorter and truncated MH1 domains and therefore do not possess DNA 
binding ability in that manner. The MH2 domain, present in all SMAD 
proteins, although the SXS activation motif is only found in R-SMADs, has 
been reported to serve as a scaffold to facilitate interaction with several 
regulatory proteins and other transcription factors (Massague et al., 2005). 
The MH1 and MH2 domains of SMAD proteins are connected by a 
Linker region. This region is rather diverse compared to the MH1 and MH2 
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domains and has been reported to integrate cross-talk regulatory inputs from 
other signalling pathways (see section 1.3.2.2) 
1.3.2 Regulation of SMADs by post-translational modifications 
As the intracellular TGF-ß and BMP signalling pathway transducers, 
the activity and function of SMAD proteins are tightly regulated at all stages 
of the pathway by post-translational modifications (PTMs) and inputs from 
other signalling networks. These PTMs have been studied extensively in the 
past and define our current knowledge of the regulation of TGF-ß and BMP 
signalling pathways (Xu et al., 2012). However, gaps remain on the precise 
molecular mechanisms by which the TGF-ß and BMP pathways are 
regulated. As key mediators of the TGF-ß and BMP signals, SMAD proteins 
have been the subject of focus over the years at understanding their 
regulation by PTMs including reversible phosphorylation and reversible 
ubiquitylation (Al-Salihi et al., 2012, Bruce and Sapkota, 2012, Xu et al., 
2012). 
1.3.2.1 Regulation of R-SMADs by reversible phosphorylation  
Although the phosphorylation motif of BMP and TGF-ß activated R-
SMADs is very similar, distinct protein phosphatases have been reported for 
each sub-groups. Pyruvate dehydrogenase (PDP) was reported to 
dephosphorylate the SMAD1-tail (Chen et al., 2006a). The nuclear small C-
terminal domain phosphatase OS4/SCP2 was identified in Xenopus as an 
inhibitor of BMP pathway. OS4/SCP2, as well as their human homologs 
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SCP1, 2 and 3, were subsequently shown to dephosphorylate BMP-activated 
SMAD tail-phosphorylation (Knockaert et al., 2006). PPM1A was reported to 
dephosphorylate both TGF-ß and BMP R-SMAD tail-phosphorylation (Bruce 
and Sapkota, 2012, Chen et al., 2006b). Despite these reports, the precise 
nature of regulation of R-SMADs by phosphatases remains undefined (Bruce 
and Sapkota, 2012). 
1.3.2.2 Reversible phosphorylation of SMADs at the linker region 
Another well-established regulatory input of R-SMADs is the 
phosphorylation of the divergent linker region. This phosphorylation occurs 
not only as a direct consequence of BMP or TGF-ß stimulation but has also 
been reported to be mediated by other signalling pathways (Xu et al., 2012). 
Cyclin-dependent kinases 8 and 9 have been shown to phosphorylate 
SMAD1 subsequent to BMP stimulation (Alarcon et al., 2009). This 
phosphorylation leads on one hand to the interaction of SMAD1 with YAP and 
results in enhanced transcription activity but on the other hand it also primes 
SMAD1 for association with the SMAD E3 ubiquitin ligase SMURF1, which in 
turn causes SMAD1 to be ubiquitylated and subsequently degraded (Alarcon 
et al., 2009). Other kinases such as MAPK and GSK3 have also been 
reported to regulate SMAD1 and SMAD3 turn-over by phosphorylating 
conserved residues within the SMAD linker regions. The phosphorylation by 
MAPK and GSK3 leads to the recognition of the E3 ubiquitin ligases 
SMURF1 and NEDD4L by SMADs resulting in their ubiquitylation and 
degradation (Aragon et al., 2011, Sapkota et al., 2007). The G protein-
coupled receptor kinase 2 (GRK2) has been reported to phosphorylate 
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SMAD2 and 3 linker region and prevent SMADs from tail-phosphorylation 
and nuclear shuttling, thus inhibiting TGF-ß signalling (Ho et al., 2005). 
The only reported R-SMAD linker region protein phosphatases are the 
SCPs 1, 2 and 3. In contrast to their ability to dephosphorylate the tail-
phosphorylation of only BMP activated SMADs, they have been shown to 
dephosphorylate BMP and TGF-ß activated SMADs at the linker regions 
(Knockaert et al., 2006, Sapkota et al., 2006, Wrighton et al., 2006). 
1.3.2.3 Regulation of R-SMADs by reversible ubiquitylation 
Attachment of ubiquitin molecules or chains on target proteins by E3 
ubiquitin ligases marks the proteins for fates that include degradation or 
ubiquitin related signalling (Al-Salihi et al., 2012). SMAD proteins, as well as, 
type I receptor kinases, have been reported to be modified by ubiquitylation. 
Polyubiquitylation of R-SMADs has been reported to target SMADs for 
proteasomal degradation (Sapkota et al., 2007, Ebisawa et al., 2001, Al-
Salihi et al., 2012). In contrast to this, K-48 polyubiquitylation of SMADs has 
been shown to enhance its activity (Bai et al., 2004). 
SMURF1, SMURF2, NEDD4L, ITCH, WWP1 and WWP2, all members 
of the C2-WW domain containing HECT E3 ligase family, have been reported 
to regulate BMP and TGF-ß signalling (Soond and Chantry, 2011, Seo et al., 
2004, Bai et al., 2004, Kavsak et al., 2000, Zhu et al., 1999). Critical for the 
ubiquitylation of their substrates in these proteins is the WW domain, as it 
mediates the interaction to SMADs via the SMAD “PPXY” motif (Al-Salihi et 
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al., 2012). The PPXY motif is located at the linker region of R-SMAD proteins, 
with the exception of SMAD8 which lacks the PPXY motif. The binding of the 
E3 ubiquitin ligases to the linker region of R-SMADs is regulated by the 
conserved phosphorylation sites surrounding the PPXY motif within R-
SMADs (Aragon et al., 2011). SMURF1 and SMURF2 have been shown to 
catalyse the ubiquitylation of SMAD1 and 5, as well as the ubiquitylation of 
TGF-ß type I and II receptor kinases, which leads to their degradation via the 
proteasome (Sapkota et al., 2007, Ebisawa et al., 2001, Zhu et al., 1999, 
Zhang et al., 2001, Kavsak et al., 2000). In addition, SMURF2 has also been 
linked to the ubiquitylation mediated degradation of SMAD2 (Lin et al., 2000) 
and monoubiquitylation of SMAD3, which does not lead to proteasomal 
degradation (Tang et al., 2011). NEDD4L and WWP1 have been reported to 
ubiquitylate SMAD2 and 3 leading to their degradation (Gao et al., 2009, Seo 
et al., 2004). WWP2 was recently shown to ubiquitylate SMAD2 and 3 as well 
as SMAD7 (Soond and Chantry, 2011). Despite the lack of a PPXY motif, 
SMAD4 has been reported to be ubiquitylated by SMURF1/2, NEDD4L and 
WWP1 (Al-Salihi et al., 2012). 
The other class of E3 ubiquitin ligases involved in the regulation of 
BMP and TGF-ß signalling are RING domain E3 ubiquitin ligases. The RING 
E3 ubiquitin ligase CHIP has been reported to ubiquitylate SMAD1, 2, 3 and 
4 , which results in the proteasomal degradation of SMADs and the inhibition 
of the BMP or TGF-ß signalling pathways (Li et al., 2004). Another RING E3 
ubiquitin ligase, ARKADIA, has been reported to enhance TGF-ß signalling 
by binding to SMAD2 and 3 and thereby ubiquitylating other SMAD2 and 3 
signal-inhibiting binding partners, such as SnoN and SMAD7 (Levy et al., 
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2007, Koinuma et al., 2003). A recent study in Zebrafish and RNF12-/- 
mouse embryonic stem cells, revealed that the E3 ubiqutin ligase RNF12 
impacts TGF-ß and BMP signalling by ubiquitylating SMAD7 (Zhang et al., 
2012).  
The RING E3 ligase TRIM33 has been shown to ubiquitylate SMAD4 
in Xenopus (Dupont et al., 2005). The ubiquitylated SMAD4 was further 
shown to be unable to bind activated SMAD2 and 3, thus TRIM33 inhibits 
TGF-ß signalling (Dupont et al., 2005). Furthermore, the recruitment of 
TRIM33 to chromatin has been reported to activate TRIM33 and in turn leads 
to the ubiquitylation of SMAD4 (Agricola et al., 2011). On the other hand, 
TRIM33 has been reported to, independently of SMAD4, bind activated 
SMAD2 and 3 (He et al., 2006). 
1.4 Transcriptional Targets of TGF-ß signalling 
Once activated, R-SMAD/SMAD4 complexes in the nucleus, together 
with other transcriptional cofactors, assemble at the promoters of many target 
genes and regulate their transcription. TGF-ß ligands are reported to regulate 
the expression of hundreds of genes (Massague et al., 2005, Shi and 
Massague, 2003). To regulate the expression of these genes, SMADs bind 
the DNA, albeit with a much lower affinity than most other transcription 
factors (Chai et al., 2003). The DNA binding sites for SMADs are well-
established and are known as SMAD binding elements (SBE) for TGF-ß 
activated SMAD2/3 and 4 complexes (Zawel et al., 1998). BMP activated 
SMAD1/5/8 and 4 complexes have been shown to preferentially bind to GC-
rich promoter regions, also known as BMP responsive element (BRE) 
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(Katagiri et al., 2002, Zawel et al., 1998). Ligand induced SMADs have been 
reported to associate with many different transcription factors, which enhance 
their transcriptional activity by enhancing the DNA binding ability. These DNA 
binding co-factors include members of the E2F4, Mixer, FoxH1, FoxO and 
Runx families (Massague et al., 2005). The association of specific co-factors 
to SMAD proteins is cell type and context dependent and therefore helps to 
fine tune the BMP and TGF-ß signalling pathways (Ross and Hill, 2008).  
Two of the transcriptional targets regulated by both BMP and TGF-ß 
signalling pathways are I-SMAD6 and 7. The expression of I-SMADs 
downstream of BMP and TGF-ß signalling acts as a negative feedback loop 
(Figure 1-1). I-SMADs have been reported to regulate the BMP and TGF-ß 
signalling pathways by facilitating ubiquitin E3 ligases and deubiquitylases 
(DUBs) to target the BMP and TGF-ß type I kinase receptor proteins as well 
as competing with R-SMADs for access to receptors (Al-Salihi et al., 2012) 
SMAD proteins have also been reported to act on transcription by 
remodelling of histones and chromatin structures (Ross et al., 2006). 
Acetylation of histones at conserved lysine residues weakens their interaction 
with DNA thereby allowing transcription factors to bind to the DNA more 
efficiently. The binding of SMADs to histone acetylation modifiers like histone 
acetyltransferases (HATs) has been associated with transcriptional activation 
and many co-activation transcription factors display HAT activity. SMAD1, 2, 
3 and 4 have been shown to interact with p300, which in turn acetylates 
histones in order to facilitate transcription (Ross et al., 2006).  
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Histone deacetylases (HDACs) inhibit transcription by reversing the 
acetylation of histones. Transcriptional repressors often display HDAC 
activity. Binding of these repressors to activated SMAD complexes as co-
factors demonstrates a neat mechanism by which BMP and TGF-ß signalling 
pathways can inhibit transcription (Ross and Hill, 2008).  
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Figure 1-1 Schematic overview of the TGF-ß/BMP signalling pathway 
BMP or TGF-ß ligands bind to their corresponding type I (light green) and type 
II (light brown) receptor kinases. This triggers the phosphorylation and activation of 
type I receptor kinase by type II receptor kinase. Subsequently the type I receptor 
kinase phosphorylates its corresponding R-SMAD. The phosphorylated R-SMADs 
translocate to the nucleus, where together with SMAD4 and other co-factors they 
regulate the transcription of hundreds of target genes that impact context-dependent 
cell differentiation, development and homeostasis. The expression of negative 
feedback genes I-SMADs 6 and 7 is also controlled by BMP/TGF-ß. The signalling 
pathway can also be inhibited by the ligand traps.   
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1.5 Non-canonical TGF-ß and BMP signalling 
Activated R-SMADs binding to SMAD4 to regulate the expression of 
general target genes such as ID1, SnoN and PAI1 is often referred to as the 
canonical BMP and TGF-ß signalling. However, TGF-ß and BMP ligands can 
exert effects on other signalling pathways and gene expression independent 
of R-SMAD activation or R-SMAD/SMAD4 complex formation. These are 
commonly referred to as non-canonical effects of BMP and TGF-ß signalling. 
Non-canonical BMP and TGF-ß signalling pathways are linked to the 
modulation of mitogen-activated protein kinases (MAPKs: ERK, JNK and p38 
MAPK), PI3 kinase/AKT and protein kinase C (PKC) signalling pathways as 
well as Rho-GTPases (Moustakas and Heldin, 2005, Zhang, 2009). Non-
canonical signalling has also been reported to be involved in processes like 
EMT, apoptosis and cytoskeleton rearrangement (Zhang, 2009). Some of the 
non-canonical signalling downstream of TGF-ß and BMP ligand could rely on 
non-SMAD substrates of type I/type II receptor kinases. This possibility has 
been poorly investigated and to date there are few or no reports of non-
SMAD substrates of TGF-ß and BMP receptor kinases. 
1.5.1 MAPK mediated non-canonical signalling 
Most studies on non-canonical BMP and TGF-ß signalling have 
focussed on the activation of MAPKs. MAPKs are a large family of protein 
kinases that can be further divided into three subgroups: extracellular signal-
regulated kinases (ERKs), c-Jun-N-terminal kinases (JNKs) and p38 MAP 
kinases (Yue and Mulder, 2000).  
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ERK1/2 are activated by TGF-ß and BMP cytokines (Zhou et al., 2007, 
Moustakas and Heldin, 2005). TGF-ß ligands have been shown to activate 
ERK1/2 via a signalling cascade from the activated receptor complex, 
involving the phosphorylation of ShcA, which then associates with the 
adapter proteins GRB2 and SOS. This leads to activation of RAS, which in 
turn triggers the sequential activation of c-Raf, MEK and finally ERK1/2 (Lee 
et al., 2007). It has been reported that GRB2 dependent ERK1/2 activation 
by TGF-ß ligands is essential for the TGF-ß mediated EMT (Davies et al., 
2005, Galliher-Beckley and Schiemann, 2008). Interestingly, ERK1/2 also 
phosphorylate SMAD1, 2 and 3 at the linker region as discussed before (see 
section 1.3.2.2). 
While BMP ligands can also induce ERK1/2 activity, reported by 
several research groups, in different cellular contexts, the underlying cellular 
process of BMP ligand induced ERK1/2 activation remains largely elusive 
(Finelli et al., 2013, Wiley et al., 2011, Jun et al., 2010, Zhou et al., 2007, 
Beck and Carethers, 2007). Nonetheless BMP-induced ERK1/2 signalling 
has been shown to be involved in angiogenesis (Wiley et al., 2011, Zhou et 
al., 2007), axon development (Finelli et al., 2013) and SMAD4 independent 
cell proliferation (Beck and Carethers, 2007). It is clear that understanding of 
the biochemical mechanisms of BMP-induced ERK1/2 activation would be 
essential. 
Activation of JNK and p38 MAPK by TGF-ß ligands has been 
extensively studied (Zhang, 2009). The general activation of JNK and p38 
MAPK are reported to be mediated by TRAF6, which binds to the activated 
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TGF-ß cell membrane receptor complexes. It has been reported that this 
interaction subsequently leads to the association and activation of TAK1 
(Sorrentino et al., 2008, Yamashita et al., 2008). TAK1 in turn has been 
reported to phosphorylate MKK4 to activate JNK and MKK3/6 to activate p38 
MAPK (Yamashita et al., 2008). Putting the above mechanisms in doubt, a 
recent study reported that the activation of p38 MAPK does not involve TAK1 
but rather MAP3K4 and 10 (Sapkota, 2013). Nonetheless, TGF-ß induced 
activation of JNK and p38 MAP kinases has been reported to play crucial 
roles in apoptosis (Edlund et al., 2003), EMT (Yamashita et al., 2008), 
regulation of cyskeletal rearrangement (Bakin et al., 2002) as well as 
transcription (Sapkota, 2013). 
The BMP induced activation of JNK and p38 MAPK has not been 
reported extensively, compared to TGF-ß. Although the biochemical 
mechanisms are poorly defined, BMP-induced activation of JNK and p38 
MAPK has been reported to play crucial roles in apoptosis and during 
Xenopus development (Kimura et al., 2000, Shibuya et al., 1998). Further 
investigation is needed to shed light on the exact molecular mechanisms on 
how BMP and TGF-ß cytokines regulate MAPK signalling. 
1.5.2 Regulation of RhoA by BMP and TGF-ß ligands 
RhoA belongs to the Rho GTPase enzyme family, which is key in the 
regulation of cytoskeletal dynamics such as cell migration, adhesion and 
EMT (Heasman and Ridley, 2008). Out of the Rho GTPase family, RhoA, 
Rac and Cdc42 are most extensively studied (Sit and Manser, 2011). The 
switch in Rho GTPases from inactive (GDP-bound) to an active (GTP-bound) 
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from is regulated by GTPase-activating proteins (GAPs), guanine-nucleotide-
exchange factors (GEFs) and guanine nucleotide-dissociation inhibitors 
(GIDs) (Bishop and Hall, 2000). 
The TGF-ß induced active type I and II receptor complex has been 
shown to bind to PAR6 in tight junctions, resulting in its phosphorylation by 
type II receptor kinase. PAR6 together with SMURF1, which is recruited by 
phosphorylated PAR6, binds to RhoA and leads to its ubiquitylation followed 
by proteasomal degradation. Dissociation of RhoA in tight junctions in 
response to TGF-ß ligands is associated with separation of tight junctions, a 
key event in TGF-ß induced EMT (Ozdamar et al., 2005). More recently, this 
pathway has been linked to BMP signalling, where it was reported that both 
TGF-ß and BMP cytokines are able to induce EMT via the 
PAR6/SMURF1/RhoA signalling cascade, albeit involving TGF-ß receptor 
type III .(Sanchez and Barnett, 2012, Townsend et al., 2011). 
1.5.3 Regulation of the PI3-kinase signalling cascade by BMP and TGF-
ß cytokines 
Upon TGF-ß ligand stimulation, type I receptor kinase associates with 
the phosphatidylinositide 3 kinase (PI3K) via its regulatory subunit p85 (Yi et 
al., 2005). This association subsequently leads to the activation of AKT by 
PI3K. AKT is a downstream mediator of PI3K signalling and is 
phosphorylated by 3-phosphoinositide-dependent protein kinase 1 (PDK1) 
and mammalian target of rapamycin complex 1 (mTORC1). TGF-ß activation 
of PI3K, AKT and subsequent mediators such as mTORC1 and S6 kinase 
(S6K), was reported to induce changes in protein synthesis, that ultimately 
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led to TGF-ß induced EMT (Lamouille and Derynck, 2007). More recently, 
mTOR complex 2 has also been implicated in TGF-ß mediated EMT by a 
similar mechanism (Lamouille et al., 2012). BMP ligands were also reported 
to induce the phosphorylation of AKT. PI3K mediated activation of NFκB was 
reported to be induced by BMP ligands, which resulted in the inhibition of 
CASPASES and subsequently in the prevention of apoptosis in chondrocytes 
(Sugimori et al., 2005). In a similar cell system, BMP mediated PI3K activity 
was also reported to activate NFκB signalling (Fong et al., 2008). However, 
the molecular mechanism of PI3K activation by BMP ligands remains to be 
defined.  
1.6 Aberrant BMP and TGF-ß signalling in human diseases 
Due to the global impact of BMP and TGF-ß signalling pathways, it is 
not surprising that the malfunction of specific components of these pathways 
can have severe outcomes. Overexpression of BMP and TGF-ß cytokines 
and mutations of multiple pathway components are linked to many somatic 
and hereditary disorders. These include diseases that range from immune 
and cardiovascular disorders to cancer progression and metastasis. In this 
chapter, I summarise some of the most common disorders related to BMP 
and TGF-ß signalling.  
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1.6.1 Aberrant BMP and TGF-ß signalling in hereditary diseases 
1.6.1.1 Ligand related diseases 
One of the most studied autosomal dominant disorders related to 
TGF-ß signalling is the Marfan syndrome. It occurs in approximately 1 in 
every 4000 individuals. It is a connective tissue disease, that was linked to 
mutations in FBN1 gene (Dietz et al., 1991). FBN1 encodes FIBRILLIN1, an 
important extra-cellular matrix glycoprotein required for the formation of 
elastic fibres in connective tissue (Kielty et al., 2002). FIBRILLIN1 binds to 
TGF-ß cytokines and inhibits TGF-ß signalling. Mutations in FIBRILLIN1, 
which result in lower levels of FIBRILLIN1 expression, leads to increased 
TGF-ß signalling, leading to the failure of vascular system and lung disorders 
(Neptune et al., 2003).  
Mutations in the NOG gene, which are reported to cause partial loss of 
NOGGIN function, are associated with a disorder called Brachydactyly Type 
B (BTB). The hypothesis is that NOGGIN partially fails in controlling the BMP 
signalling pathway especially during the development of hands and feet 
resulting in abnormally fused finger and toe joints (Lehmann et al., 2007). 
Persistent Müllerian duct syndrome (PMDS) is an autosomal recessive 
congenital disease characterised by development of female organs in males. 
PMDS type I is caused by mis-regulation of AMH cytokines, leading to 
developmental disorders during embryogenesis (Belville et al., 1999). The 
expression of AMH is required during normal embryogenesis in order to 
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prevent the development of female organs like uterus in males. Usually the 
levels of AHM are not sufficient in patients with PMDS type I to prevent the 
development of female organs (Josso et al., 2005). 
1.6.1.2 Disorders related to intracellular TGF-ß and BMP pathway 
components 
Some of the hereditary diseases are linked to mutations in type I and 
type II receptor kinases. PMDS type II is one such example, as it is also 
known to be caused by mutations in AHM type II receptor (Imbeaud et al., 
1996). Marfan syndrome has also been described to result from mutations in 
TGF-ß type I and type II receptor kinases (Matyas et al., 2006). 
Other diseases known to be caused by aberrant TGF-ß or BMP cell 
membrane receptors include the Loeys-Dietz syndrome (LDS) and hereditary 
haemorrhagic telangiectasia (HHT) (Loeys et al., 2005, Abdalla and Letarte, 
2006, Johnson et al., 1996). LDS has been associated with inactivating 
mutations in TGF-ß receptor type I and II. Some of the LDS patient 
phenotypes are similar to those seen in patients with Marfan syndrome, as 
LDS patients can suffer from aortic rupture (Dietz et al., 2005). Patients with 
HHT have developmental disorders in blood vessels in skin and internal 
organs that can lead to bleeding (Govani and Shovlin, 2009). HHT has been 
linked to mutations in ALK1 and its co-receptor endoglin (Abdalla and Letarte, 
2006, Johnson et al., 1996). 
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Furthermore, inactivating mutations in TGF-ß receptor type I gene 
TGFBR1 have been associated with multiple self-healing squamous 
epithelioma (MSSE). MSSE is an autosomal dominant disorder that displays 
aggressive and invading skin tumours that spontaneously self-heal within a 
few weeks (Goudie et al., 2011). 
The most studied hereditary disorder associated with SMAD proteins 
is Juvenile polyposis syndrome (JPS). Juvenile polyposis describes the 
formation of spontaneous polyps in the gastrointestinal tract in young 
children. Autosomal dominant mutations of SMAD4 and ALK3 have been 
reported in patients with JPS (Sayed et al., 2002, Howe et al., 1998). 
1.6.2 The role of BMP and TGF-ß signalling pathways in cancer 
Not all disorders that have been linked to BMP and TGF-ß signalling 
components are hereditary as aberrant signalling in somatic cells, as a result 
of mutations or epigenetic changes, are often associated with cancer. BMP 
and TGF-ß signalling in normal epithelial cells controls proliferation, causes 
growth arrest and can induce apoptosis. Thus it acts as a tumour suppressor 
(Massague, 2008, Inman, 2011, Ikushima and Miyazono, 2010, Wakefield 
and Hill, 2013). The crucial steps in cancer development driven by TGF-ß 
and BMP signalling are that cancerous cells and tumours develop 
mechanisms that turn BMP and TGF-ß signalling from tumour suppressors to 
tumour promoters. Some mutations in key signalling components render the 
pathways inactive thereby losing the cytostatic potential. Other more subtle 
mutations of certain components not only inactivate the growth inhibitory 
effects of TGF-ß but also enhance tumour traits, such as epithelial to 
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mesenchymal transition and induction or angiogenesis, that promote tumour 
progression (Inman, 2011, Massague, 2008).  
In normal cells, TGF-ß signalling controls and limits proliferation by 
regulating the expression of CDK inhibitors such as p15, p21 or p27 (Siegel 
and Massague, 2003). In order to evade the growth inhibition of TGF-ß 
signalling, inactivating mutations of the TGF-ß type I and II receptor kinases 
or SMAD4 are found in many cancers (Ikushima and Miyazono, 2010, Xu 
and Pasche, 2007, Goggins et al., 1998, Schutte et al., 1996). SMAD4 has 
long been known as a tumour suppressor as it has been reported to be 
mutated in ~50% of pancreatic tumours (Hahn et al., 1996).  
Loss of SMAD4 expression or its mutation and mutations of BMP 
receptor type I play important role in colorectal cancer in order to evade the 
growth inhibitory effects of TGF-ß and BMP signalling (Zhang et al., 2010, 
Kodach et al., 2007). In contrast other cancers, such as certain types of 
aggressive breast cancer, have been reported to exploit TGF-ß signalling to 
enhance their metastatic ability (Massague, 2008). MDA-MB-231 breast 
cancer cells have been reported to require SMAD4 expression for metastasis 
(Deckers et al., 2006). 
The role of BMP signalling pathways in cancer in general has not been 
covered as extensively as the TGF-ß signalling pathway in terms of number 
of research reports. However it is clear that BMP signalling plays a crucial 
role in many different cancers and impacts cancer progression. Nonetheless, 
the role of BMP signalling, especially the BMP antagonists, in cancer remains 
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elusive (Singh and Morris, 2010, Wakefield and Hill, 2013). Bone metastasis 
is the most common secondary tumour site in prostate cancer progression 
and these are accompanied by aberrant BMP signalling (Ye et al., 2007). 
Prostate cancer is usually dependent on androgen receptor (AR) signalling. 
Therefore the androgen-deprivation therapy (ADT) is often used to treat 
prostate cancer. Once the cancer becomes resistant to ADT at latter stages, 
the cancer becomes more aggressive and the mortality rates are increased 
(Klotz, 2000, Labrie et al., 2004). Interestingly, the proliferative inhibition by 
the BMP signalling pathway was reported to be diminished in androgen 
insensitive compared to sensitive prostate cancer cell lines (Brubaker et al., 
2004, Ide et al., 1997). A direct link between AR and BMP signalling has also 
been reported. Linker phosphorylated SMAD1 was shown to interact to AR in 
response to androgen or BMP in androgen sensitive prostate cancer cells 
(Qiu et al., 2007).  
1.7 Aims of the thesis 
The fundamental steps in the TGF-ß and BMP signalling pathway, as 
described above, have been well established. However, many aspects of the 
signalling pathways pertaining to their regulation are still not completely 
defined. In order to identify novel regulators of BMP signalling and 
understand the molecular mechanisms by which BMP signalling is regulated 
in cells, a proteomic approach was undertaken to identify interactors of 
SMADs. FAM83G/PAWS1 was identified as a novel Protein Associated With 
SMAD1. The first aim of my thesis is to characterise the role of 
FAM83G/PAWS1 in regulating BMP signalling and its potential impact on 
other signalling networks. 
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Specific small molecule inhibitors of type I BMP and TGF-ß receptors 
are routinely employed to dissect the TGF-ß and BMP pathways and are 
useful in characterising the roles of novel pathway regulators. Furthermore 
selective small molecule inhibitors have therapeutic potential to control 
diseases caused by aberrant TGF-ß and BMP signalling. However, it is 
critical to establish the specificities and potencies of small molecule inhibitors 
against their intended targets. For the second aim of my thesis, I characterise 
the specificities and potencies of the most commonly employed small 
molecule inhibitors of the TGF-ß and BMP pathways. 
  
- 25 - 
2 Materials and Methods 
2.1 Materials 
2.1.1 Reagents 
Reagent Source 
1 Kb Plus DNA Ladder Life Technologies Inc 
A-83-01 Tocris Bioscience 
Acetic acid BDH Chemicals Ltd. 
Acetone BDH Chemicals Ltd. 
Acetonitrile (HPLC grade) Rathburn Chemicals 
Acrylamide:bis-acrylamide (40% 
(w/v) 29:1) 
Flowgen Bioscience 
Adenosine 5’-triphosphate (ATP) Roche 
agarose (electrophoresis grade) Life Technologies Inc 
ammonium persulphate Sigma-Aldrich 
ampicillin Sigma-Aldrich 
Blasticidin Life Technologies Inc 
BMP-2 R&D Systems 
bromophenol blue Sigma-Aldrich 
Colloidal Coomassie Blue 
staining kit 
Life Technologies Inc 
Complete protease inhibitor 
cocktail tablets 
Roche 
Coomassie brilliant blue G-250 Sigma-Aldrich 
Coomassie protein assay 
reagent (Bradford reagent) 
Pierce 
dimethyl sulphoxide (DMSO) Sigma-Aldrich 
Dithiobis succunimidyl 
propionate (DSP) 
Thermo Scientific 
dithiothreitol (DTT) Sigma-Aldrich 
Dorsomorphin Sigma-Aldrich 
Dulbecco’s modified Eagle 
medium (DMEM) 
Life Technologies Inc 
Dulbecco’s phosphate buffered 
saline (PBS) 
Life Technologies Inc 
Ethanol BDH Chemicals Ltd. 
FLAG-agarose Sigma-Aldrich 
foetal bovine serum (FBS) Sigma-Aldrich 
G418 Life Technologies Inc 
GFP-Trap agarose beads Chromotek 
Glycerol BDH Chemicals Ltd. 
HA-agarose Sigma-Aldrich 
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Reagent Source 
Hygromycin-B Life Technologies Inc 
IgG–free BSA Jackson Immunoresearch 
Immobilon Western 
chemiluminescent HRP 
substrate (ECL) 
Merck-Millipore 
Isopropanol BDH Chemicals Ltd. 
LDN-193189 Stemgent 
L-glutamine Life Technologies Inc 
LY-364947 Sigma-Aldrich 
Magnesium acetate BDH Chemicals Ltd. 
Manganese chloride BDH Chemicals Ltd. 
Methanol BDH Chemicals Ltd. 
Microcystin-LR Life Technologies Inc 
NE-PER Nuclear and 
Cytoplasmic Extraction Kit 
Thermo Scientific 
Nitrocellulose membranes Schleicher and Schuell 
NuPAGE MOPS running buffer 
(20x) 
Life Technologies Inc 
NuPAGE Novex 4-12% Bis-Tris 
polyacrylamide gels 
Life Technologies Inc 
Opti-MEM Life Technologies Inc 
Penicillin/streptomycin Life Technologies Inc 
Plasmid Maxi kit Qiagen 
polyethylene glycol sorbitan 
monolaurate (Tween-20) 
Sigma-Aldrich 
polyethylenimine (PEI) Sigma-Aldrich 
Polyvinylidene fluoride (PVDF) 
membrane 
Merck-Millipore 
Ponceau S solution Sigma-Aldrich 
Prestained See Blue protein 
markers for SDS-PAGE 
BioRad 
ProLong Gold mounting reagent Life Technologies Inc 
Protein G Sepharose Life Technologies Inc 
puromycin dihydrochloride Sigma-Aldrich 
RNeasy kit Qiagen 
SB-431542 Sigma-Aldrich 
SB-505124 Sigma-Aldrich 
Skimmed milk powder Premier Brands 
Sodium acetate BDH Chemicals Ltd. 
Sodium chloride BDH Chemicals Ltd. 
Sodium dodecyl sulphate BDH Chemicals Ltd. 
Sodium 
ethylenediaminetetraacetate 
(EDTA) 
BDH Chemicals Ltd. 
ß-mercaptoethanol (biochemical 
grade) 
Sigma-Aldrich 
Sucrose BDH Chemicals Ltd. 
Superscript VILO cDNA kit Life Technologies Inc 
- 27 - 
Reagent Source 
SuperSignal West Pico 
Chemiluminescent Substrate 
Thermo Scientific 
SYBR green BioRad 
SYBR® Safe Life Technologies Inc 
tetramethylethylenediamine 
(TEMED) 
Sigma-Aldrich 
TGFß1 R&D Systems 
t-octylphenoxypolyethoxyethanol 
(Triton) X-100 
Sigma-Aldrich 
Transfectin BioRad 
tris (hydroxymethyl) methylamine 
(Tris) 
BDH Chemicals Ltd. 
Trypsin Gold mass spectrometry 
grade 
Promega 
Trypsin-EDTA Life Technologies Inc 
urea Sigma-Aldrich 
Zeocin Life Technologies Inc 
Table 2-1 Reagents used in this thesis 
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2.1.2 Buffers and solutions 
Polyethylenimine (PEI):  1mg/ml PEI in 25mM HEPES pH7.5.  
TBS-Tween (TBS-T):   50 mM Tris/HCl pH 7.5, 0.15M NaCl and 0.25% 
(v/v) Tween-20. 
Buffer A:   50mM Tris/HCl pH 7.5, 0.1mM EGTA and 0.1% 
(v/v) ß-ME. 
TAE Buffer:   40mM Tris-Acetate pH 8, 1mM EDTA.  
DNA loading dye:   20 mM EDTA pH 8, 50% (v/v) glycerol, 0.05% 
(w/v) bromophenol blue.  
5x SDS Sample Buffer:  5% (w/v) SDS, 5% (v/v) ß-ME, 50mM Tris/HCl pH 
6.8, 6.5% (v/v) glycerol and 0.02% (w/v) bromophenol 
blue.  
SDS-PAGE Buffer:   25mM Tris/HCl pH 8.3, 192mM glycine, 0.1% SDS 
(v/v).  
SDS.Transfer Buffer:   25mM Tris/HCl pH 8.3, 192mM glycine, 20% (v/v) 
methanol.  
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Luria Bertani broth plus Ampicillin (LB-Amp):      
 1% (w/v) tryptone peptone, 0.5% (w/v) yeast 
extrac, 86mM NaCl, 100 µg/ml Ampicillin after 
autoclaving for 20 min 
LB-Amp plates:   1% (w/v) tryptone peptone, 0.5% (w/v) yeast 
extrac, 86mM NaCl, 2% (w/v) bacto-agar 100 µg/ml 
Ampicillin after autoclaving for 20 min  
Gel filtration buffer:   150mM NaCl, 50mM Tris/HCl pH 7.5, 0.03% (v/v) 
Brij35. Bacterial lysis buffer: 25mM HEPES pH 7.6, 
10% glycerol (v/v), 0.1mM EDTA, 150mM KCl, 1mM 
DTT, 1mM PMSF, 1 tablet of Complete protease 
inhibitor per 50ml lysis buffer. 
Kinase assay buffer:   50mM Tris/HCl pH 7.5, 0.1% ß-mercaptoethanol, 
0.1 EGTA, 10 mM MgCl2, 0.5 µM Microcystein-LR 
Lysis buffer:   50mM Tris/HCl pH 7.4, 0.27M sucrose, 150mM 
NaCl, 1mM EDTA pH 8.0, 1mM EGTA pH 8.0, 1mM 
sodium orthovanadate, 10mM sodium ß-
glycerophosphate, 50mM sodium fluoride, 5mM 
sodium pyrophosphate, 1% v/v) Triton X-100, 0.5% 
(v/v) Nonidet P-40, 0.1% (v/v) ß-mercaptoethanol (ß-
ME) and complete protease inhibitors.  
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Lysis buffer with DSP cross-linking agent:      
 40mM HEPES pH 7.4, 120mM NaCl, 1mM EDTA 
pH 8.0, 10mM sodium ß-glcerophosphate, 50mM 
sodium fluoride, 1mM sodium orthovanadate, 5mM 
sodium pyrophosphate, 1% (v/v) Triton X-100, 
complete protease inhibitors, 2.5mg/ml DSP added 
drop wise immediately prior to usage. 
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2.1.3 Plasmids 
Mammalian expression constructs encoding human SMAD1, SMAD2, 
SMAD3, SMAD4, SMAD5, SMAD6, SMAD7, SMAD8, FAM83G/PAWS1, 
CULLIN3 and various truncation or point mutants of these genes (Table 2-2) 
were cloned into either pCMV5 or pcDNAFrtTO (Life Technologies, Paisley, 
U.K) vectors with N-terminal FLAG, haemagglutinin (HA) or green fluorescent 
protein (GFP)-tags. Untagged FAM83G/PAWS1 and various point mutants 
were in addition cloned into pBABE-puro. pCMV-Gag-Pol and pCMV-VSVG 
constructs were purchased from Cell Biolabs Inc. All plasmids used in this 
study are listed in Table 2-2. 
For bacterial expression, constructs encoding N-terminal GST-tagged 
FAM83G/PAWS1, SMAD1, SMAD2 and mutants of these genes were cloned 
into pGex6p vector and subsequently transformed into BL21 cells. All 
constructs, unless stated otherwise, used in this thesis were generated the 
cloning team at the DSTT (Table 2-2). For baculoviral expression, constructs 
encoding N- or C-terminal GST-or 6x HIS tagged FAM83G/PAWS1, ALK5 
and mutants of these genes were cloned into pFB GST-expression vectors. 
All DNA constructs employed were verified by DNA sequencing, performed 
by DNA Sequencing & Services (MRC PPU, College of Life Sciences, 
University of Dundee, Scotland, www.dnaseq.co.uk) using Applied 
Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 3730 
automated capillary DNA.  
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DU number Plasmid Source 
DU33273 pCMV5-FLAG-1 PAWS1 Thomas Macartney 
DU19263 pCMV5-HA-1 SMAD1 Thomas Macartney 
DU19305 pCMV5-HA-1 SMAD2 Thomas Macartney 
DU19396 pCMV5-HA-1 SMAD3 Thomas Macartney 
DU19308 pCMV5-HA-1 SMAD4 Thomas Macartney 
DU19310 pCMV5-HA-1 SMAD5 Thomas Macartney 
DU19604 pCMV5-HA-1 SMAD6 Thomas Macartney 
DU19220 pCMV5-HA-1 SMAD7 Thomas Macartney 
DU19568 pCMV5-HA-1 SMAD8 Thomas Macartney 
 
pCMV5-HA-1 SMAD1 MH1 Gopal Sapkota 
 
pCMV5-HA-1 SMAD1 MH1+Linker Gopal Sapkota 
 
pCMV5-HA-1 SMAD1 Linker Gopal Sapkota 
 
pCMV5-HA-1 SMAD1 MH2 Gopal Sapkota 
DU33272 pcDNA5-FRT/TO-GFP PAWS1 Thomas Macartney 
DU33460 pBabe.puro PAWS1 Thomas Macartney 
DU33461 pBabe.puro PAWS1 S610A Thomas Macartney 
DU19338 pcDNA5-FRT/TO-GFP SMAD4 Thomas Macartney 
 
pBabe.puro Control Thomas Macartney 
DU19269 pGEX6P-1-SMAD1 Thomas Macartney 
DU19395 pGEX6P-1-SMAD2 Thomas Macartney 
DU19440 pGEX6P-1-PAWS1 (523-end) Thomas Macartney 
DU33233 pGEX6P-1-PAWS1 (523-end) S610A Thomas Macartney 
DU33235 pGEX6P-1-PAWS1 (523-end) S613/14/16A Thomas Macartney 
DU42168 pBabe.puro mPAWS1 Simone Weidlich 
DU33547 pFB GST ALK4 T204D 200-end Thomas Macartney 
DU33574 pFB GST ALK5 T204D 200-end Thomas Macartney 
DU33022 pGEX6P-1-PAWS1 (753-815) Thomas Macartney 
Table 2-2 Plasmids used in this thesis 
 
2.1.4 qRT-PCR Primers & siRNA oligonucleotide sequences 
Human qRT-PCR primers were designed by PerlPrimer® and ordered 
from Life technologies and are listed in Table 2-3. siRNA oligonucleotides 
were purchased from Qiagen and are listed in Table 2-4. 
Target Sequence (5’-3’) 
GAPDH  
F- TGCACCACCAACTGCTTAGC 
R- GGCATGGACTGTGGTCATGAG, 
HPRTI F- TGACACTGGCAAAACAATGCA 
R- GGTCCTTTTCACCAGCAAGCT 
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Target Sequence (5’-3’) 
PAWS1 
F- CACAGAAGGTGATAGCTGTG 
R- ACTTGACGTTACTCTCATCCA 
FOXO4 
F- TTGGAGAACCTGGAGTGTGACA 
R- AAGCTTCCAGGCATGACTCAG 
ID1  
F- AGGCTGGATGCAGTTAAGGG 
R- GGTCCTTTTCACCAGCAAGCT 
NEDD9  
F- GCTCTATCAAGTGCCAAACCC, 
R- GGTTCCCCCAATGCTTCTCT) 
ASNS  
F- AACTGCTGCTTTGGATTTCAC 
R- GCTGTTGCATCTTCTTATGGT 
BMPR2   F- TGGAACATACCGTTTCTGCT 
R- GAATGAGGTGGACTGAGTGG 
TGFBI  F- ATCACCAACAACATCCAGCA 
R- CCGTTACCTTCAAGCATCGT,  
FST  F- GATCTTGCAACTCCATTTCGG 
R- GGCTATGTCAACACTGAACAC,  
TGFBR2  F- GCTGTATGGAGAAAGAATGACGA 
R- ACAGGAACACATGAAGAAAGTC,  
TSC22D1  
F- CTATCAGTGGTGACAGTGGG.  
R- TTCACTAGATCCATAGCTTGCTC 
WASF3 
F- CATGCTGAAGACATATTTGGTGAG 
R- TCCTGTAGTGAGACCTCTTCC 
CCNA1  
F- CCCTATGCTGGTAGATTCATCTC 
R- GTGCCTTATTTCAGCTTCCCT 
NPY1R 
F- GTGGAGTTCGGCTTTAAGGA 
R- TGAACTGAACAATCCTCTTTGG 
BEX1 
F-  TAGGCCCAGGAGTAATGGAG 
R- CCTACGATTTCCTCTAGGCAC 
CKAP2  
F- GGTCTGAGGAAGTTCTATCTTGG 
R- TTCTTTGCTCTTTGAATGCGG 
MMP1 F- TAAAGACAGATTCTACATGCGC 
R- GTATCCGTGTAGCACATTCTG 
LRP4  F- GGATTGCCAAGACTCAAGGA 
R- CAAGACAAATGGATGTTCTCTAGG,  
ARHGAP44 F- AGGCTCTATGGAATGCTTGTG 
R- GTAATGTTCCCTTCTGCTTGTG,  
TPX2  F- CCAAAGAAGATGAGGAAGAGGA 
R- AGAATCAAACGAGAAAGGGCA,  
PDGFRA  
F- GGAGAAGTGAAAGGCAAAGG.  
R- CAGCACATTCGTAATCTCCAC 
PDZRN3 
F- ACAGGATTATTGAGGTCAACGG 
R- ATGTTCAAAGGTGATGTCGGT 
GTF2F2 
F- GGATTGCCAAGACTCAAGGA 
R- CAAGACAAATGGATGTTCTCTAGG 
MLLT11 
F- TTGATAACAGGAAGCTATGAGGG 
R- TTGTAGGTGGCTGTATCTGAC 
AR 
F- CCTGGCTTCCGCAACTTACAC 
R- GGACTTGTGCATGCGGTACTC 
MMP13 
F-  CAGTCTTTCTTCGGCTTAGAGG 
R- GGGTGTAATTCACAATTCTGTAGG 
Table 2-3 qRT-PCR primers used in this thesis 
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Target Sequence (5’-3’) 
PAWS1-1  AAGATGATGACGACTACGTAA 
PAWS1-2 CCGGGCTAGCGTCTACATGCA 
FOXO4 CCCGACCAGAGAUCGCUAA 
Table 2-4 siRNA used in this thesis 
 
2.1.5 Antibodies 
Antibodies raised in sheep or rabbit (Table 2-5) using standard 
protocols of the Division of Signal Transduction and Therapy (DSTT), School 
of Life Sciences, University of Dundee. The antibodies were affinity purified 
on CH-Sepharose covalently coupled to the antigens used to raise the 
antibodies. For the purification of phospho-specific antibodies, the antibodies 
purified on the column containing the phosphopeptide immunogen were 
passed through a peptide column made with the non-phosphorylated form of 
the peptide immunogen. The antibodies that did not bind to the non-
phosphorylated peptide column were collected and used. 
Antibody Company 
Product 
ref 
Source 
Ab 
Dilution 
Ab 
Conditions 
Flag-M2 HRP Sigma A 8592 mouse 1:2000 Milk 
GFP 
Cell 
Signaling 
#2555 rabbit 1:2000 Milk 
HA HRP Roche 
12 013 
819 001 
rat 1:2000 Milk 
GAPDH 
Cell 
Signaling 
#2118 rabbit 1:5000 Milk 
LAMIN A/C 
Cell 
Signaling 
#2032 rabbit 1:1000 Milk 
P-SMAD1/5/8 
Cell 
Signaling 
#9511 rabbit 1:1000 Milk 
p-SMAD2 
Cell 
Signaling 
#3101 rabbit 1:1000 Milk 
p-SMAD3 
Rockland 
Ind. 
600-401-
919 
rabbit 1:2000 Milk 
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Antibody Company 
Product 
ref 
Source 
Ab 
Dilution 
Ab 
Conditions 
Cullin3 DSTT S347D sheep 1:1000 Milk 
SMAD2/3 
Cell 
Signaling 
#3102 rabbit 1:1000 Milk 
Cyclin A 
Cell 
Signaling 
#4656 mouse 1:1000 Milk 
SMAD4 
Cell 
Signaling 
#9515 rabbit 1:1000 Milk 
Cyclin D 
Cell 
Signaling 
#2922 rabbit 1:1000 Milk 
p44/42 MAPK 
Cell 
Signaling 
#9102 rabbit 1:1000 Milk 
Cyclin E 
Cell 
Signaling 
#4132 rabbit 1:1000 Milk 
PLK1 
Cell 
Signaling 
#4513 rabbit 1:1000 Milk 
Fibronectin Sigma F3648 rabbit 1:2000 Milk 
P-p38  
Cell 
Signaling 
#9211 rabbit 1:1000 Milk 
p38 
Cell 
Signaling 
#9212 rabbit 1:1000 Milk 
E-cadherin 
Cell 
Signaling 
#3195 rabbit 1:1000 Milk 
FAM83G/PAWS1 DSTT S876C sheep 1:1000 Milk 
SMAD1 DSTT S618C sheep 1:1000 Milk 
P-FAM83G/PASW1 DSTT R2783 rabbit 1:1000 Milk 
P-SMAD1 S206 
Cell 
Signaling 
#5753 rabbit 1:500 Milk 
Table 2-5 Antibodies used in this thesis 
 
2.1.6 Proteins and Enzymes 
N- or C-terminal GST- or 6x His-tagged FAM83G/PAWS1, SMAD1, 
SMAD2 and various mutants of these proteins were all expressed and 
purified by the Protein Production Team (DSTT) (Table 2-2). N-terminal GST-
tagged ALK2, ALK3 and ALK6 were purchased from Carna Biosciences. 
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2.2 Methods 
2.2.1 Cell culture 
Human Keratinocytes (HaCaT), breast cancer MDA-MB231, 
osteosarcoma U2OS, HEK293, colon carcinoma RKO, breast cancer MCF7, 
human myeloid leukemia KBM-7, HeLa and prostate cancer PC3 cells were 
cultured at 37°C in a humidified incubator with 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (v/v) foetal bovine 
serum (FBS), 100units/ml penicillin, 100μg/ml streptomycin and 2mM L-
glutamine (standard medium). HEK293 T-Rex cells (Life Technologies) were 
grown in standard medium plus the addition of 15µg/ml Blasticidin and 
100μg/ml zeocin (both Life Technologies). PC3 put-back cell lines were 
grown in standard medium plus the addition of 2 µg/ml puromycin.  All cells, 
unless stated otherwise, were grown in 10-cm plates with 10ml of media 
solution covering them. When cells were passaged, the culture medium was 
removed and they were washed once with sterile Dulbecco’s phosphate 
buffered saline (PBS). 1 to 3ml of sterile trypsin/EDTA was added per plate 
(depending on cell type) to disassociate them from the plate surface. The 
plates were then returned to a 37ºC incubator for 5-25 minutes, depending 
on the adherence of the cell line. Detached cells were re-suspended in 10 ml 
of standard media. The cell suspension was carefully pipettes up and down 
several times to prevent cell clumps. The cell suspension was subsequently 
used to seed the desired number of new plates. 
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2.2.2 Cell transfections 
Cells were grown to a confluency of about 50-60% and then 
transfected with plasmids using 25µl of 1mg/ml polyethylenimine (PEI, 
Polysciences) in 1ml DMEM with a maximum of 10µg plasmid DNA. The 
transfection mix was vortexed for 15 seconds before incubation at room 
temperature (RT) for 15 minutes. The transfection mix was then carefully 
added to the cells. 16h after the transfection, the media was replaced with 
fresh media and cells were lysed 48h post transfection, if not stated 
otherwise. SiRNA was transfected using Transfectin (BioRad). A total of 
300pmols of siRNA oligonucleotides was used for a 10 cm plate. The cells 
were transfected directly at the time of seeding during passaging. The 
transfected cells were lysed at 48h after the transfection. The oligonucleotide 
sequences of the siRNA’s are listed in Table 2-4. 
2.2.3 Generation of cell lines stably expressing pBABE-puromycin 
constructs 
A retroviral system was used to generate cell lines that stably express 
a protein at comparable levels to endogenous protein expression. Retroviral 
pBABE-puromycin control vector (1 µg each) or vectors encoding human or 
mouse untagged FAM83G/PAWS1 or FAM83G/PAWS1 S610A were co-
expressed with CMV-Gag/Pol (0.9μg) and CMV-VSVG (0.1μg) constructs in 
HEK-293T cells. Retroviruses were collected 48h-post transfection from the 
culture media by filtering it through 0.25 µm filters into sterile falcon tubes. 
PC3 or NMuMG cells, plated at ~40% confluent for 24-h, were infected by 
transferring the filtered retroviruses directly onto the cells together with 8 
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µg/ml Polybrene reagent. The cells were cultured in selection medium 
containing puromycin (2 µg/ml) for selection of infected cells, 24h after 
infection. Immunoblots using cell extracts with a PAWS1 antibody was used 
to verify the expression of infected cells.  
2.2.4 Generation of tetracycline inducible Flp-IN® HEK293 and U2OS 
cells stably integrated with N-terminally GFP-tagged proteins 
FLP-In T-Rex HEK293 or U2OS cell lines (Life Technologies) were 
used to generate stably expressing tetracycline inducible GFP-
FAM83G/PAWS1 cell lines. These cells were maintained as described in 
section 2.2.1. The antibiotics zeocin and blasticidin were added to the media 
to select for the FLP recombination target (FRT) sites and tetracycline 
repressor sequence, respectively. 2 passages before the transfection, cells 
were split into 10 cm plates containing standard medium and grown to a 
confluence of about 70%. Transfections were performed using PEI with 1μg 
pcDNA5FRT GFP-FAM83G/PAWS1 and 9μg of pOG44 plasmid (Life 
Technologies). pOG44 encodes the FLP recombinase that leads to site 
specific recombination of the sequence of interest. 24h after transfection the 
medium was replaced with fresh DMEM plus the addition of 15μg/ml 
blasticidin and 50μg/ml hygromycin-B. Hygromycin-B selection is to ensure 
the correct integration of the sequence of interest. This selection media was 
changed at least every four days until cell colonies were visible under the 
microscope. To test the correct expression of GFP-FAM83G/PAWS1, the 
cells were treated with 20 ng/ml doxycycline for a time course of 4h to 24h 
and the expression assessed by fluorescence microscopy and 
immunoblotting. 
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2.2.5 Cell lysis 
Cells were lysed in 4°C cold lysis buffer (50mM Tris/HCl  pH 7.4, 
0.27M sucrose, 150mM NaCl, 1mM EDTA pH 8.0, 1mM EGTA pH 8.0, 1mM 
sodium orthovanadate, 10mM sodium ß-glycerophosphate, 50mM sodium 
fluoride, 5mM sodium pyrophosphate, 1% (v/v) Triton X-100, 0.5% (v/v) 
Nonidet P-40, 0.1% (v/v) ß-mercaptoethanol (ß-ME), 1μg/ml microcystin-LR 
and complete protease inhibitors (Roche). When the chemical cross-linking 
agent  Dithiobis (succinimidyl propionate) (DSP; Thermo Scientific) was 
used, cells were lysed in 4°C cold HEPES lysis buffer (40mM HEPES pH 7.4,  
120mM NaCl, 1mM EDTA pH 8.0, 10mM sodium pyrophosphate, 50mM 
sodium fluoride, 1mM sodium orthovanadate, 5mM sodium pyrophosphate, 
1% (v/v) Triton X-100, complete protease inhibitors) containing 2.5mg/ml 
DSP, which was added just before usage. Cell extracts were subsequently 
incubated at 4°C for 30min before DSP was quenched with 1M Tris/HCl pH 
7.5 at a final concentration of 0.2M. Cell extracts were further incubated for 
30min at 4°C before subsequent usage. Extracts were boiled for 5min in 1x 
sodium dodecyl sulphate (SDS) sample buffer containing either 1% ß-
mercaptoethanol or 50mM dithiothreitol (DTT). 
2.2.6 Protein concentration determination 
The concentration of proteins in cell extracts was determined using the 
Bradford method (Bradford, 1976). This assay is done by extrapolating the 
protein concentration from a standard curve determined with known 
concentration of protein standards. This was performed with a BSA standard 
solution with dilutions ranging from 0.1 mg/ml to 5 mg/ml. The standards 
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were diluted in millipore water in order to get to a final volume of 0.1ml. 
These solutions were subsequently mixed with 0.9ml Bradford reagent 
(Thermo Scientific) in 1.5 ml plastic cuvettes. The final mixture was incubated 
for at least 5 minutes at RT. The measurement of all the standards and 
samples was done using a photospectrometer with a wavelength of 595 nm 
after it has been normalised to a blank probe containing only 0.1ml distilled 
water and 0.9ml Bradford reagent. 1 to 2 µl of the extracts were diluted in 
distilled water to a final volume of 0.1ml and mixed again with 0.9ml Bradford 
reagent as before. If needed, an additional dilution was done to maintain the 
absorbance of each sample within the linear range of the Bradford asaay 
(Absorbance at 595nm between  0.1 and 0.7). All Bradford measurements 
were performed in duplicate.  
2.2.7 Immunoprecipitation 
To minimise unspecific binding of proteins to the solid phase resins, 
the cleared extracts were subjected to pre-clearing by incubating with the 
appropriate resin (agarose or protein-G Sepharose) for 1h at 4°C prior to 
immunprecipitation (IP). The pre-cleared extracts were then subjected to IPs 
with anti-FLAG or anti-HA agarose beads (Sigma-Aldrich), GFP-Trap agarose 
beads (Chromotek) or appropriate pre-immune IgG or antibodies coupled to 
protein G-Sepharose beads. For standard IPs, 1 to 2 mg of the cell extract 
protein was incubated with the appropriate resin. Large scale endogenous 
IPs and proteomic fingerprinting generally were done using >50 mg of cell 
extract proteins. IPs were performed for up to 4 h at 4°C with constant 
shaking. Then the beads were collected by centrifugation at 5000 rpm for 1 
min and the supernatant was removed (an aliquot was collected to detect the 
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efficiency of immune-depletion of the appropriate target). The beads were 
washed twice with lysis buffer containing 0.5 M NaCl and 0.1% (v/v) ß-
mercaptoethanol and twice with Buffer A (50 mM Tris/HCl pH 7.4, 0.1 mM 
EGTA and 0.1% (v/v) ß-mercaptoethanol) at 4°C. The IPs were reconstituted 
in 50 µl Buffer A and 1x SDS sample buffer with 1% (v/v) ß-mercaptoethanol 
and boiled for 5 min prior to SDS-PAGE. 
2.2.8 Conjugation of antibodies to protein G Agarose and Sepharose 
The required volumes of protein G-Agarose/Sepharose beads were 
washed twice in PBS (1 ml) and the final volume was adjusted to 50% (v/v) 
slurry in PBS prior to antibody conjugation. For each IP, 2-5 µg of the 
antibody was added to 20 μl of protein G Agarose or Sepharose beads slurry. 
This mixture was left on a shaker at 4°C to allow conjugation of the 
antibodies to the protein-G beads. After 1h, the beads were washed twice in 
PBS and re-suspended as 50% (v/v) slurry. The antibody coupled bead slurry 
was then ready to be used for IPs. 
2.2.9 Subcellular Fractionation 
Cells were grown to about 60 to 70 % confluency, prior to separation 
into nuclear and cytosolic fractions. The fractionation was performed using 
the Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific) following the 
manufacturer’s instruction manual, except that the lysis buffers were 
supplemented with complete protease inhibitor tablets (Roche) to prevent 
protein degradation. Subcellular fractions were reduced with 1x SDS sample 
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buffer containing 1% (v/v) ß-mercaptoethanol and boiled for 5 min prior to 
analysis by immunoblotting. 
2.2.10 Size exclusion chromatography 
The AKTA Explorer was operated according to manufacturer’s 
instructions using the Unicorn 4.1 software. All buffers and extracts were 
sterile filtered before loading onto the column. Extracts from HaCaT cells 
treated with or without BMP-2 (25 ng/ml) or TGF-ß (50 pM) for 1 h prior to 
lysis, were cleared by centrifugation and further cleared through Spin-X 
columns. 1 mg of protein extract was subjected to separation through a 
Superose™ 10/300 GL Column (GE Health Care), which was washed and 
equilibrated with three column volumes of degassed gel filtration buffer (150 
mM NaCl, 50 mM Tris/HCl pH 7.5, 0.03% (v/v) Brij35). 32 fractions of 0.2 ml 
each were collected at a flow-rate of 0.15 ml/min. The eluted fractions were 
reduced with 1x SDS sample buffer containing 1% (v/v) ß-mercaptoethanol 
and boiled for 5 minutes at 95°C before SDS-PAGE and immunoblot analysis 
were performed. 
2.2.11 Cell migration assay 
The PC3 Control, PC3 PAWS1 or PC3 PAWS1 S610A cells were 
seeded with 80 % confluency into migration inserts (Ibidi) and left growing for 
36 h. Afterwards the inserts were removed, the cells were serum starved for 
4 h and stimulated with or without BMP (25 ng/ml). Cellular migration was 
monitored in a 37 °C humidified chamber supplied with 5 % CO2 using an 
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Eclipse Ti live cell imaging microscope (Nikon Corp.) with pictures taken 
every 2 minutes for 24 h. 
2.2.12 In vitro kinase assays of FAM83G/PAWS1 with ALK receptors 
For each kinase assay, 20 µl reactions were set up consisting of 150 
ng of kinase (GST-ALK2, GST-ALK3 or GST-ALK6; Carna Biosciences) and 
2 µg substrate protein (GST-SMAD1, GST-SMAD2, GST-PAWS1(523-end) 
or other mutants of PAWS1 as indicated) in a buffer containing 50 mM 
TrisHCl pH 7.5, 0.1% ß-mercaptoethanol, 0.1 mM EGTA, 10 mM MgCl2, 0.5 
µM Microcystein-LR and 0.1 mM 32P-ATP (500 cpm/pmole). All assays were 
performed at 30°C for 30 minutes and stopped by adding 1X SDS sample 
buffer containing 1% ß-mercaptoethanol and heating at 95°C for 5 minutes. 
The samples were resolved by SDS-PAGE and the gels were stained with 
Coomassie Blue and dried. The radioactivity was analysed by 
autoradiography. For the identification of the phospho-residues within PAWS1 
see section 2.2.16.3. 
2.2.13 Specificity kinase panel 
All protein kinases in the specificity panel were expressed, purified and 
assayed at The National Centre for Protein Kinase Profiling 
(http://www.kinase-screen.mrc.ac.uk/) as previously described (Bain et al., 
2007). The assays were carried out robotically at RT (21 °C) and were linear 
with respect to time and enzyme concentration under all conditions used. The 
assays were performed for 30 min using Multi drop Micro reagent dispensers 
(Thermo Electron Corporation, Waltham, MA, U.S.A.) in a 96-well format. The 
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concentration of magnesium acetate in the assays was 10 mM and [γ-32 
P]ATP (~800 cpm/pmol)was used at 5μM for ABL, Aurora A, CK2α, CLK2, 
DAPK1, DYRK3, EF2K, EIF2AK3, ERK1, ERK8, GSK3ß, HER4, HIPK2, IGF-
1R, IKKß, IRAK1, IRR, JAK2, MARK3, MKK1, MKK2, p38αMAPK, 
p38γMAPK, PAK2, PAK5, PIM3,PKBα,PKCζ,PRAK, RIPK2, TAK1, 
TLK1andZAP70, 20μMfor AuroraB, BRK, BRSK1, CAMKKß, CDK2-Cyclin A, 
CHK1, CHK2, CK1δ, CSK, EPH-B1, EPH-B2, EPH-B3, ERK2, FGF-R1, 
GCK, HIPK1, HIPK3, IR, IRAK4, JNK1, JNK2, JNK3, LKB1, MAPKAP-K2, 
MAPKAP-K3, MARK1, MARK2, MEKK1, MLK3, MNK1, MSK1, MST4, 
NEK2α,OSR1, p38δMAPK, PAK4, PAK6, PDK1, PIM1, PIM2, PKA, PKCγ, 
PKD1, PLK1, PRK2, ROCK2, RSK1, SGK1, SmMLCK, SYK, TAO1, TIE2, 
TrkA, TTK, VEG-FR and YES1. 50μM were used for AMPK, ASK1, BRSK2, 
BTK, CAMK1, DYRK1A, DYRK2, EPH-A2, EPH-A4, EPH-B4, 
IKKε,Lck,MARK4,MELK, MINK1, MKK6, MLK1, MNK2, MPSK1, MST2, 
NEK6, NUAK1, p38ßMAPK, PHK, PKBß,PKCα, RSK2, S6K1, Src, SRPK1, 
STK33 and TBK1 in order to be at or below the Km for ATP for each enzyme. 
For kinase assays with CK1 isoforms, 300μM CK1-peptide 
KRRRALS*VASLPGL (where S* is phosphor Serine) was used as the 
substrate. 
2.2.14 SDS-PAGE separation of proteins 
Two different SDS-PAGE systems were used for this study. NuPAGE 
4-12% Bis-Tris pre-cast gels (Life Technologies) were used for mass 
spectrometry applications and for autoradiography after kinase assays. For 
all other experiments, the ATTO self-assemble gel system for gel 
electrophoresis was employed (ATTO, Japan). The SDS-PAGE gels were 
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assembled by first pouring the SDS-PAGE gel mix (a solution containing 
0.375 M Tris/HCl pH 8.8, 0.1% (w/v) SDS, 10% (w/v) acrylamide and 0.075% 
(w/v) ammonium persulphate) to which polymerisation was initiated by the 
addition of 0.1% (v/v) tetramethylethylenediamine (TEMED) just prior to 
pouring. 100 % ethanol was then pipetted on top of the gel gently to level the 
surface and extract bubbles. After at least 20 minutes of polymerisation the 
ethanol was removed and a stacking gel (0.125 M Tris/HCl pH 6.8, 0.1% 
(w/v) SDS, 4% (w/v) acrylamide, 0.075% (w/v) ammonium persulphate and 
finally 0.1% (v/v) TEMED) was poured immediately on top of the pre-set 
SDS-PAGE gel. A 12-well comb was inserted into the stacking gel prior to its 
polymerisation. Life Technologies 4-12% Bis-Tris gels were run using Novex 
NuPAGE 3-[N-morpholino] propane sulphonic acid (MOPS) running buffer. 
ATTO gels were run using running buffer which contained 25 mM Tris/HCl pH 
8.3, 192 mM glycine and 0.1% (v/v) SDS. Unless stated otherwise 20 µg of 
proteins was loaded for gel electrophoresis. The gel electrophoresis was 
performed at a constant voltage of 200V for 1h for the Novex gels and 180V 
for 1h and 25 minutes for ATTO gels.  
2.2.15 Coomassie Blue Protein staining of gels 
After SDS-PAGE, protein separation could be visualised by in gel 
staining of the proteins using colloidal Coomassie Blue staining solution (Life 
Technologies). Gels were stained using the manufacture’s protocol for 1h to 
overnight, depending on the staining level that was needed, at RT with 
constant shaking on a rocking platform. To destain the gel, deionised water 
was used with several changes of water until the background staining was 
reduced and the protein bands were visible. 
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2.2.16 Mass spectrometry 
2.2.16.1 In gel digestion of proteins 
All preparation steps for mass spectrometry analysis, unless stated 
otherwise, were performed under a laminar flow hood (Model A3VB, Bassaire 
Limited) to minimize contamination of the samples. Accordingly clean 
disposable scalpels were used to excise the protein bands of interest from 
Coomassie-stained SDS-PAGE gel. Gel pieces were sequentially washed 
with 0.5 ml 50% acetonitrile (ACN), 100 mM NH4HCO3 and finally in 50% 
ACN and 50 mM NH4HCO3. All washes were performed by shaking for 10 
minutes and aspirating the supernatant after each wash. In order to reduce 
the disulphide bonds, the excised gel bands were first reduced with 10 mM 
DTT in 100 mM NH4HCO3 for 45 min at 65°C and then alkylated by 
incubation with 50 mM iodoacetamide in 100 mM NH4HCO3 for 30 min at RT 
with constant agitation. To destain the gel pieces completely, they were 
washed repeatedly with 100 mM NH4HCO3 until Coomassie was not visible 
and subsequently with 50% ACN and 50 mM NH4HCO3. Then 0.3 ml ACN 
was used per gel piece for 15 min at RT. Subsequently the ACN was 
removed and the dehydrated gel pieces were dried completely in a 
SpeedVac. To digest the proteins in the gel pieces, 30 µl of 25 mM 
Triethylammonium bicarbonate containing Trypsin (5 μg/ml) was added to the 
gel pieces and incubated for 30 minutes at 30°C. Then 170 µl of deionised 
water was added and the digestion allowed to proceed overnight at 30°C with 
constant shaking. The following morning 200 µl of ACN was added to the 
digest and incubated at RT for 15 min. The supernatant was transferred to 
clean, keratin-free, Eppendorf tubes and subsequently SpeedVac-ed to 
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complete dryness. In the meantime, 100 μl 50% ACN/2.5% formic acid was 
added to the remaining gel pieces to maximise the peptide recovery. When 
the first SpeedVac was complete, the supernatant from the gel pieces was 
combined with the dried extraction and the sample were SpeedVaced to 
complete dryness. Peptide samples were stored at -20°C prior to analysis by 
Mass spectrometry. 
2.2.16.2 Protein mass fingerprinting 
The digested peptides (see 2.2.15.1) were reconstituted in 5% ACN 
and 0.1% formic acid and afterwards injected into a nano liquid 
chomatography system coupled to a LTQ-orbitrap mass spectrometer 
(Thermo Scientific). The obtained data files (raw files) were converted to 
MSM files that were afterwards submitted to the in-house Mascot server. The 
matching database was the IPI human database and the oxidation of 
methionine was specified as a variable modification. Peptide tolerance was 
20ppm for precursor ions and 1.0Da for fragment ions (MSMS tolerance). 
Liquid chromatography-mass spectrometry (LC-MS) analysis was performed 
in the in-house mass spectrometry facility by Dr. David Campbell and Mr 
Robert Gourlay. 
2.2.16.3 Identification of phosphorylated peptides 
The phosphorylated FAM83G/PAWS1 protein (see section 2.2.12) was 
digested as described above (see section 2.2.16.1). The dried peptides were 
reconstituted in 5 % ACN and 0.1 % trifluoroacetic acid (TFA) before injected 
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into a 218TP5215 C18 column that was equilibrated with 0.1 % TFA for 
reverse phase HPLC run. The column was developed with a linear ACN 
gradient at a flow rate of 0.2 ml/min and fractions of 100 µl were collected. 
The major eluting peptides were analysed by LTQ-orbitrap mass 
spectrometer (Thermo Scientific). The peptides were also coupled to 
Sequelon-AA membrane and subjected to solid-phase Edman degradation as 
previously described (Campbell and Morrice, 2002). The HPLC, LTQ-orbitrap 
mass spectrometry and Edman degradation was performed by Mr. Robert 
Gourlay.  
2.2.17 Immunoblotting analysis 
Following resolution of extracts and IPs by SDS-PAGE (see section 
2.2.14), samples were transferred onto nitrocellulose or methanol activated 
polyvinylidene fluoride (PVDF) membranes. This was performed using a 
Mini-Cell (BioRad) transfer system at 90V for 1.5 h in 1X transfer buffer 
(25mM Tris/HCl pH 8.3, 192mM glycine, 20% (v/v) methanol). Efficiency of 
the transfer was assessed by visualising the blue molecular weight markers 
or by staining the membranes with PonceauS solution. The transferred 
membranes were blocked in TBS-T containing either dried non-fat milk (5% 
(w/v)) or IgG-free BSA (5% (w/v)), depending on the primary antibody. In both 
cases, blocking was done for 1 h at RT. The primary antibodies were diluted 
in 5 ml of TBS-T containing either dried non-fat milk (5% (w/v) or IgG-free 
BSA (5% (w/v)) and added to the membranes for 16 h at 4°C with constant 
agitation to ensure an even access across the membranes. Membranes were 
then washed 4x5 minutes with TBS-T, before being incubated with the HRP-
conjugated secondary antibodies for 1 h at RT under constant agitation. All 
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secondary antibodies were used at 1:10000 dilutions in TBS-T containing 5% 
(w/v) dried non-fat milk. The membranes were then washed 4x5 minutes in 
TBS-T. Detection was performed by using enhanced chemiluminescence 
reagent (ECL) (incubated for 3 minutes) followed by exposure on the Medical 
X-Ray Film in the dark and development of the film using an SRX-101A 
automatic film processor (Konica Minolta). 
2.2.18 Generation of antibody 
Derived peptides from human FAM83G/PAWS1 (amino acids ranging 
from 715-815), P-FAM83G/PAWS1 S610 (amino acids 603-613) as well as 
polypeptides of SMAD1 (amino acids 144-268), SMAD2 (amino acids 87-
107), SMAD3 (amino acids 158-178) and CULLIN3 (amino acids 544-end) 
were N-terminal GST-tagged. These polypeptides were then used as 
antigens for antibody production by injection into sheep (all peptides except 
P-FAM83G/PAWS1 S610) or rabbit (P-FAM83G/PAWS1 S610). The antigens 
were emulsified, prior to the injection, in Freund’s adjuvant. A pre-immune 
bleed was taken on the same day as the first injection of antigen. Each 
animal was immunised every 28 days up to a total of 4 injections. Seven 
days after injections two, three and four a blood sample was collected. These 
were called bleed 1 to 3. Each bleed had to clot at 4°C overnight. Afterwards, 
the antiserum was decanted though glass wool, after centrifugation for 1h at 
1500g at 4°C, and was stored at -20°C. Antisera were raised in sheep or 
rabbit at Scottish National Blood Transfusion Service (Penicuik). In order to 
purify the serum, it was heated for 20min at 56°C and then filtered through a 
0.45 µm filter. The anti-serum was subsequently diluted 1:1 in 50mM Tris/HCl 
pH 7.5, 2% Triton X-100 and in order or minimse the cross reactivity of the 
- 50 - 
antibodies present in the anti-serum with GST, the GST antibodies were 
depleted using activated CH Sepharose beads coupled to GST. The GST 
cleared flow-through was affinity purified against the given antigen. The 
antibodies were first eluted in 50mM glycine pH 2.5 before being dialyzed 
overnight in PBS. All in-house antibodies used in this thesis were generated 
and purified by the DSTT antibody production team, as described above. The 
coordination of the antibody production is done by Dr. H. McLauchlan and Dr. 
J. Hastie (DSTT/University of Dundee). 
2.2.19 Double thymidine block for cell cycle arrest 
The cells were seeded at about 20% confluency before treated with 2 
nM thymidine for 16 h. Afterwards the cells were washed twice with PBS and 
left growing in standard medium for 10 h before treated again with 2nM 
thymidine for further 16 h. Finally, the cells were washed three times with 
PBS and given standard medium afterwards in order to be subsequently 
harvested at indicated time points for FACS and immunoblotting analysis. 
The cells were harvested by using standard trypsinisation as described in 
section 2.2.1, and then resuspended in 10 ml of ice-cold PBS. 9 ml where 
spun down at 1000 rpm for 5 min before being processed for cell lysis and 
subsequent immunoblotting analysis as described above. The remaining 1 ml 
was resuspended with ice-cold 70% (v/v) ethanol while vortexed. Samples 
were then stored at -20 °C until or immediately washed twice in PBS with 1% 
(w/v) BSA before resuspensed in 300 µl PBS containing propidium iodide (50 
µg/ml), ribonuclease A (50 µg/ml) and TritonX-100 (0.1% v/v). Samples were 
subsequently incubated at room temperature for 20 min in the dark before 
analysis by flow cytometry on a Beckman FACS Calibur Flow. Cells were 
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gated on the flow cytometer using forward scatter and side scatter 
parameters (linear scale), DNA was detected in the FL2-H channel (linear). 
FL2-W and FL2-A were used to distinguish single cells. Cell numbers in 
different cell cycle stages were measured on FlowJo using the Dean-Jett-Fox 
method (Fox, 1980). 
2.2.20 Fluorescence microscopy 
U20S cell stably expressing GFP-PAWS1 were seeded onto glass 
chamber slides and were allowed to grow for 24 h, while the expression of 
GFP-PAWS1 was induced by doxycycline. The cells were stimulated with 
BMP-2 (25 ng/ml) or TGFß (50 pM) for 45 min before fixation with 4% 
paraformaldehyde for 10 minutes at RT. The cells were then washed 3 times 
with PBS and once with deionised water before Prolong Gold mounting 
medium (Life Technologies), which contained the nuclear stain 4',6-
diamidino-2-phenylindole (DAPI), was added and a coverslip mounted onto 
the chamber slides. The mounted slides were left to dry in the dark for at 
least 2 h. Flourescence images were analysed using a Deltavision Core 
Restoration microscope (Applied Precision, USA). 
2.2.21 DNA and RNA concentration measurements 
In order to measure the concentrations of isolated DNA or RNA in 
aqueous solution, the NanoDrop spectrophotometer (Life Technologies) was 
used. It was calibrated using nuclease free water. The absorbance 
measurements were done at 260 nm according to the manufacturer’s 
instructions. 
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2.2.22 Real time quantitative reverse transcription PCR (qRT-PCR) 
cDNA was made using the SuperScript cDNA kit (Life Technologies) 
from 1 µg of the isolated total RNA using the RNeasy kit (Qiagen), both used 
as stated in the manufacturers protocols. qRT-PCR reactions were 
performed either using a 96-well plate or 384-well plate format. When 96-well 
format was used, the reactions were performed in triplicates, where each 20 
µl reaction included forward and reverse primers (0.5 µM each), 50% SYBR 
Green (BioRad) and cDNA (2.5% of reverse transcriptase reaction). When 
the 384-well format was used the reactions where performed in 
quadruplicates (10 µl each), with forward and reverse primers (0.5 µM each), 
50% SYBR Green (BioRad) and cDNA (2.5% of reverse transcriptase 
reaction) in a CFX 384 Real time System qRT-PCR machine (BioRad). In 
both cases all the data presented in the thesis represent at least three 
independent biological replicates. 
The data was normalised to the geometrical mean of two 
housekeeping genes (GAPDH and HPRTI) and the 2(-∆∆C(T)) method (Livak 
and Schmittgen, 2001) was used to analyse the qRT-PCR data in Microsoft 
Excel. The graphical visualisation and statistical analysis was done using 
GraphPad Prism 5 
2.2.23 Statistical analysis and representation of results 
The data is presented as the mean ± SD. Statistical significance of 
differences between experimental groups was assessed using the two-way 
analysis of variance (ANOVA) test with Bonferroni post tests. Differences in 
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means were considered significant if the p-value was smaller than 0.05. 
Differences with p<0.05 were indicated as “*”, p<0.005 were indicated as “**” 
and p<0.001 were indicated as “***”. 
All results shown in this thesis are representatives of independent 
biological replicate experiments that have been performed at least 3 times if 
not indicated otherwise. 
2.2.24 DNA and RNA agarose gels 
The size and the purity of DNA PCR products and the RNA quality for 
the RNA sequencing were assessed by electrophoresis on 1% agarose gels. 
Each gel contained a 1:1000 dilution of SYBR Safe nucleotide gel stain (Life 
Technologies). Gels were submerged in 1x TAE running buffer using an 
agarose gel tank. Between 100 and 500ng of DNA and RNA, respectively 
was loaded onto a gel together with DNA loading dye. 500 ng of a 1 kbp DNA 
ladder (Life Technologies) was used as a marker. Gels were run at 100V for 
approximately 20 to 25 minutes. The stained nucleotide complexes were 
visualised using a UV transilluminator. 
2.2.25 RNA-sequencing 
1 µg of total RNA, isolated with the RNeasy kit (Qiagen), was used to 
generate libraries using Illuminia’s TruSeq RNA kit according to the 
manufacturer’s instructions. Indexed adapters were ligated to the ends of the 
cDNAs in order to perform single end multiplex sequencing on Illumina’s 
HiSeq2000 platform. Reads were mapped to the human genome using CLC 
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Genomics Workbench v 5.0. Mapped reads were subsequently analysed for 
differential expression using Avadis® NGS software, Version 1.3.0, Build 
163982 (Strand Scientific Intelligence, Inc., San Francisco, CA, USA). The 
analysis of RNAseq data was performed by Dr. Kevin Dingwell (MRC NIMR, 
London). 
2.2.26 Plasmid transformation, amplification and isolation 
For transformation of plasmids on to competent E. coli DH5α cells, 
cells stored at -80°C were thawed slowly on ice. Approximately 10 ng of 
plasmid DNA was added to the cell suspension and mixed gently by tapping. 
After 2 min incubation on ice, the cells were subjected to heat-shock at 42°C 
for 1 minute to facilitate DNA uptake. The cells were then placed on ice for 2 
min. Finally, the cells were plated onto LB/100μg/ml ampicillin agar plates 
and incubated for 16 h at 37 °C.  
One transformed colony was used to inoculate 250 ml LB/100 μg/ml 
Amp media. This culture was left growing overnight at 37°C under constant 
shaking. The culture was harvested by centrifugation at 3,000 rpm for 10 min 
at 4°C in a J-6 Beckman centrifuge. The plasmid DNA was then isolated 
using the Qiagen DNA Maxi Kit according to the manufacturer’s instructions. 
Bacteria from 250 ml log phase cultures typically yielded between 500 ng and 
1000 ng of plasmid DNA. 
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2.2.27 Purification of GST-tagged FAM83G/PAWS1 from E.coli 
The bacterial expression vector (pGEX6T) encoding wild type or 
various truncation mutants of GST-PAWS1 were transformed into BL21 E.coli 
strain. A single colony of transformed bacteria was added to 50 ml LB/100 
μg/ml Amp medium and incubated overnight at 37°C in a shaking incubator, 
to generate a starter culture. This culture was then added to 1 L LB/100 
μg/ml Amp medium. The bacterial growth was monitored by measuring the 
optical density (OD) of the culture medium at 600 nm. Once the OD reached 
0.5, the expression of the GST-tagged protein was induced using 0.1 mM 
isopropyl ß-D-1-thiogalactopyranoside (IPTG). After 16 h of further growth at 
16°C, bacteria were harvested by centrifugation in a Beckman J6 rotor at 
4000 rpm for 20 min at 4°C. The pellet was re-suspended in 30 ml bacterial 
lysis buffer (25mM HEPES pH 7.6, 10% glycerol (v/v), 0.1mM EDTA, 150mM 
KCl, 1mM DTT, 1mM PMSF plus 1 tablet of Complete protease inhibitor for 
each 50 ml of lysis buffer). The bacterial lysis was facilitated by sonication 
(4x45 s bursts at 4°C). If the isolation was not continued immediately, the 
extracts were snap frozen in liquid nitrogen and stored at -80°C. 
Subsequently the extracts were centrifuged at 20000 g for 20 min at 4°C. 1 
ml equilibrated Glutathione Sepharose 4B (GSH-Sepharose) beads per 
500ml of original culture were added to the cleared extracts and incubated for 
1 h at 4°C in a shaking platform. The beads were collected afterwards by 
centrifugation at 3000 rpm for 15 min at 4°C. After removal of the 
supernatant, the beads were pipetted onto new tubes. The beads were 
washed five times with bacterial lysis buffer containing 0.5 M NaCl and twice 
with buffer A. The proteins were eluted by adding an equal volume of 
glutathione elution buffer to the beads and incubate this mixture for 5 minutes 
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at 4°C. The eluate was collected before a second elution was done using 
50% of the bead volume. Both eluates were combined and dialysed using 1 L 
of buffer A on a Slide-A-Lyzer Cassette (Thermo Scientific) for 16 h at 4°C. 
The protein concentration of the purified proteins was determined (see 2.2. 6) 
before they were aliquoted, snap frozen in liquid nitrogen and stored at -
80°C. 
2.2.28 Xenopus laevis embryo manipulations 
Xenopus laevis embryos were generated by in vitro fertilization and 
staged according to Nieuwkoop and Faber (Nieuwkoop and Faber, 1994). 
Microinjections were carried out in 4% Ficoll in 75% Normal Amphibian 
Medium (Manning et al.), and when they reached stage 8, they were 
transferred to 10% NAM. RNA for injections was synthesized in vitro using 
the MessageMachine kit (Ambion) according to the manufacturer’s 
instructions. For axis duplication assays, mRNA was injected into a single 
ventral blastomere at the 4 cell stage. Secondary axes were scored at stage 
32 and were classed as complete if the second axis had eyes and a cement 
gland. 
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3 The role of FAM83G/PAWS1 in BMP signalling and 
beyond 
3.1 Introduction 
The basic mechanisms of the canonical BMP pathway are well 
established: binding of BMP ligands to their corresponding receptors leads to 
the phosphorylation of SMAD1, 5 and 8 transcription factors. This leads to 
their association with SMAD4 and translocation to the nucleus, where they 
regulate the transcription of target genes. Yet the outcome of cellular 
responses to BMP cytokines is cell type and context dependent. Complex 
mechanisms have evolved to control and regulate the fate of BMP signals in 
cells in different biological contexts. Multiple signalling networks modulate 
BMP signalling by providing regulatory inputs at each step of the pathway. 
While many regulatory inputs have been reported, gaps remain in our 
understanding of the full scope of regulation. SMAD proteins, as key 
intracellular mediators of BMP signalling, are prominent for regulatory inputs 
from other proteins or signalling networks. 
A proteomic approach was undertaken to identify interactors of 
SMAD1 fragments. From this screen, FAM83G was identified as a novel 
interactor of FLAG-SMAD1 fragment consisting of the linker and MH2 
domains. Interestingly, no cellular functions of FAM83G have been reported. 
Therefore, I set out to investigate the biochemical mechanisms by which 
FAM83G could potentially regulate BMP signalling.  
- 58 - 
3.1.1 Family with sequence similarity member 83 (FAM83A-H) 
The family with sequence similarity 83 (FAM83) consists of 8 different 
members (FAM83A-H). They all share sequence similarity within the domain 
of unknown function 1669 (DUF1669), which is located towards the N-
terminus of the protein (Figure 3-1). The DUF1669 contains a putative 
phospholipase D active site motif (PLDc). Sequence alignment of members 
of the FAM83 protein family revealed that they share between 32 and 48% 
protein sequence similarity within the DUF1669 domain. Outside the 
DUF1669 domain, the different FAM83 class members are very divergent 
and show no obvious protein sequence similarities (Figure 3-1). 
FAM83A was recently identified from a breast cancer cell 
overexpression screen for proteins whose expression resulted in resistance 
to EGF receptor tyrosine kinase inhibitors (EGFR-TKI) (Lee et al., 2012). 
Cells with high levels of FAM83A were found to have increased proliferation 
and invasion rates as well as resistance to EGFR-TKI. In contrast, depletion 
of FAM83A inhibited tumour proliferation in mice and significantly inhibited 
the malignant nature of cancer cells to EGFR-TKI susceptible phenotype 
(Lee et al., 2012).  
FAM83B was also reported as a potential oncogene, using a 
validation-based insertional mutagenesis (VBIM) approach, whereby it was 
found to drive the transformation of human mammary epithelial cells 
(Cipriano et al., 2012). Cipriano and colleagues demonstrated that the 
expression of FAM83B, like FAM83A, was linked to tumour growth and 
EGFR-TKI resistance. FAM83A was found to be highly expressed in a variety 
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of different tumours and linked to poor prognosis in cancer patients (Cipriano 
et al., 2012)  
Because FAM83A and B were both reported to play a role in EGFR-
TKI resistance and cancer progression, it was hypothesized that FAM83 
members could comprise a novel oncogene family that could potentially be 
targeted for drug discovery (Grant, 2012, Cipriano et al., 2012, Lee et al., 
2012). 
FAM83D or CHICA has been reported to associate with the mitotic 
spindle apparatus, and interact with the spindle protein KID (Santamaria et 
al., 2008). It was shown to be cell cycle regulated and phosphorylated. 
Depletion of FAM83D from cells resulted in shorter spindle assembly and 
spindle misalignment (Santamaria et al., 2008). 
FAM83H is associated with the autosomal dominant hypocalcified 
amelogenesis imperfecta disease. Amelogenesis imperfecta (AI) is a group of 
diverse inherited disorders that cause dental enamel defects, whereby the 
calcification of the enamel is abnormal (Lee et al., 2008). Although several 
reports have shown the relationship between AI and mutations in FAM83H, 
there is still complete lack of insights into the biochemical properties by which 
FAM83H is involved in amelogenesis (Kweon et al., 2013, Lee et al., 2011, 
Ding et al., 2009, Hyun et al., 2009, Lee et al., 2009, Wright et al., 2009, Hart 
et al., 2009, Lee et al., 2008, Kim et al., 2008). The calcification defect 
phenotypes of FAM83H mutations are potentially interesting as they imply 
potential defects in BMP signalling in tooth development. 
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The other members of the FAM83 family, FAM83C, E, F and G remain 
to be characterised and as of yet there are no reports describing their 
function or links to any diseases. 
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Figure 3-1 The FAM83 (A-H) family of proteins 
(A) Sequence alignment of amino acids of theFAM83 family members using 
BoxShade server. Conserved amino acids are presented in black boxes while 
similar residues are in grey boxes. Amino acids in yellow indicate the conserved 
DUF1669 domain and amino acids in blue indicate the putative PLDc motif. (B) 
Phylogenetic tree of FAM83A-H generated using ClustalW.  
A 
B 
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3.1.1.1 FAM83G/PAWS1 
The human family with sequence similarity member 83G (FAM83G) is 
823 amino acid long protein that is encoded by the FAM83G gene located on 
chromosome 17p11.2. Apart from the domain of unknown function 1669 
(DUF1669; amino acids 9-310) in its N-terminal region (Figure 3-2), there are 
no other known domains within FAM83G. The DUF1669 domain contains a 
putative phospholipase D active site motif (PLDc; Figure 3-2).  
In humans FAM83G is most closely related to FAM83F (Figure 3-23B) 
FAM83G is highly conserved in mammals and closely related to chimpanzee 
(Figure 3-3A and B). Xenopus laevis FAM83G shares 45% overall amino acid 
identity, whereby the N-terminus is highly conserved. Although the C-
terminus is diverse, there are some regions that are highly conserved (Figure 
3-3A and Table 3-1) 
The biochemical roles of FAM83G in cells and organisms are 
unknown. To date there is only one short report, which was published only 
very recently, describing the wooly (wly) phenotype in mice (Radden et al., 
2013). The authors demonstrate that in these mice there was a deletion of 
955 bp from the genomic DNA transcribing the FAM83G gene, resulting in a 
frame shift mutation predicted to lead to a shortened FAM83G gene. The 
FAM83G protein expression in these mice was not investigated (Radden et 
al., 2013). One report identified FAM83G as an interactor of CIN85. In this 
study, the SH3 domain of CIN85 was used as bait to identify novel SH3 
domain binding proteins (Havrylov et al., 2009).  
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Several putative phosphorylation sites on FAM83G have been 
reported ((Figure 3-2) (Christensen et al., 2010, Dephoure et al., 2008, 
Rigbolt et al., 2011, Shiromizu et al., 2013, Van Hoof et al., 2009)). All of 
these phosphorylation sites have been identified by mass spectrometry and 
none have been confirmed by other techniques, albeit all of the listed 
phosphorylation sites have been reported by more than one group. 
Furthermore no kinases that mediate the phosphorylation have been 
assigned for each phosphorylation site.  
Using the Sanger Institute cancer COSMIC database for gene 
mutations in cancer patients and cells, I have generated a map of point 
mutations in FAM83G (Figure 3-32) that are reported for various cancers 
(http://cancer.sanger.ac.uk/cosmic/gene/overview?ln=FAM83G). 
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Figure 3-2 Schematic diagram of FAM83G/PAWS1 
Schematic diagram of FAM83G/PAWS1 protein showing all reported 
phosphorylation sites (black). All the point mutations included in the Sanger 
Institute COSMIC database for FAM83G/PAWS1 in cancer cell lines and 
patient samples are indicated (Groppe et al.). The DUF1669 domain (yellow) 
and the putative PLDc domain (blue) are also indicated. 
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Figure 3-3 FAM83G/PAWS1 is conserved in vertebrates  
(A) Amino acid sequence alignment of FAM83G/PAWS1 in different 
species using BoxShade server. Conserved amino acids are presented in 
black boxes and similar amino acids in grey boxes. (B) Phylogenetic tree of 
FAM83G/PAWS1 in different species generated using ClustalW. 
 
Organism 
amino acid 
sequence identity 
Protein length 
in amino acids 
Human (Homo sapiens) 100% 823 
Chimpanzee (Pan troglodytes) 99.00% 823 
Dog (Canis lupus familiaris) 83.10% 822 
Cattle (Bos taurus) 81.60% 817 
Mouse (Mus musculus) 80.70% 812 
Frog (Xenopus laevis) 45.30% 933 
Table 3-1 Summary of the analysis of FAM83G/PAWS1 protein sequence 
similarity and length in different species  
Homo sapiens
Pan troglodytes
Canis lupus familiaris
Bos taurus
Mus musculus
Xenopus laevis
A
B
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3.1.2 The interplay between BMP and Wnt signalling during early 
Xenopus development 
Xenopus laevis, the African clawed frog is an established experimental 
model to study vertebrate embryogenesis. Its development is very tightly 
regulated whereby the fertilised egg develops into a complete organism. 
Nieuwkoop and Faber divided Xenopus develpment into 50 different stages, 
the initial cleavage stages that results in the formation of the blastula, which 
subsequently undergoes gastrulation followed by the initiation of neurulation 
and organogenesis. Axis elongation occurs during the tailbud stages that 
eventually develops into an independently feeding tadpole (Nieuwkoop and 
Faber, 1994). Two important and extensively studied signalling pathways in 
this context are the BMP and Wnt pathways (Hoppler and Moon, 1998). 
3.1.2.1 Wnt signalling pathway 
The Wnt signal transduction pathway can be divided into canonical (ß-
catenin-dependent) Wnt signalling pathway, non-canonical planar cell polarity 
(PCP) Wnt signalling pathway and non-canonical Wnt/calcium signalling 
pathway (Rao and Kuhl, 2010). The focus of this thesis, in respect to Wnt 
signalling, concentrates on the canonical Wnt signalling pathway. Canonical 
Wnt signalling starts with Wnt ligands binding to the extra-cellular binding 
domain of their corresponding transmembrane G-protein coupled receptors 
((Figure 3-4(Schulte and Bryja, 2007)). These receptors are called Fizzled 
receptors (Fz) and together with co-receptors LRP 5/6 are activated when 
they bind Wnt ligands (Kestler and Kuhl, 2008). The canonical Wnt pathway 
is defined by the intracellular signal transducer protein ß-catenin. ß-catenin 
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is, in the absence of Wnt ligands, constitutively phosphorylated and 
ubiquitylated and subsequently degraded by the proteasome (MacDonald et 
al., 2009). ß-catenin is phosphorylated by the “destruction complex” 
comprising AXIN, APC, GSK3, CK1α and PP2A that leads to its recognition 
by the E3 ubiquitin ligase ß-TrCP (Stamos and Weis, 2013). Binding of Wnt 
ligands to the receptors, leads to the breakdown of the destruction complex 
by trapping the complex at the plasma membrane (Kestler and Kuhl, 2008). 
This leads to the accumulation of ß-catenin in the cytosol which subsequently 
translocates to the nucleus, where it drives transcription by binding to the 
TCF/LEF family of factors (DasGupta and Fuchs, 1999). Active Wnt signalling 
has been reported to co-regulate adult tissue homeostasis and is of high 
importance in Xenopus axis specification and development (Logan and 
Nusse, 2004). Tight spatial and temporal regulation of Wnt signalling is 
especially important during embryogenesis. Therefore specific antagonists, 
like DKK, WIF1, SFRP and others have evolved that can block Wnt signalling 
(Logan and Nusse, 2004). 
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Figure 3-4 A schematic overview of the canonical Wnt signalling pathway 
Top panel illustrates the intracellular canonical Wnt signalling cascade that 
leads to the degradation of ß-catenin in the absence of Wnt ligands. Lower panel 
illustrates the intracellular canonical signalling cascade in the presence of Wnt 
ligands.  
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3.1.2.2 Early Xenopus embryogenesis 
Sperm entry at the animal pole of the egg initiates an internal 
reorganisation of the yolk driven by microtubules (Rowning et al., 1997). This 
is called cortical rotation and is characterised by the first patterning of the 
dorso-ventral (D-V) axis. The D-V axis patterning is initiated by the 
relocalisation of maternal Wnt pathway components like Dsh from the vegetal 
pole (opposite of the animal pole) towards the dorsal side of the embryo 
(Miller et al., 1999, Itoh et al., 1998). This, in turn, leads to ß-catenin 
stabilisation and subsequent nuclear translocation in the whole dorsal region 
of the embryo (Schneider et al., 1996).  
In the early blastula stage, the vegetal side expresses other signalling 
molecules like maternal VegT, which belongs to the TGF-ß signalling 
pathway. This leads to the induction of NODAL associated protein expression 
(XNRs). This NODAL signal induction is further enhanced by ß-catenin driven 
signalling on the vegetal-dorsal side (Nieuwkoop center), leading to a 
NODAL signalling gradient along the vegetal embryo side, which is now 
referred to as the endoderm (Figure 3-5 (Takahashi et al., 2000, Agius et al., 
2000). Vegetal NODAL signalling induces mesoderm formation, high NODAL 
in the dorsal-mesoderm induces the Spemann organizer while low NODAL 
signalling defines the ventral-mesoderm formation that later gives rise to the 
ventral signalling center (Figure 3-5 (De Robertis and Kuroda, 2004)). 
Furthermore, ß-catenin signalling in the dorsal animal side leads to the 
expression of BMP antagonists like NOGGIN and CHORDIN, that later play a 
role in the development of the central nervous system (CNS) (Wessely et al., 
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2001). These defined signalling processes described above restructure the 
embryo during the blastula by inducing the formation of the three germ 
layers: ectoderm (animal/anterior side), mesoderm and endoderm 
(vegetal/posterior side), each of which later forms different tissues and 
organs (De Robertis and Kuroda, 2004, Blitz et al., 2006). 
During gastrulation the D-V axis pattering is further defined by the two 
opposing signalling centers at the ventral (Ventral centre) and dorsal sides 
(Spemann organizer, (Hamburger, 1988)). Whereas the ventral centre 
expresses the BMP and BMP related cytokines, in the Spemann organizer 
antagonists of BMP and also Wnt signalling pathways like CHORDIN, 
NOGGIN, DKK1 and CERBERUS among many others are expressed (Figure 
3-5 (De Robertis and Kuroda, 2004)) . This leads to a gradient of BMP 
signalling along the D-V axis and a gradient of Wnt signalling along the 
anterior-posterior (A-P) axis (Eivers et al., 2008). The inhibition of both Wnt 
and BMP signalling at the dorsal side is important for the development of the 
CNS and the induction of head structures (De Robertis and Kuroda, 2004, 
Kiecker and Niehrs, 2001). CERBERUS, a powerful antagonist of both 
signalling pathways, has been shown to induce head structures when 
expressed ectopically (Glinka et al., 1997). 
Taken together BMP and Wnt signalling pathways are key pathways 
during Xenopus embryogenesis and are of special interest because of their 
defining dorso-ventral and anterior-postirior axis pattering ability. 
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Figure 3-5 Organisation in early Xenopus embryo 
Schematic overview of the Xenopus laevis embryogenesis from the blastula 
to gastrula (adapted from (De Robertis and Kuroda, 2004)). ß-catenin signalling on 
the dorsal side and VegT signalling at the vegetal side leads to the formation of the 
Nieuwkoop centre at the intersection. NODAL signalling in the vegetal pole induces 
mesoderm formation. High NODAL signalling is needed for the induction of the 
Spemann Organizer at the dorsal-mesoderm and low NODAL signalling is needed 
for the formation of the ventral signalling centre. 
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3.2 Results 
3.2.1 A proteomic approach identifies FAM83G/PAWS1 as a novel 
interactor of SMAD1  
In order to uncover novel regulators of the BMP pathway, a proteomic 
approach was undertaken to identify interactors of SMAD1. For this, a N-
terminally FLAG-tagged SMAD1 fragment consisting of the linker and MH2 
domains or empty FLAG control was expressed in HEK293 cells and 
immunoprecipitated with anti-FLAG antibody (Figure 3-6A). Subsequently 
these immunoprecipitates (IPs) were incubated with cleared HeLa extracts. 
The immunoprecipitated proteins were resolved by SDS-PAGE and stained 
with Coomassie. The gel pieces covering the whole lane were excised and 
digested with trypsin for identification by mass fingerprinting (Figure 3-6B and 
C). The proteins identified as interactors of FLAG-SMAD1[L+MH2] IPs but 
not the control FLAG IPs included LEMD3, SMURF2 and SMAD4, all 
previously reported to be interacting partners of SMAD1 ((Pan et al., 2005, 
Zhang et al., 2001) (Figure 3-6C)). Interestingly a previously uncharacterised 
protein called FAM83G was also identified as a novel interactor of FLAG-
SMAD1[L+MH2] but not control FLAG IPs (Figure 3-6C). I have renamed this 
protein as PAWS1 (Protein Associated With SMAD1). Therefore, from here 
on the protein will be referred to as PAWS1.  
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Figure 3-6 Proteomic approach to identify novel SMAD1 interacting proteins  
(A) Schematic diagram of SMAD1 comprising the MH1, the linker and 
the MH2 domains in the upper panel. The bottom panel shows a truncation 
version of SMAD1 comprising the linker and MH2 domains. (B) Overview of 
the proteomic approach undertaken. (C) Coomassie stained gel in which the 
eluted proteins after FLAG immunoprecipitation were resolved. 
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3.2.2 Analysis of interaction between PAWS1 and SMADs 
The interaction between PAWS1 and SMAD1 was analysed using an 
N-terminal FLAG-tagged mammalian expression construct of PAWS1 (FLAG-
PAWS1) and different N-terminally HA-tagged SMAD constructs. These 
constructs were co-expressed in HEK293T cells to determine the specificity 
of the interaction between PAWS1 and SMAD proteins. HA-SMAD1 was 
detected in the FLAG-PAWS1 IPs, but HA-SMADs 2 or 3 were not (Figure 
3-7A and B). Although HA-SMADs 5 and 8 did not appear to be detected in 
FLAG-PAWS1 IPs, their expression was much lower compared to other 
SMADs (Figure 3-7A and B). Co-SMAD HA-SMAD4 and inhibitory SMAD, 
HA-SMAD7 were not detected in FLAG-PAWS1 IPs (Figure 3-7B). As BMP 
and TGF-ß can induce phosphorylation of R-SMAD proteins, it was important 
to test whether this phosphorylation could alter the association of PAWS1 to 
any of these R-SMADs. FLAG-PAWS1 was co-transfected with HA-SMAD1, 
HA-SMAD3 or HA-vector control in HEK293T cells. These cells were treated 
with or without BMP or TGF-ß and the cell extracts were subjected to a FLAG 
IPs. As expected, HA-SMAD1 was detected in FLAG-PAWS1 IPs. BMP 
treatment slightly enhanced the interaction between PAWS1 and HA-SMAD1 
(Figure 3-7C). Treating cells with or without TGF-ß did not alter the lack of 
association between HA-SMAD3 and FLAG-PAWS1 (Figure 3-7C). 
To investigate if PAWS1 interacts with SMAD1 at the endogenous 
level, extracts from HaCaT cells were used to IP SMAD1. Endogenous 
PAWS1 was detected in SMAD1 IPs but not pre-immune IgG IPs employed 
as control (Figure 3-7E). Using the crosslinking agent DSP in extracts prior to 
SMAD1 IP did not further enhance this interaction (Figure 3-7D). To ensure 
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that PAWS1 detected in SMAD1 IPs was not a contaminant, PAWS1 
expression was depleted by siRNA in HaCaT cells. SMAD1 IPs from these 
extracts were not able to pull down PAWS1 (Figure 3-7E). Consistent with the 
interaction between PAWS1 and SMAD1 at the endogenous level, 
endogenous SMAD1 was detected in PAWS1 IPs from HaCaT extracts. 
However, endogenous SMAD2 or SMAD3 was not detected in PAWS1 IPs 
(Figure 3-7F). Treatment of these cells with or without BMP or TGF-ß , did 
not significantly alter the binding of PAWS1 with SMAD1 or induce binding 
with SMAD2 and SMAD3 (Figure 3-7F).  
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Figure 3-7 PAWS1 interacts with SMAD1  
(A) HEK293 cells were transfected with FLAG-PAWS1 or indicated HA-
tagged SMADs 48 h prior to lysis. Cell extracts were subjected to FLAG 
immunoprecipitation. Extracts and IPs were subjected to SDS-PAGE before an 
immunoblotting analysis using the indicated antibodies. (B) Same as (A) except HA-
SMAD4 and 7 were included. (C) FLAG-PAWS1 and HA-tagged SMAD1 or SMAD3 
were co-transfected in HEK293 cells 48 h prior to cell lysis. The cells were treated 
with or without BMP-2 (25 ng/ml) or TGF-ß (50 pM) 1 h prior to cell lysis. FLAG 
immunoprecipitation was performed and the IPs as well as the extracts were 
subjected to SDS-PAGE before an immunoblotting analysis using the indicated 
antibodies was performed. (D) HaCaT cells were lysed in the presence or absence 
of the protein crosslinking agent DSP. Cell extracts were used for 
immunoprecipitations with either sheep IgG or anti-SMAD1 antibodies. IPs and 
inputs were subjected to SDS-PAGE before analysis by immunoblotting using 
indicated antibodies. (E) HaCaT cells were transfected with siRNA against FOXO4 
as a control or against PAWS1 (300 pmoles each per 10-cm dish) 48 h prior to lysis. 
Cell extracts were subjected to immunoprecipitation with either sheep IgG or anti-
SMAD1 antibodies. IPs and inputs were subjected to SDS-PAGE prior to 
immunoblotting analysis using the indicated antibodies. (F) HaCaT cells were 
treated with or without TGF-ß (50 pmoles) or BMP-2 (25 ng/ml) for 1 h prior to lysis. 
Cell extracts were subjected to immunoprecipitation with anti-PAWS1 antibody. IPs 
and extract inputs were subjected to SDS-PAGE and subsequently analysed by 
immunonblotting using the indicated antibodies.  
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3.2.3 Mapping interaction domains on SMAD1 and PAWS1 
In order to map the interaction between PAWS1 and the functional 
domains of SMAD1, FLAG-PAWS1 was co-expressed with N-terminal HA-
tagged SMAD1 truncation fragments comprising the MH1, the MH2, the 
linker domain or combinations of these domains in HEK293T cells (Figure 
3-8A). As expected, FLAG-PAWS1 IPs displayed interaction with the full-
length HA-SMAD1 (Figure 3-8B). Among the HA-SMAD1 truncated domains, 
the MH2 domain of SMAD1 interacted with FLAG-PAWS1, however there 
truncated MH2 domain also interacted with the FLAG-beads. The MH1 and 
the linker domains or the combination of these (MH1+Linker domains) did not 
interact with PAWS1 (Figure 3-8B). Nonetheless, these results are not 
sufficient to confidently suggest that the MH2 domain is sufficient to mediate 
the interaction between SMAD1 and PAWS1. No clear domain could be 
mapped within PAWS1 that could mediate the interaction with SMAD1.  
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Figure 3-8 Mapping the interaction domains between SMAD1 and PAWS1 
(A) Schematic representation of the wild-type SMAD1 together with the 
indicated domain truncations of SMAD1. (B) HEK293 cells were co-transfected with 
FLAG-PAWS1 and the indicated HA-tagged truncation versions of SMAD1 48 h prior 
to lysis. Extracts were used for anti-FLAG immunoprecipitation and subsequently 
IPs and extract inputs were subjected to SDS-PAGE before analysis by 
immunoblotting using the indicated antibodies. 
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3.2.4 SMAD1 linker phosphorylation does not impact PAWS1 
interaction 
The linker domain of SMAD1 is known to be phosphorylated by 
MAPKs like ERK1/2, p38 MAPK and JNK as well as CDK8/9. These 
phosphorylation events have been reported to occur at Ser187, Ser195, 
Ser206 and Ser214. To test if the linker phosphorylation interferes with 
SMAD1 binding to PAWS1, HA-SMAD1 or HA-SMAD1 EPSM mutant, where 
the four linker domain serine residues were mutated to alanine to prevent 
phosphorylation (Figure 3-9A), were co-expressed with FLAG-PAWS1 in 
HEK293 cells. The cells were treated with or without BMP. FLAG IPs from the 
cell extracts displayed a robust interaction with either the wild-type HA-
SMAD1 or the HA-SMAD1 EPSM mutant (Figure 3-9B). The linker domain 
phosphorylation at Ser206 in SMAD1 was evaluated by the phospho-linker 
antibody (P-SMAD1 S206). The difference detected in the linker 
phosphorylation intensity in the presence or absence of FLAG-PAWS1 was 
consistent with the lower levels of HA-SMAD1 when co-expressed with 
FLAG-PAWS1 (Figure 3-9B).  
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Figure 3-9 SMAD1 linker phosphorylation does not impact association with 
PAWS1  
(A) Schematic representation of the SMAD1 wild-type protein (top) and the 
SMAD1 phospho-linker mutant, SMAD1 EPSM (bottom). (B) HEK293 cells were co-
transfected with or without FLAG-PAWS1 and HA-SMAD1 or HA-SMAD1 EPSM 48 
h prior to lysis. The cells were treated with or without BMP-2 (25 ng/ml) for 1 h prior 
to lysis. Extracts were used for anti-FLAG immunoprecipitation. The IPs and extract 
inputs were subjected to SDS-PAGE and subsequently analysed by immunoblotting 
using the indicated antibodies. 
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3.2.5 PAWS1 co-elutes with SMAD1 in a size exclusion 
chromatography 
The robust endogenous interaction between PAWS1 and SMAD1 
prompted me to investigate if they form a macromolecular complex. To 
address this, cell extracts from HaCaT cells treated with or without BMP or 
TGF-ß, were subjected to separation by size-exclusion chromatography in a 
Superose™ 6 Column. 32 fractions were collected (Figure 3-10). Under basal 
unstimulated conditions, SMAD1 and SMAD2/3 predominantly eluted in 
fractions X-Z which by and large corresponds to their native molecular 
masses (around 50-55 kDa) (Figure 3-10A). Stimulating the cells with BMP, 
which induces the posphorylation of SMAD1, resulted in a slight shift in the 
elution of phospho-SMAD1 towards higher molecular weight fractions 
(Fractions V-W; Figure 3-10B). Additionally phospho-SMAD1 also eluted at 
its predicted molecular weight (Fractions X-Z; Figure 3-10B). TGF-ß 
stimulation, which induces the phosphorylation of SMAD2/3, caused a 
significant change in the elution profile of phospho-SMAD2/3. The majority of 
phospho-SMAD2/3 eluted in fractions T-Y, which is significantly higher than 
their predicted molecular weights (Figure 3-10C). 
Consistent with the canonical TGF-ß signalling implicated in the 
complex formation between phosphorylated R-SMADs and the co-SMAD4, 
TGFß-induced phospho-SMAD2/3 and BMP-induced phospho-SMAD1 
eluted in overlapping fractions with SMAD4 (Fractions T-X; Figure 3-10B and 
C). Interestingly, the elution profile of SMAD4 was unchanged under all 
stimulation conditions and represented a higher than predicted monomeric 
molecular weight (Figure 3-10A, B and C). A portion of phospho-SMAD1 was 
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detected in fractions O&P corresponding to molecular weights greater than 
670 kDa under all conditions, albeit to a greater extent under BMP 
stimulation. This overlaps with the elution profile of PAWS1 (Figure 3-10A, B 
and C). Total SMAD1 was confirmed in these fractions by immunoblotting 
SMAD1 IPs from these fractions (Figure 3-10D). The PAWS1 elution profile 
did not overlap with SMADs 2, 3 and 4. Interestingly BMP caused a slight 
shift in the elution proflie of PAWS1 towards lower molecular weight fractions 
(Figure 3-10A, B and C).  
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Figure 3-10 Size exclusion chromatography  
(A) Unstimulated HaCaT cell extracts were fractionated by gel filtration 
chromatography on a Superose™ 10/300 GL Column (GE Health Care). 5 µl each 
of recovered fractions were resolved by SDS-PAGE and subsequently analysed by 
immunoblotting using the indicating antibodies. (B) Same as A except the cells were 
treated with BMP (25 ng/ml) for 1 h prior to lysis (C) Same as A except the cells 
were treated with TGFß (50 pM) for 1 h prior to lysis. (D) Inputs and SMAD1-
immunoprecipitations from gel filtration chromatography fraction 16 were analysed 
by immunoblotting using SMAD1 antibody. 
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3.2.6 SMAD4 independent interaction between SMAD1 and PAWS1 
To assess if PAWS1 affects SMAD1 association with SMAD4, a 
HEK293 cell line stably expressing GFP-SMAD4 under tetracycline induction 
was used. The expression of GFP-SMAD4 was induced by doxycycline and 
the cells were transfected with HA-SMAD1, FLAG-PAWS1 or both and 
treated with or without BMP. In the absence of FLAG-PAWS1 
overexpression, GFP-SMAD4 IPs pulled down HA-SMAD1 predominantly 
upon BMP treatment (Figure 3-11). This association was slightly reduced 
when FLAG-PAWS1 was co-expressed with HA-SMAD1. However, under 
these conditions, the levels of HA-SMAD1 in extracts were significantly lower 
than when HA-SMAD1 was overexpressed in the absence of FLAG-PAWS1. 
GFP-SMAD4 did not pull down FLAG-PAWS1 in the presence or absence of 
HA-SMAD1 (Figure 3-11).  
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Figure 3-11 The impact of PAWS1 on SMAD1:SMAD4 interaction 
HEK293 cells stably expressing tetracycline inducible GFP-SMAD4 were co-
transfected with or without FLAG-PAWS1 and HA-SMAD1 48 h prior to lysis. The 
expression of GFP-SMAD4 was induced for 24 h prior to lysis with 20 ng/ml 
doxycycline. The cells were treated with or without BMP-2 (25 ng/ml) for 1 h prior to 
lysis. Extracts were used for GFP-Trap immunoprecipitation. The IPs and extract 
inputs were subjected to SDS-PAGE and subsequently analysed by immunoblotting 
using the indicated antibodies. 
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3.2.7 PAWS1 expression in various mouse tissues and different cell 
lines 
PAWS1 expression in tissues and cell lines has not been 
characterised previously. Therefore, I analysed its expression in different 
mouse tissues as well as in various cell lines routinely used in the lab by 
immunoblotting. High levels of PAWS1 protein expression at predicted 
molecular weight were detected in tissue extracts derived from liver, adipose 
and pancreatic tissue (Figure 3-12A). PAWS1 expression, albeit to a lesser 
extent, was also detected in brain, lung, kidney and thymus tissue extracts 
(Figure 3-12A, high exposure). Additionally the anti-PAWS1 antibody also 
cross-reacted with higher than predicted molecular weight proteins in brain 
and liver tissue extracts (Figure 3-12A). PAWS1 expression could not be 
detected in heart, skeletal muscle, testis, epididymis and ovary tissue 
extracts (Figure 3-12A).  
PAWS1 expression at the predicted molecular weight was detected by 
immunoblotting in several human cell lines including breast cancer MDA-
MB231, osteosarcoma U2OS, HEK293, colon carcinoma RKO, human 
keratinocyte HaCaT, HeLa, breast cancer MCF7 and human myeloid 
leukaemia KBM-7 (Figure 3-12B). Endogenous PAWS1 protein expression 
was absent in prostate cancer cell line PC3 (Figure 3-12B).  
Furthermore the expression was tested in the NCI-60 cancer cell line 
panel. PAWS1 protein expression was observed to be absent in 30 out of the 
54 cell lines employed in the panel. However, SMAD1 expression did not 
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appear to mirror the expression profile of PAWS1 in the tissue and cell 
extracts (Figure 3-12).  
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Figure 3-12 PAWS1 protein expression in tissues and cells 
(A) Indicated mouse tissues were lysed and the extracts were subjected to 
SDS-PAGE. The subsequent immunoblotting analysis was performed using the 
indicated antibodies. (B) Extracts from different routinely used cell lines were 
analysed by immunoblotting for the protein expression of PAWS1. Immunoblotting 
analysis was performed using the indicating antibodies. 
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Figure 3-13 PAWS1 protein expression in the NCI-60 cancer cell line panel 
Extracts from the NCI-60 panel of cancer cell lines were resolved by SDS-
PAGE and subsequently analysed by immunoblotting using the indicated antibodies. 
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3.2.8 Sub-cellular localisation of PAWS1 
As the sub-cellular localisation of PAWS1 in cells is unknown, I 
analysed its localisation by sub-cellular fractionation and 
immunofluorescence approaches. 
HaCaT cells treated with or without BMP and TGF-ß were separated 
into cytosolic and nuclear fractions. Under all conditions, PAWS1 was 
detected predominantly in the cytosolic fractions. However upon BMP 
treatment a portion of PAWS1 was detected in the nuclear fraction. As 
expected, phospho-SMAD1 and phospho-SMAD2 were mainly detected in 
the nuclear fractions upon BMP and TGF-ß stimulations respectively (Figure 
3-14A). Lamin A/C and GAPDH were used as controls and were detected in 
the nuclear and cytosolic fractions respectively (Figure 3-14A). 
Fractionating cells for immunoblot analysis has limitations when it 
comes to assessing the precise sub-cellular localisation and co-localisation of 
proteins. Immunofluorescence studies on endogenous proteins are essential 
for robust conclusions on protein localisation. I tested all available anti-
PAWS1 antibodies for immunofluorescence studies using PC3 cells that lack 
endogenous PAWS1 expression or PC3 cells restored with PAWS1 
expression (Figure 3-15A). There was no differential fluorescence in these 
cells with any of the antibodies, indicating that they were unsuitable for 
endogenous immunofluorescence studies. I therefore looked at the 
intracellular localisation of GFP-PAWS1 stably expressed in U2OS cells. 
While GFP-PAWS1 fluorescence was observed in both cytosolic and nuclear 
compartments, the fluorescence was more pronounced in the cytosol and 
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nuclear periphery (Figure 3-14B). Treating the cells with BMP did not change 
the GFP-fluorescence intensities in either the nucleus or the cytosol (Figure 
3-14B).   
- 92 - 
Figure 3-14 Subcellular localisation of PAWS1: 
 (A) HaCaT cells were treated with or without BMP (25 ng/ml) or TGFß (50 
pM) for 1 h prior to separation into indicated subcellular fractions. Fractions or whole 
cell extract (WCL) were resolved by SDS-PAGE and analysed by immunoblotting 
using the indicated antibodies. GAPDH and Lamin A/C were used as cytosolic and 
nuclear controls respectively. (B) U2OS cells stably expressing GFP-tagged PAWS1 
cultured on glass chamber slides were treated with or without BMP (25 ng/ml) for 1 
h prior to fixation with 4% paraformaldehyde. Fluorescence was analysed using a 
Deltavision Core Restoration microscope. DAPI staining was used to detect the 
nuclei.  
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3.2.9 Re-introduction of PAWS1 in PC3 cells does not alter BMP 
induced phosphorylation of SMAD1  
To investigate the impact of PAWS1 on canonical BMP signalling, I 
used PC3 cells that lack endogenous expression of PAWS1. Using a 
retroviral infection approach, I stably reintegrated either a control vector (PC 
Control) or a vector encoding the human PAWS1 gene (PC3 PAWS1) into the 
cells. PC3 PAWS1 cells displayed PAWS1 protein expression that was 
comparable to the endogenous PAWS1 expression observed in HEK293 and 
HaCaT cells, whereas PC Control cells did not express PAWS1 (Figure 
3-15A). A BMP time course experiment in PC Control and PC3 PAWS1 cells 
was performed to investigate the effect of PAWS1 on BMP-induced 
phosphorylation of SMAD1 (Figure 3-15B). Independent of the cell type, BMP 
induced the phosphorylation of SMAD1 within 15 min., reaching maximal 
level by 1 h and falling thereafter (Figure 3-15B). Reintroducing PAWS1 in 
PC3 cells did not significantly alter the kinetics or the extent of BMP-induced 
SMAD1 phosphorylation or the levels of SMAD1 protein compared to the PC 
Control cells (Figure 3-15B). Cells were also treated with increasing amounts 
of BMP to investigate if PAWS1 impacts the BMP threshold in PC3 cells 
(Figure 3-15C). No significant differences were observed between the two 
cell types at all applied doses of BMP (Figure 3-15C).   
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Figure 3-15 The effect of PAWS1 on BMP-induced SMAD1 phosphorylation 
(A) HaCaT cells or PC3 cells stably integrated with a control vector (PC 
Control) or a vector encoding wild type PAWS1 (PC3-PAWS1) were lysed. Extracts 
were resolved by SDS-PAGE and analysed by immunoblotting using the indicated 
antibodies. (B) PC Control and PC3-PAWS1 cells were treated with BMP-2 (25 
ng/ml) for the indicated time (h) prior to lysis. Extracts were resolved by SDS-PAGE 
and analysed by immunoblotting using the indicated antibodies. (C) PC Control and 
PC3-PAWS1 cells were treated with the indicated concentrations of BMP-2 for 1 h 
prior to lysis. Extracts were resolved by SDS-PAGE and analysed by immunoblotting 
using the indicated antibodies. 
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3.2.10 Size exclusion chromatography of PC Control and PC3 PAWS1 
cells 
In order to test if the reintroduced PAWS1 in PC3 cells elutes in similar 
fractions to the endogenous PAWS1 in HaCaT cells (Figure 3-10), PC3 
PAWS1 and PC Control cell extracts were used in a similar size exclusion 
chromatography experiment. PC3 PAWS1 or Control cells were treated with 
or without BMP and the extracts were resolved by gel filtration 
chromatography using a Superose™ 6 Column (see section 0). 32 fractions 
were collected and analysed by immunoblotting. When PAWS1 was present 
in PC3 cells, it was detected in fractions M-O for unstimulated cell extracts 
and in fractions M-R in BMP stimulated fractions (Figure 3-16A upper panel). 
This corresponds to a macromolecular complex bigger than 670 kDa in size. 
A faint signal corresponding to tail-phosphorylated SMAD1 (P-SMAD1) was 
detected only in fraction N in the unstimulated cell extract, whereas it was 
detected in fractions N and O and also in fractions S-X in BMP stimulated cell 
extracts (Figure 3-16A lower panel). 
PC Control cells, that lack the expression of PAWS1, were also 
fractionated in the same manner. As expected, PAWS1 could not be detected 
in any fraction, independent of the BMP treatment. Phosphorylated SMAD1 
could be detected in fractions N and O in unstimulated cells. Upon BMP 
stimulation, P-SMAD1 was detected in fractions N and O and, additionally, 
fractions R-X (Figure 3-16B). 
The elution profile of PAWS1 using PC3 PAWS1 cells is comparable to 
the endogenous PAWS1 elution profile observed in HaCaT cells (Figure 
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3-10). However, the distribution pattern of fractionated P-SMAD1 in PC3 
PAWS1 cells shows no significant difference when compared to the 
fractionation pattern of P-SMAD1 in PC Control cells (Figure 3-16).  
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Figure 3-16 Size exclusion chromatography using PC Control of PC3 PAWS1 
cells 
(A) Unstimulated or BMP-2 (25 ng/ml) treated PC3 PAWS1 cell extracts were 
fractionated by gel filtration chromatography on a Superose™ 10/300 GL Column 
(GE Health Care). 5 µl each of recovered fractions were resolved by SDS-PAGE 
and subsequently analysed by immunoblotting using the indicating antibodies. (B) 
Same as A except that PC Control cells were used. 
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3.2.11 In vitro phosphorylation of FAM83G/PAWS1 by ALK receptor 
kinases 
The observation that BMP treatment leads to partial nuclear 
localisation of PAWS1 (Figure 3-14) and a portion of phosphorylated SMAD1 
elutes in the same fractions with PAWS1 (Figure 3-10 and Figure 3-16), 
prompted me to evaluate whether BMP could also induce a post translational 
modification within PAWS1. To investigate this, I generated a HEK293 cell 
line stably integrated with a single copy of GFP-PAWS1 under a tetracycline 
repressor (see section 2.2.4). After 24 h tetracycline induction (1 µg/ml), the 
cells were treated with or without BMP. Subsequently the GFP IPs from these 
cells were analysed for phosphorylation sites by mass spectrometry (Figure 
3-17A). Interestingly, a triply phosphorylated peptide corresponding to 
residues 608-623 (RPSVASSVSEEYFEVR) of human PAWS1 was identified 
(Figure 3-17A). This internal SS(V/M)S motif identified in PAWS1 is not only 
conserved across different species but identical to the C-terminal SS(V/M)S 
activation motif within SMAD proteins (Figure 3-17A). The triphospho peptide 
was identified from cells treated with BMP. While the mass spectrometric 
analysis was able to establish Serine 610 as one of the phosphorylation 
sites, it was unable to precisely establish the two remaining phosphorylation 
residues within this peptide. 
Despite the failure to map the precise BMP-induced phosphorylation 
residues within the SSVS motif in PAWS1 by mass-spectrometry, based on 
the above observations, I predicted that PAWS1 could be a novel target for 
the BMP type I receptor kinase (BMPR1A/ALK3). To date, there are no non-
SMAD substrates reported for ALK3 or any other ALK. To test this 
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hypothesis, I set up an in vitro kinase assay in the presence of 32P-ATP 
using a GST-tagged PAWS1 (523-end) fragment as a substrate for ALK3. 
PAWS1 was phosphorylated in vitro by ALK3 (Figure 3-17B). GST-SMAD1, 
which was used as a positive control, was also phosphorylated by ALK3, 
while GST-SMAD2, used as a negative control, was not phosphorylated by 
ALK3 (Figure 3-17B). Other BMP activated type I receptors, ALK2 and ALK6, 
also phosphorylated GST-PAWS1(523-end) in vitro and this phosphorylation 
was efficiently blocked by LDN-193189, an inhibitor of BMP activated ALKs 
(1, 2, 3 & 6) (Figure 3-17C).  
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Figure 3-17 Phosphorylation of PAWS1 by BMPR1 (ALK3) 
(A) GFP IPs from HEK293 cells stably expressing GFP-PAWS1 treated with 
or without BMP-2 (25 ng/ml) were resolved by SDS-PAGE. The gel was Coomassie 
stained and bands representing GFP-PAWS1 excised and digested with trypsin. The 
phospho-peptides were identified by mass spectrometry. The sequence alignment of 
the PAWS1 tri-phospho peptide identified upon BMP treatment with other 
vertebrates is shown. Also shown for comparison is the sequence alignment of the 
SXS motif in different R-SMADs. h: human; m: mouse; x: Xenopus laevis (B) Kinase 
assays were set up with BMPR1 (ALK3) using GST-SMAD1, GST-SMAD2 and 
GST-PAWS1 (523-end) as substrates using 32P-ATP (500 cpm/pmole) as described 
in methods section 2.2.12. Samples were resolved by SDS-PAGE, the gel was 
Coomassie stained and radioactivity was analysed by autoradiography. (C) Kinase 
assays were performed with ALK2 or ALK6 and PAWS1 in the presence of the 
indicated concentration of LDN-193189. Samples were resolved by SDS-PAGE. 
Subsequently the gels were Coomassie stained, dried and analysed by 32P 
autoradiography 
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3.2.12 Mapping ALK3 phosphorylation sites in PAWS1  
I set out to map the in vitro ALK3 phosphorylation sites within PAWS1 
by a combination of mass spectrometry and solid-phase Edman sequencing. 
GST-PAWS1(523-end) was phosphorylated by ALK3 using 32P-ATP. 32P-
labelled GST-PAWS1(523-end) was digested with trypsin and the resulting 
peptides were separated by chromatography on a C18 column. Three 32P-
labelled peaks, one major (P1) and two minor (P2 & P3), were observed 
eluting at 26%, 25% and 24% acetonitrile respectively (Figure 3-18A). For 
P1, 32P radioactivity was released after the third cycle after Edman 
degradation (Figure 3-18C). The molecular mass of this peak as determined 
by mass spectrometry (961.4382 Da) was identical to that expected for a 
tryptic phospho-peptide comprising residues 608–623 with a single 
phosphorylation modification. Taken together, these results imply that ALK3 
phosphorylates PAWS1 at Ser610. For the second peak, P2, the 32P 
radioactivity was released after the seventh and the ninth cycles after Edman 
degradation, indicating phosphorylation at Ser614 and Ser616 of PAWS1 
(Figure 3-18B). For Peak 3 (P3) the material was insufficient for mass 
spectrometric and Edman degradation analysis of potential phosphorylation 
sites within peak P3 (Figure 3-18A). These results taken together show that 
ALK3 phosphorylates PAWS1 predominantly at Ser610 but can also 
phosphorylate Ser614 and Ser616 in vitro. Consistent with this observation, 
when Ser610 was mutated to Ala, the phosphorylation of GST-PAWS1(523-
end) by ALK3 in vitro was almost completely abolished (Figure 3-18D). On 
the other hand, mutation of Ser613, Ser614 and Ser616 to Ala resulted in a 
significant but not complete inhibition of phosphorylation of GST-
PAWS1(523-end) by ALK3 in vitro (Figure 3-18D).   
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Figure 3-18 Mapping ALK3 phosphorylation sites in PAWS1  
(A) GST-PAWS1(523-end) phosphorylated by BMPR1 (ALK3) as described 
in methods section 2.2.12 was excised, digested with trypsin and resolved by HPLC 
on a C18 column on an increasing acetonitrile gradient as indicated. Three peaks 
(P1-3) of 32P release were observed. Analysis of the phospho-peptide in peak P1 
revealed a mass of 961.4382. (B) Solid-phase sequencing of peak P2 revealed the 
release of 32P radioactivity after the seventh and ninth cycles of Edman degradation. 
(C) Solid-phase sequencing of peak P1 revealed the release of 32P radioactivity after 
the third cycle of Edman degradation. (D) BMPR1 (ALK3) was incubated in a kinase 
assay with GST-PAWS1(523-end), GST-PAWS1(523-end) S610A or GST-
PAWS1(523-end) S613A, S614A and S616A as substrates. Samples were resolved 
by SDS-PAGE. Subsequently the gels were Coomassie stained, dried and analysed 
by 32P autoradiography.   
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3.2.13 PAWS1 is phosphorylated upon BMP stimulation in cells 
To further elucidate the role of Ser610 in PAWS1, I generated PC3 cell 
line stably integrated with a PAWS1-Ser610Ala mutation (PC3 PAWS1 
S610A). I also generated an antibody against PAWS1 phosphorylated at 
Ser610 (P-PAWS1) (see section 2.2.18). Using these tools, I investigated the 
nature and role of BMP induced phosphorylation of PAWS1 at Ser610 in 
cells. In PC3 PAWS1 cells, stimulation with BMP but not control or TGF-ß, 
resulted in the phosphorylation of PAWS1 at Ser610 as detected by the P-
PAWS1 antibody (Figure 3-19A). In contrast, stimulation of PC Control cells 
or PC3 PAWS1 S610A cells with BMP did not result in the detection of 
PAWS1 phosphorylation at Ser610 (Figure 3-19A). These results not only 
confirm the specificity of P-PAWS1 antibody but indicate that BMP induces 
phosphorylation of PAWS1 at Ser610. The re-introduction of wild type or the 
Ser610Ala mutant PAWS1 in PC3 cells did not significantly alter the levels of 
BMP induced phosphorylation of SMAD1 (Figure 3-19A and Figure 3-15). 
Next, I also investigated whether BMP could induce the phosphorylation of 
endogenous PAWS1 at Ser610 in HaCaT cells. PAWS1 phosphorylation at 
Ser610 was detected in HaCaT cell extracts treated with BMP. This was 
inhibited by LDN-193189, a potent albeit non-selective ALK3 inhibitor (Figure 
3-19B). Furthermore, I assessed the kinetics of BMP induced PAWS1 
phosphorylation at Ser610. The BMP-induced phosphorylation of PAWS1 at 
Ser610 mirrored the kinetics of SMAD1 tail phosphorylation (Figure 3-19C).  
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Figure 3-19 PAWS1 is phosphorylated at Ser610 upon BMP stimulation in cells  
(A) PC3 Ccontol, PC3 PAWS1 or PC3 PAWS1 S610A cells were treated with 
BMP-2 (25 ng/ml), TGF-ß (50 pM) or left untreated for 1 h prior to lysis. Extract were 
resolved by SDS-PAGE and immunoblotted with the indicated antibodies (B) HaCaT 
cells were left unstimulated or stimulated with BMP-2 (25 ng/ml) with or without 
LDN193189 (100 nM) for 1 h prior to lysis. PAWS1 was immunoprecipitated from 
cell extracts (1 mg protein) using anti-PAWS1 antibody. PAWS1 IPs or extract inputs 
were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (C) 
HaCaT cells were treated with BMP-2 (25 ng/ml) for the indicated time prior to lysis. 
Extracts were resolved by SDS-PAGE and analysed by immunoblotting using the 
indicated antibodies. 
  
A
IB: PAWS1
IB: P-SMAD1
IB: GAPDH
IB: SMAD1
IB: P-PAWS1 S610
BMP-2  for min.15 480120450 240
PC3 PAWS1
IB: P-PAWS1 S610
IB: PAWS1
IB: P-SMAD1
IB: SMAD1
IB: GAPDH
- - - + ++ - - - PC3 Control
PC3 PAWS1 S610A
-/TGF-ß/BMP
+ ++ - - - - - -
+ ++- - - - - -
- - -T T T BB B
CB
+
IB: P-PAWS1 S610
IB: PAWS1
IB: P-SMAD1
IB: SMAD1
IB: GAPDH
BMP 25ng/ml
LDN-193189 100nM
+
+--
-
- 105 - 
3.2.14 PAWS1 regulates the expression of some non-canonical BMP 
target genes 
Both SMAD4-dependent (canonical) and independent (non-canonical) 
modes of TGF-ß signalling have been reported to control the transcription of 
distinct target genes (Derynck and Zhang, 2003). ID1 is a prominent example 
for a BMP target gene reported to be SMAD4 dependent (Miyazono and 
Miyazawa, 2002). However, in cells lacking endogenous SMAD4 expression, 
BMP stimulation can still induce the transcription of many different target 
genes, including NEDD9 and ASNS (Deng et al., 2009). 
Because PAWS1 can form a complex with SMAD1 independently of 
SMAD4 (Figure 3-10 and Figure 3-11), I hypothesised that the transcription of 
SMAD4-independent BMP target genes could be regulated by PAWS1. In 
order to test this hypothesis, I used PC Control and PC3 PAWS1 cells. I also 
included the PC3 PAWS1 S610A mutant cell line to test whether the BMP-
induced phosphorylation of PAWS1 affected the transcription of these genes. 
In PC3 PAWS1 cells, BMP induced the expression of NEDD9 and ASNS, two 
SMAD4-independent BMP-target genes ((Deng et al., 2009)Figure 3-20 A 
and B)). Interestingly, in PC3 Control or PC3 PAWS1 S610A cells, BMP-
induced expression of NEDD9 and ASNS was not induced (Figure 3-20A and 
B). This would suggest that the phosphorylation of PAWS1 at Ser610 in 
response to BMP is important for the transcription of these genes. The 
expression of the BMP receptor type 2 gene (BMPR2) was unchanged in 
PC3 PAWS1 or PC3 PAWS1 S610A cells, when compared to PC Control 
cells (Figure 3-20C). Finally, I also investigated whether phosphorylation of 
PAWS1 Ser610 impacts the ability of PAWS1 to interact with SMAD1. Both 
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wild-type PAWS1 and PAWS1 S610A mutant expressed in PC3 cells 
interacted with endogenous SMAD1 with similar affinities (Figure 3-20D).  
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Figure 3-20 The role of PAWS1 in the BMP pathway 
(A-C) PC3 Contol, PC3 PAWS1 or PC3 PAWS1 S610A cells were treated 
with BMP-2 (25 ng/ml) or left untreated for 6 h prior to RNA isolation. The relative 
expression of the indicated genes was analysed by qRT-PCR as described in the 
methods (see section 2.2.22). The results are presented as fold change in gene 
expression relative to unstimulated controls. Data are represented as mean of three 
biological replicates and error bars indicate standard deviation (n=3). (D) PC3 
Contol, PC3 PAWS1 or PC3 PAWS1 S610A cells were lysed and PAWS1 was 
immunoprecipitated from cell extracts using anti-PAWS1 antibody. IgG was used as 
a control. PAWS1 IPs or extract inputs were resolved by SDS-PAGE and 
immunoblotted with the indicated antibodies. 
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3.2.15 Biased qRT-PCR array of TGF-ß signalling components and TGF-
ß signalling targets in PC3 cells 
In order to evaluate whether the restoration of PAWS1 expression in 
PC3 cells regulates the expression of 155 transcripts known to be TGF-ß and 
BMP pathway components or targets, I performed quantitative real-time 
(qRT) PCR macroarrays (Sabiosciences). I identified 35 genes in which the 
change in expression was more than 2 fold upon restoration of PAWS1 in 
both untreated and BMP treated PC3 cells (Figure 3-21, Table 3-2 and Table 
3-3). Among these, 15 genes were low expression genes (qRT-PCR cycle 
above 30 (Table 3-3)) and 20 high to medium expression genes (qRT-PCR 
cycle below 30 (Table 3-2)). Of the high expression genes, only 3 genes 
(CDKN1A, HEY1 and INHA) appeared to be BMP-inducible, albeit the fold 
change was small (Table 3-2 second row). 
Next I sought to verify the observed changes in gene expression from 
the macroarray by qRT-PCR. In PC Control or PAWS1 cells treated with or 
without BMP, using a similar set up as for the macroarray, I confirmed that 
PAWS1 expression augmented the expression of TGFBI, FST and TGFBR2 
while it diminished the expression of AR and TSC22D (Figure 3-22A). ID1 
expression, which serves as a control for BMP stimulation, was not 
significantly altered between PC Control and PC3 PAWS1 cells. All other 
genes from the macroarray displaying significant changes in expression 
between PC Control and PAWS1 were found to be false positive. 
Furthermore, to ensure that the expression changes of the genes were 
directly dependent on PAWS1 expression in PC3 cells, I analysed the 
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expression of FST and TGFBI in HaCaT cells by qRT-PCR upon RNAi-
mediated depletion of PAWS1, which results in ~80% reduction in PAWS1 
protein expression (Figure 3-22B). PAWS1 depletion in HaCaT cells results in 
repression of FST and TGFBI expression (Figure 3-22C), confirming the 
results from PC Control and PAWS1 cells. I also investigated whether BMP 
affected the expression of these genes. I found that stimulation of cells with 
BMP did not alter the expression of FST, TGFBI, AR, TGFBR2 and TSC22D 
in both PC Control or PC3 PAWS1 cells (Figure 3-22A). Consistent with this, 
BMP stimulation did not affect the expression of FST and TGFBI in HaCaT 
cells expressing control or PAWS1 siRNAs (Figure 3-22C). Taken together 
these results imply that PAWS1 can regulate the expression of some genes 
that have been previously described as being components of the TGF-ß and 
BMP pathways, albeit independently of BMP stimulation.  
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Figure 3-21 PAWS1 impacts the expression of multiple genes in the TGF-
ß/BMP pathway independent of BMP treatment 
(A) Scatter plots of log fold change in gene expression in PC3 PAWS1 over 
PC Control cells of 150 TGF-ß/BMP pathway components or target genes analysed 
by qRT-PCR. Each dot represents the expression of a single gene. (B) Same as A 
but cells were treated with BMP-2 (25 ng/ml) for 6 h prior to lysis. 
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Table 3-2 High expression genes that are regulated by PAWS1 
Genes identified with the macroarray whose expression changed at least 2-
fold upon PAWS1 expression. All genes represented in this table were identified by 
qRT-PCR with an expression below the cycle 30 threshold in PC Control and PC3 
PAWS1 cells. Red indicates upregulation and blue indicates downregulation in gene 
expression. 
 
  
High expression genes (<30 cycles) 
 Effect of PAWS1 Effect of PAWS1 + 
BMP 
 Fold change 
TGFBI 8.53 4.73 
FST 3.02 3.27 
BMP6 2.96 3.23 
TGFBR2 2.61 2.40 
PDGFA 2.60 1.84 
MECOM 1.74 1.85 
INHBA -1.91 -1.65 
MYC -2.04 -1.86 
FOS -2.10  
SNAI1 -2.13 -2.06 
IGFBP3 -2.17 -1.93 
MSX2 -2.17 -1.86 
IL6 -2.38  
DLX2 -2.47 -2.97 
SERPINE1 -3.69 -6.04 
TSC22D1 -4.05 -3.37 
AR -7.74 -15.62 
CDKN1A  1.79 
HEY1  -1.86 
INHA  -2.17 
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Table 3-3 Low expression genes that are regulated by PAWS1 
Genes identified from the macroarray whose expression changed at least 2-
fold upon PAWS1 expression. All genes represented in this table were identified by 
qRT-PCR with an expression above the cycle 30 threshold in PC Control and PC3 
PAWS1 cells. Red indicates upregulation and blue indicates downregulation in gene 
expression. 
 
  
Low expression genes (>30 cycles) 
 Effect of PAWS1 Effect of PAWS1 + 
BMP 
 Fold change 
AIPL1 8.53 4.73 
GSC 3.02 3.27 
IL10 2.96 3.23 
MYOD1 2.61 2.40 
AGT 2.60 1.84 
BMPER 1.74 1.85 
CHRD -1.91 -1.65 
SHH -2.04 -1.86 
ACVRL1 -2.10  
BMP3 -2.13 -2.06 
BMP7 -2.17 -1.93 
CER1 -2.17 -1.86 
GDF6 -2.38  
BDNF -2.47 -2.97 
COL3A1 -3.69 -6.04 
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Figure 3-22 PAWS1 impacts the expression of multiple genes in the TGF-
ß/BMP pathways independent of BMP treatment 
(A) PC3 PAWS1 or PC Control cells were treated with or without BMP-2 (25 
ng/ml) for 6 h prior to lysis. RNA was extracted and the cDNA synthesized. The 
expression of the genes was analysed by qRT-PCR. The results show the fold 
change in gene expression relative to the levels observed for unstimulated PC 
Control cells. Data are represented as mean of three biological repeats and error 
bars indicate standard deviation (n=3). (B) PAWS1 depleted HaCaT cells (siPAWS1) 
or HaCaT cells expressing FOXO4 siRNA (siCONTROL) were lysed. Extracts were 
resolved by SDS-PAGE and immunoblotted with the indicated antibodies. (C) 
PAWS1 depleted HaCaT cells (siPAWS1) or HaCaT cells expressing FOXO4 siRNA 
(siCONTROL) were treated with or without BMP-2 (25 ng/ml) for 6 h prior to lysis.  
RNA was extracted and the cDNA synthesized. The expression of FST and TGFBI 
genes was analysed by qRT-PCR. The results respresent the fold change in gene 
expression relative to the levels observed for unstimulated siPAWS1 HaCaT cells. 
Data are represented as mean of three biological repeats and error bars indicate 
standard deviation (n=3).   
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3.2.16 Analysis of global PAWS1-dependent gene expression by RNA 
sequencing 
The macroarray (Figure 3-21) described above was limited with 
respect to the gene number (155 genes) and it was biased towards TGF-ß 
and BMP pathway components and target genes. Therefore, I decided to 
undertake a transcriptomic approach to identify candidate genes that might 
be regulated by PAWS1 globally. In order to do this, our lab initiated 
collaboration with Prof. Jim Smith (MRC NIMR, London). I isolated RNA from 
PC Control and PC3 PAWS1 cells treated without or with BMP for 3 h and 16 
h in triplicates. The quality of the RNA was verified by running 0.5 µg of each 
RNA sample on 1% agarose gel prior to RNA seq. (Figure 3-23). Dr. Kevin 
Dingwell in Prof. Smith’s laboratory performed RNA sequencing analysis on 
the isolated RNAs. We identified more than 800 genes that changed 
expression as a result of PAWS1 expression in PC3 cells (Appendix Table 1). 
Out of these 800 genes, more than 300 changed expression by more than 2 
fold (Appendix Table 1). To validate the identified genes, I employed the qRT-
PCR approach and out of 30 genes randomly picked from 50 top hits, I 
verified the differential expression caused by PAWS1 for 19 genes (Figure 
3-24 and Figure 3-25). Among these, 7 were up-regulated (Figure 3-24) and 
12 were down-regulated upon PAWS1 expression (Figure 3-25). 
Stimulating the cells with BMP for 3 or 16 h prior to RNA isolation did 
not yield many genes for which expression was dependent on both PAWS1 
and BMP stimulation. However, ASNS was one of the genes that displayed a 
slight change in expression (Appendix Table 3). 
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Furthermore, in order to gain confidence that the observed changes in 
gene expression are indeed regulated by PAWS1, an RNAi approach using 
HaCaT cells as described above was used alongside the PC Control/PAWS1 
cells. RNA was isolated from PC Control, PC3 PAWS1 and HaCaT cells 
expressing siPAWS1 or siControl that were treated with or without BMP. The 
isolated RNA was analysed by qRT-PCR for some of the PAWS1 target 
genes (Figure 3-26). As expected the expression of BEX1, CCNA1, GTF2F2 
and ASNS was reduced by PAWS1 expression in PC3 cells (Figure 3-26 left 
panel). In contrast, in HaCaT cells expressing PAWS1 siRNA, the expression 
of these genes was enhanced compared to cells that expressed control 
siRNA (Figure 3-26 right panel). The treatment of BMP did not significantly 
alter the expression these genes in either cell system (Figure 3-26).  
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Figure 3-23 PAWS1 regulated genes in PC3 cells identified by RNA sequencing 
RNA isolated from PC Control and PC3 PAWS1 cells treated with BMP-2 (25 
ng/ml) for the indicated time points prior to isolation of RNA. 250 ng of isolated RNA 
was resolved on a 1% agarose gel to test its quality prior to an RNA sequencing 
analysis. 
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Figure 3-24 Genes that are upregulated by PAWS1 expression 
PC Control and PC3 PAWS1 cells were treated with or without BMP-2 (25 
ng/ml) for 3 h prior to RNA isolation. RNA was extracted and the cDNA synthesized. 
The expression of the genes was analysed by qRT-PCR. The results represent fold 
change in gene expression relative to the levels observed for unstimulated PC 
Control cells. Data are represented as mean of three biological repeats and error 
bars indicate standard deviation (n=3). 
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Figure 3-25 Genes that are downregulated by PAWS1 expression 
PC Control and PC3 PAWS1 cells were treated with or without BMP-2 (25 
ng/ml) for 3 h prior to RNA isolation. RNA was extracted and the cDNA synthesized. 
The expression of the genes was analysed by qRT-PCR. The results represent fold 
change in gene expression relative to the levels observed for unstimulated PC 
Control cells. Data are represented as mean of three biological repeats and error 
bars indicate standard deviation (n=3). 
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Figure 3-26 PAWS1 dependent genes in PC3 cells are also controlled by 
PAWS1 in HaCaT cells 
PC Control, PC3 PAWS1 or HaCaT cells transfected with siRNA against 
PAWS1 or FOXO4 (control) were treated with or without BMP-2 (25 ng/ml) for 3 h 
prior to RNA isolation. RNA was extracted and the cDNA synthesized. The 
expression of the indicated genes was analysed by qRT-PCR. The results represent 
fold change in gene expression relative to the levels observed for unstimulated PC 
Control cells or HaCaT cells depleted of PAWS1 respectively. Data are represented 
as mean of three biological repeats and error bars indicate standard deviation (n=3). 
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3.2.17 The role of PAWS1 in epithelial to mesenchymal transition  
Epithelial to mesenchymal transition is an important process in 
embryogenesis and plays a role in adult tissue wound healing. It has also 
been implicated in cancer progression and metastasis (Kalluri and Weinberg, 
2009). EMT is a multistep cellular process that can be induced in many cell 
types by TGF-ß stimulation. It has been reported that TGF-ß stimulation 
induces EMT through the induction of SNAIL, TWIST and SLUG (Xu et al., 
2009). SNAIL and SLUG induction leads to down-regulation of E-cadherin, a 
cell-cell adhesion marker, which in turn leads to loss of cell-cell contact. 
TWIST has been reported to be an oncogene (Ansieau et al., 2008). 
Because PAWS1 regulates the expression of a number of TGF-ß pathway 
components and target genes, including TGFBR2, FST and SNAIL, I 
investigated whether PAWS1 played a role in TGF-ß induced EMT using 
NMuMG cells. NMuMGs are mouse mammary epithelial cells, which have 
been previously used to study TGF-ß induced EMT (Wrana et al., 1994). 
Interestingly PAWS1 expression is absent in NMuMG cells. NMuMG 
cells were infected with retroviruses containing either an empty vector with 
puromycin resistance (NMuMG Control; Figure 3-27A) or wild-type mouse 
PAWS1 (NMuMG PAWS1 Figure 3-27B). The cells were selected with 
puromycin for 4 days before treating them with or without TGF-ß or with TGF-
ß plus the addition of SB-505124 (1 µM), a potent TGFBR1 inhibitor, for 24 or 
48 h (Figure 3-27). Control Cells treated with TGF-ß undergo a rapid EMT, 
noticeable even after 24 h by the longitudinal/epithelial shape and by the loss 
of cell-cell contact (Figure 3-27A). This is inhibited by SB-505124, as there is 
no visible difference between untreated and TGF-ß plus SB-505124 
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treatment (Figure 3-27A). On the other hand, if the NMuMG PAWS1 cells are 
used, there is no obvious difference compared to NMuMG Control cells for 
any treatment (Figure 3-27A and B). However, in order to verify the 
morphological observations biochemically, the same cells (Figure 3-27A and 
B) were used for immunobloting analysis (Figure 3-27C) with antibodies 
against Fibronectin and E-cadherin. Increased Fibronectin levels were 
observed upon TGF-ß stimulation while changes in E-cadherin levels were 
not detected (Figure 3-27C). No significant differences between the NMuMG 
Control and NMuMG PAWS1 cells were observed, suggesting that PAWS1 is 
probably not involved in EMT.  
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Figure 3-27 Role of PAWS1 in EMT 
(A) NMuMG cells stably expressing an empty puromycin resistance vector 
were left untreated or treated with TGF-ß (75 pM) with or without SB505124 (1 µM) 
for 24 and 48 h, respectively. (B) Same as A, except that NMuMG cells stably 
expressing mouse PAWS1 were used. (C) Cell extracts from A and B were 
subjected to SDS-PAGE and subsequently analysed by immunoblotting using the 
indicated antibodies. 
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3.2.18 The role of PAWS1 in cellular migration 
One of the PAWS1 target genes, NEDD9, has been implicated in 
cellular migration (Zhong et al., 2012, Ahn et al., 2012). TGF-ß and BMP 
pathways are known to be involved in cellular migration (Platten et al., 2000, 
Inai et al., 2008). Therefore, I tested whether PAWS1 impacts cellular 
migration. In order to do this, PC Control, PC3 PAWS1 or PC3 PAWS1 
S610A cells were cultured to confluency in adjacent chambers of inserts 
separated by a small fixed-sized spacer. When the inserts were removed, a 
uniform gap was formed. Cellular migration onto the gap was monitored by 
live cell imaging for 24 h (1 frame every 2 minutes). At the 18 h time point, 
the gap is filled by cells to about 80 to 90 % in PC Control cells (Figure 3-28). 
This is also observed for PC3 PAWS1 and PC3 PAWS1 S610A cells (Figure 
3-28). Therefore, it appears that there was no significant impact on lateral 
migration of these three cell types. The movement of individual cells onto the 
gap as seen on live cell imaging movies appeared to be slightly different in 
different cell types. However these observations were hard to quantify 
because of the disorderly nature of individual cell movements within the gap 
(supplementary movies 1-6).Treatment of all cell types with BMP did not 
significantly alter the nature of cellular migration onto the gap (Figure 3-28, 
supplementary movies 1-6). 
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Figure 3-28 The role of PAWS1 in lateral migration 
(A) PC Control, PC3 PAWS1 and PC3 PAWS1 S610A cells were plated to 
confluence in migration chambers as described in methods. Images were taken at 
time 0 when cells were left unstimulated or stimulated with BMP-2 (25 ng/ml). (B) 
Images of cells in A were taken at 18 h time point. 
 
  
PC3 Control PC3 PAWS1
PC3 PAWS1 
S610A
unstimulated
BMP
0 hour time point
PC3 Control PC3 PAWS1
PC3 PAWS1 
S610A
unstimulated
BMP
18 hour time point
A
B
- 125 - 
3.2.19  Identification of PAWS1 interactors by mass fingerprinting 
As the biochemical roles of PAWS1 remain largely uncharacterised, in 
order to get insights into the possible roles of PAWS1 in cells, I employed a 
proteomic approach to identify interactors of GFP-PAWS1 from cells stably 
expreesing GFP-PAWS1. Any identified interacting partners could help define 
functional roles of PAWS1 in cells.  
Stable, tetracycline inducible GFP or GFP-PAWS1 HEK293 cells (see 
section 2.2.4) were treated with doxycycline for up to 24 h (Figure 3-29A). 
The expression of GFP-PAWS1 was increased upon doxycycline treatment in 
a time-dependent manner (Figure 3-29A). For identification of GFP-PAWS1 
interactors by mass spectrometry, GFP or GFP-PAWS1 HEK293 cells were 
treated for 24 h with doxycycline, and treated with or without BMP prior to 
lysis. The GFP IPs from extracts were resolved by SDS-PAGE, which was 
stained by colloidal coomassie, and proteins in the entire lanes excised and 
analysed by mass spectrometry (Figure 3-29B). 
The identified proteins are listed in Appendix (Table 4), sorted 
according to their identification confidence score (called PEP score). The list 
of GFP-PAWS1 interactors was compared against the list of GFP-interactors 
as well as common contaminants collected over time from multiple similar 
experiments performed in the lab and the contaminants were removed from 
this list. One of the top scoring interactors was CULLIN3, the key component 
of the CUL3-E3 ubiquitin ligase complex ((Petroski and Deshaies, 2005), 
Appendix Table 4). More importantly, other components of the complex such 
as the unique adaptor protein KLHL13 or KLHL15 and the essential ring box 
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protein RBX1 were also identified ((Sumara et al., 2007) Appendix Table 4). 
Another protein shown to be interacting with PAWS1 was CD2AP, a poorly 
characterised protein that has been previously linked to TGF-ß signalling 
(Xavier et al., 2009). SMADs were also identified as PAWS1-interacting 
proteins (Appendix Table 4). Stimulating the cells with BMP did not alter the 
interactors identified for GFP-PAWS1 IPs.  
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Figure 3-29 Identification of PAWS1 interactors by mass spectrometry 
(A) HEK293 cells stably integrated with tetracycline inducible GFP or GFP-
PAWS1 were lysed following induction by tetracycline (1 µg/ml) for the indicated 
times. Extracts were resolved by SDS-PAGE and analysed by immunoblotting for 
PAWS1 protein levels. (B) HEK293 cells stably expressing GFP-PAWS1 were 
treated with or without BMP-2 (25 ng/ml) for 1 h prior to lysis. Cell extracts were 
subjected to immunoprecipitation using GFP-Trap beads and IPs were resolved by 
SDS-PAGE gel electrophoresis. The gel was stained with Coomassie and the 
numbered boxes indicating individual gel pieces were excised, trypsinised and 
analysed by mass spectrometry. 
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3.2.20  PAWS1 interacts with CULLIN3 at the endogenous level 
To verify the observations from mass spectrometry on the interaction 
between PAWS1 and CULIN3 (CUL3) at the endogenous level, PAWS1 was 
immunoprecipitated from HaCaT cell extracts. PAWS1 IPs were subjected to 
SDS-PAGE and immonoblotted with anti-CUL3 antibody. Both neddylated 
and un-neddylated forms of CUL3 were identified in PAWS1 IPs but not in 
pre-immune IgG IPs employed as control (Figure 3-30A). Furthermore I 
demonstrate that CUL3 and PAWS1 elute in overlapping fractions when 
HaCaT extracts were resolved by a size exclusion chromatography (Figure 
3-30B).  
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Figure 3-30 Interaction between PAWS1 and CULLIN3 
(A) HaCaT cells were lysed and extracts were subjected to 
immunoprecipitation with either IgG (control) or anti-PAWS1 antibodies. Extracts and 
IPs were resolved by SDS-PAGE and subsequently analysed by immunoblotting 
using the indicated antibodies. (B) Unstimulated HaCaT cell extracts were 
fractionated by gel filtration chromatography on a Superose™ 10/300 GL Column 
(GE Health Care). 5 µl each of recovered fractions were resolved by SDS-PAGE 
and subsequently analysed by immunoblotting using the indicated antibodies. 
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3.2.21  Tracking PAWS1 protein levels during cell cycle 
I have shown above that PAWS1 interacts with CUL3 and potentially 
forms a complex (Figure 3-30). CUL3 is implicated in the regulation of the cell 
cycle, whereby it mediates the ubiquitylation of AURORA B marking it for 
proteasomal degradation (Sumara and Peter, 2007, Sumara et al., 2007). In 
order to investigate whether CUL3 regulates PAWS1 in a similar manner, I 
tested the expression of PAWS1 during the cell cycle.  
HaCaT cells were synchronised by treating the cells twice with 
thymidine (see section 2.2.19). This leads to a cell cycle arrest in the G1/S 
border because excess thymidine in a dividing cells generates negative 
feedback on the production of deoxycytidine triphosphate and prevents the 
progression of the cells in the cell cycle. This is reversible and cells released 
after thymidine block progress through the cell cycle in a synchronised 
manner. U2OS cells were released from thymidine block and harvested at 2 
h intervals, with the first harvest at 1 h after release. The cells were analysed 
by fluorescence activated cell sorting (FACS) according to their DNA content. 
This allows for the assessment of synchronous progression through the cell 
cycle (Figure 3-31A and B). As shown in Figure 3-31, the cell cycle arrest in 
G1/S was successful and the majority of the cells progress synchronised 
through the cell cycle. This was also confirmed by assessing the levels of 
Cyclins A, D and E that are reported to be cell cycle regulated (Johnson and 
Walker, 1999) by immunoblotting extracts collected at fixed time points after 
release (Figure 3-31C). Under these conditions, PAWS1 is uniformly 
expressed throughout the different stages of cell cycle (Figure 3-31A top 
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panel). Therefore, PAWS1 expression appears not to be cell cycle regulated 
(Figure 3-31). 
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Figure 3-31 PAWS1 expression during cell cycle 
(A) HaCaT cells were treated with thymidine (2 mM) for 16 h, washed, left for 
10 h and treated again with thymidine (2mM) for 16 h. FACS profile of the HaCaT 
cells showing the cell cycle distribution at the indicated time points after thymidine 
release. (B) Graph representing the percentage of cells in an indicated cell cycle 
state at the given time point. (C) Cells were lysed at the indicated time points after 
thymidine release and extracts subjected to SDS-PAGE prior to analysis by 
immunoblotting using the indicated antibodies.  
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3.2.22 The role PAWS1 expression in Xenopus laevis development 
The BMP signalling pathway, among others, is a very important 
pathway in Xenopus development and has been extensively studied (see 
section 3.1.2). SMAD1, being the intracellular transducer of BMP ligands, has 
been established as an interactor of PAWS1 in this thesis. Therefore, in order 
to gain insight on the role of PAWS1 in vertebrate development, we 
collaborated with Dr. Kevin Dingwell in the laboratory of Prof. Jim Smith 
(MRC NIMR London). Dr. Kevin Dingwell injected X.laevis PAWS1 mRNA 
into the ventral side of 4 cell embryos (Figure 3-32A). The injected embryos 
showed complete duplication of axis at tailbud stages (Figure 3-32C). Given 
the limited role for PAWS1 in the BMP-induced phosphorylation of SMAD1 
and transcription of downstream target genes, the axis duplication caused by 
PAWS1 could be unrelated to its role in the BMP pathway. Consistent with 
this, a similar phenotype is observed by injecting xWnt8 into the embryo 
(Figure 3-32D). The uninjected embryos displayed a normal developmental 
phenotype (Figure 3-32A). In all, more than 70% of embryos injected with 
PAWS1 mRNA (250 pg) displayed the axis duplication phenotype and a 
further 10% showed a partial axis duplication (Figure 3-32E and F). This was 
comparable to the phenotypes observed when xWnt8 (5 pg) was injected in 
embryos (Figure 3-32E and F). 
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Figure 3-32 The impact of PAWS1 on X. laevis embryogenesis 
(A) Schematic representation of strategy employed to inject xPAWS1 mRNA. 
(B) Uninjected (C) 250 pg xPAWS1 mRNA injected or (D) 5 pg xWnt8 mRNA 
injected embryos were imaged at tadpole stage. (E) Graph representing the total 
number of phenotypes observed for injected embryos at tadpole stage. (F) Graph 
representing the percentage of the different phenotypes observed in (E). 
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3.3 Discussion 
In this chapter I discuss the role of PAWS1 as a novel player in the 
BMP pathway and beyond. I have shown that PAWS1 forms a SMAD4-
independent complex with SMAD1 and identify PAWS1 as the first non-
SMAD substrate for type I BMP receptor kinases. Furthermore, I demonstrate 
that PAWS1 regulates the expression of some BMP-dependent SMAD4-
independent target genes as well as a large number of BMP-independent 
target genes. This indicates a potential non-canonical, SMAD4-independent 
SMAD1-dependent, BMP signalling pathway. 
3.3.1 PAWS1 selectively interacts with SMAD1 and not with SMAD2/3 
PAWS1 selectively interacts with SMAD1 but not SMAD2 or SMAD3 
unlike reported before (Brown et al., 2008). Despite the fact that R-SMADs 
are very similar (Shi and Massague, 2003), the selective binding of PAWS1 
to SMAD1 is intriguing (Figure 3-7). The linker region that connects the MH1 
and MH2 domains of R-SMADs is the least conserved domain (Massague, 
2003). However, SMAD1-linker does not mediate the interaction with PAWS1, 
nor does the linker phosphorylation of SMAD1 affect its interaction with 
PAWS1 (Figure 3-8 and Figure 3-9). I demonstrate that MH2 domain of 
SMAD1 is sufficient to mediate the interaction with PAWS1 (Figure 3-8). 
Because the MH2 domains across the R-SMADs are very similar, the 
selectivity of SMAD1 interaction to PAWS1 could be determined by the 
accessibility of MH2 domain within SMAD1 structural conformation. I was 
unable to determine the minimal domain within PAWS1 that mediated the 
interaction with SMAD1. A crystal structure of the PAWS1-SMAD1 complex 
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would address the selective nature of the complex as well as the interaction 
interface. Alternatively, yeast two-Hybrid screen employing random 
mutagenesis approach would be appropriate to identify the exact amino acid 
sequence that mediates the interaction between PAWS1 and SMAD1. 
Treatment of cells with TGF-ß or BMP ligands leads to the 
phosphorylation of R-SMADs at the C-terminal SXS motif within the MH2 
domain (Shi and Massague, 2003). Phosphorylated R-SMADs bind the co-
SMAD4 and form an active complex (ten Dijke and Hill, 2004). SMAD4 is not 
detected in PAWS1 IPs (Figure 3-7). Furthermore, in control or BMP treated 
extracts, PAWS1 forms a unique complex with a small proportion of SMAD1 
that does not include SMAD4 (Figure 3-10). Further evidence suggests that 
SMAD1 binds either SMAD4 or PAWS1, as GFP-SMAD4 under conditions 
where it binds to HA-SMAD1 still fails to interact with FLAG-PAWS1 (Figure 
3-11). Consistent with the above observations, GFP-PAWS1 IPs in the 
presence or absence of BMP treatment fail to pull down SMAD4 (Figure 
3-29, Appendix Table 4). The SMAD4-independent interaction between 
PAWS1 and SMAD1 suggests a non-canonical function of this complex within 
the BMP pathway, despite the fact that the majority of SMAD1 still forms a 
canonical complex with SMAD4 upon BMP treatment (Figure 3-10). On the 
other hand, PAWS1 and SMAD4 may compete for access to SMAD1. This 
has to be investigated further.  
The high molecular weight (>670 kDa) co-elution of PAWS1 and P-
SMAD1 in a gel filtration assay implies that there are potentially more 
proteins contributing to the PAWS1:SMAD1 macromolecular complex as the 
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combined molecular weight of SMAD1 and PAWS1 is 140 kDa. Furthermore, 
as full-length PAWS1 did not express in bacteria, it is not known whether 
recombinant PAWS1 and SMAD1 associate directly. Identification of all the 
components of the PAWS1:SMAD1 complex could provide us with important 
functional insight. Even in the absence of PAWS1, P-SMAD1 was still 
detected in a high molecular weight fraction in a gel filtration assay (Figure 
3-16). This could mean that there are other proteins that could substitute the 
place of PAWS1, possibly the members from the FAM83 family. Because 
PAWS1 elutes in the same high molecular weight fractions after size 
exclusion chromatography in PC3 PAWS1 cells compared to HaCaT cells 
(Figure 3-10 and Figure 3-16), it is likely that PAWS1 re-introduced in PC3 
PAWS1 cells forms functional complexes.  
The interaction between PAWS1 and SMAD1 in cell extracts is 
independent of stimulation with BMP or TGF-ß cytokines (Figure 3-7). 
However, when cells are treated with BMP, more P-SMAD1 was observed in 
overlapping fractions with PAWS1 upon size exclusion chromatography 
(Figure 3-10 and Figure 3-16). It is possible that posttranslational 
modifications of either SMAD1 or PAWS1 could impact on their interaction, 
although none have been identified yet. Immunoprecipitation interaction 
assays and gel filtration chromatography were performed on cell extracts, 
which allow for soluble proteins to spontaneously interact and potentially form 
macromolecular complexes. Therefore it is essential to confirm interactions 
between endogenous proteins by performing co-localisation studies in cells. 
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3.3.2 The impact of PAWS1 on BMP signalling 
Because PAWS1 was identified, and verified, as an interactor of 
SMAD1, I investigated its role in the BMP pathway. The manipulation of 
PAWS1 protein expression does not influence the kinetics or threshold of 
BMP induced phosphorylation of SMAD1 (Figure 3-15). Furthermore, PAWS1 
does not alter the expression of the SMAD4-dependent BMP target gene 
ID1. These results, together with the observation that PAWS1 forms a 
complex with SMAD1 independently of SMAD4, imply a unique role for 
PAWS1 in the BMP pathway. A microarray analysis on the expression of 
BMP-target genes in SMAD4-deficient SW480 cells revealed that BMP still 
induced the expression multiple genes including NEDD9 and ASNS (Deng et 
al., 2009). Interestingly, the BMP-dependent expression of NEDD9 and 
ASNS was lost in PC Control cells (Figure 3-20). After re-introduction of wild 
type PAWS1 (PC3 PAWS1), BMP was able to induce the expression of both 
NEDD9 and ASNS in these cells. BMP-induced phosphorylation of PAWS1 at 
Ser610 is necessary for the expression of these genes as the re-introduction 
of PAWS1 S610A (PC3 PAWS1 S610A) mutant did not rescue the expression 
of NEDD9 and ASNS in response to BMP (Figure 3-20). NEDD9 has 
previously been linked to TGF-ß signalling and it was shown that the binding 
to SMAD3 led to its degradation (Liu et al., 2000, Zheng and McKeown-
Longo, 2002). Furthermore, the role of NEDD9 in FAK and SRC signalling 
has been studied extensively, whereby NEDD9 plays a role in integrin-
dependent adhesion and cellular migration (Fashena et al., 2002, O'Neill and 
Golemis, 2001, van Seventer et al., 2001). More recently, NEDD9 was shown 
to impact cancer progression by facilitating the invasion and metastasis of 
cancer cells (Ahn et al., 2012). Misregulated ASNS expression has also been 
- 139 - 
linked with many cancers (Cui et al., 2007, Scian et al., 2004). It will be 
important to further investigate if these events can be linked to abnormal 
BMP signalling and whether PAWS1 plays a central role in the regulation of 
NEDD9 and ASNS expression and NEDD9/ASNS-dependent homeostasis of 
cells. 
3.3.3 PAWS1 is the first non-SMAD protein substrate for a type I BMP 
receptor kinase 
Nuclear accumulation of phospho-SMAD complexes upon BMP 
treatment is fundamental to transcriptional responses controlled by BMP. 
Even in the absence of SMAD4, BMP can induce the nuclear localization of 
phospho-SMAD1 (Liu et al., 1997). It was therefore quite interesting to 
observe that a small portion of PAWS1 was detected in the nuclear fractions 
upon BMP treatment from cell extracts fractionated into nuclear and cytosolic 
compartments (Figure 3-14). Even though a robust immunofluorescence 
study to look at the endogenous PAWS1 localisation in intact cells is 
necessary to complement the nuclear localisation, upon overexpression of 
PAWS1, some nuclear localisation was observed, albeit independently of 
BMP treatment (Figure 3-14). At this time, immunofluorescence of 
endogenous PAWS1 has not been possible due to the unavailability of 
suitable antibodies. Nonetheless, the observation of endogenous PAWS1 in 
nuclear fractions upon BMP treatment prompted me to evaluate possible 
mechanisms of PAWS1 localisation.  
It is possible that by association with SMAD1, PAWS1 could 
translocate to the nucleus under conditions that SMAD1 does. However, the 
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determinants of PAWS1:SMAD1 association are not yet known to test this in 
cells. Alternatively, PAWS1 could be modified by type I BMP receptors 
(ALKs2, 3 & 6). Consistent with this, rather intriguingly, a triphospho-peptide 
was repeatedly observed in PAWS1 IPs from BMP-treated extracts. The 
observed phospho-peptide identified contained a SXS motif that is conserved 
in species (Figure 3-3) and identical to the motif in SMAD1 that is 
phosphorylated by the type I BMP receptor kinase (ALK3) (Figure 3-17). The 
phosphorylation motif in PAWS1 is internally located compared to the C-
terminal location of the SSXS motif in SMAD1. To date, no non-SMAD 
substrates for type I BMP receptor kinases (ALKs 1, 2, 3 and 6) have been 
reported. I was able to demonstrate that BMPR1 (ALK3) phosphorylated 
PAWS1 at Ser610, Ser614 and Ser616 in vitro. Although I predicted that 
Ser614 and Ser616 (equivalent to the SVS motif in SMAD1) would be the 
major ALK3 phosphorylation sites, it was rather surprising that Ser610 (a SV 
motif) was the major ALK3 in vitro phosphorylation site on PAWS1 (Figure 
3-18). Consistent with this, mutating Ser610 to Ala significantly inhibited the 
phosphorylation of PAWS1 by ALK3 in vitro (Figure 3-18). This indicates that 
SXS motif may not be absolutely necessary for ALK3, or possibly other ALKs, 
to phosphorylate potential substrates in vitro. Furthermore, ALK3 could 
phosphorylate a Ser residue, which is followed by Val, in vitro. However, 
despite the fact that SMAD3 SXS motif is identical to SMAD1, ALK3 does not 
phosphorylate SMAD3. This clearly implies that specific substrate-kinase 
interactions are probably essential for a kinase to phosphorylate its target. 
I was able to demonstrate that PAWS1 is phosphorylated at Ser610 in 
response to BMP in cells (Figure 3-19). These findings imply for the first time 
- 141 - 
that type I BMP receptor kinases have substrates other than SMADs in cells, 
although the precise roles of BMP induced phosphorylation needs to be 
investigated further and could also potentially be extended to other type I 
TGF-ß receptor kinases. Indeed, knockout studies in mice demonstrate that 
the loss of ALKs 2, 3 or 6 expression results in distinct phenotypes that 
cannot be fully explained by phenotypes observed following the loss in 
expression of SMADs 1, 5 or 8 (Chang et al., 1999, Clarke et al., 2001, 
Fukuda et al., 2006, Hester et al., 2005, Komatsu et al., 2007, Sun et al., 
2007, Tremblay et al., 2001). These observations imply that depending on 
the biological context, different type I BMP receptor kinases could signal in a 
unique way by phosphorylating distinct non-SMAD substrates.  
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3.3.4 The impact of PAWS1 beyond BMP signalling 
To further characterise the role of PAWS1 in cells, I undertook a qRT-
PCR macroarray to analyse the changes in gene expression caused by 
PAWS1. I identified and verified several genes in the TGF-ß and BMP 
pathway that displayed differential expression patterns upon PAWS1 re-
introduction in PC3 cells, independent of ligand treatment. The PAWS1-
dependent expression of some of these genes was also verified in HaCaT 
cells upon RNAi-mediated depletion of PAWS1 (Figure 3-22). Clearly PAWS1 
appears to control the expression of many genes independently of BMP 
signalling. Therefore a global transcriptomic analysis of genes affected by 
PAWS1 was performed by RNA sequencing in order to yield clues to its 
possible biochemical roles beyond the BMP pathway. 
This RNA seq. analysis not only confirmed the differentially expressed 
genes including AR, TSC22D, FST, TGFBI and TGFBR2 that were identified 
from qRT-PCR macroarray but also revealed about 800 differentially 
expressed genes upon PAWS1 expression in PC3 cells (Figure 3-22 and 
Appendix Table 1). Out of these 800, 300 were differentially expressed with 
more than 2-fold (Appendix Table 1). TGFBR2 and FST are important 
components of the TGF-ß signalling pathway (Shi and Massague, 2003), 
while TSC22D, AR and TGFBI have also been linked to TGF-ß signalling 
(Choi et al., 2005, Kang et al., 2001, Thapa et al., 2007). This would imply 
that PAWS1 potentially could play a role in TGF-ß signalling, albeit it does not 
appear to bind to SMAD2 or SMAD3 nor does it impact on TGF-ß induced 
EMT in NMuMG cells (Figure 3-7 and Figure 3-27). The possible role for 
PAWS1 in the TGF-ß pathway has not been investigated yet. TGFBI, which is 
- 143 - 
involved in binding of integrin to ECM proteins like collagen, where it has 
been reported to activate a variety of cell functions including proliferation, 
migration and differentiation (Kim et al., 2000). The regulation of TGFBI 
expression by PAWS1 in PC3 cancer cells is interesting as misregulation of 
TGFBI has been linked to cancer progression (Calaf et al., 2008, Ivanov et 
al., 2008, Kitahara et al., 2001, Schneider et al., 2002). Similarly, PAWS1-
dependent down-regulation of AR in PC3, a prostate cancer cell line is 
interesting. Although PC3 cells were first reported to be AR-negative, they 
were later shown to express AR (Alimirah et al., 2006). AR plays important 
roles in normal prostate development as well as certain prostate cancers, 
where it has been reported to influence cancer progression (Heinlein and 
Chang, 2004). When I analysed the protein expression in the NCI-60 panel of 
cancer cell lines, endogenous PAWS1 expression was not detectable in 30 
out of the 54 tested cell lines (Figure 3-13) These findings, together with 
potential pathogenic mutations of PAWS1 reported in cancer patients (Figure 
3-2), suggest that PAWS1 could be implicated in certain cancers. Whether 
the loss of PAWS1 in cancer is causative or a consequence remains elusive. 
Other genes verified to be differentially expressed include MMP1, 
MMP13, WASF3 and ARHGAP44, 4 genes that have been associated in cell 
morphology and motility. Whereas the matrix metalloproteinases 1 and 13 
(MMP1 and MMP13) were up-regulated upon PAWS1 re-expression, WASF3 
and ARGAPG4 were down-regulated (Figure 3-24 and Figure 3-25). MMPs 
are secreted proteins that degrade extracellular matrix (ECM) and WASF3 is 
an important protein in the SCAR/WAVE complex that activates the ARP2/3 
complex and thereby regulate actin structure assembly (Suetsugu et al., 
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1999, Takenawa and Suetsugu, 2007, Kahari and Saarialho-Kere, 1999). 
ARGAP44 is a RhoGAP that also has been implicated in the formation of 
apical microvilli by interactin with the CD317 intergin cell surface receptor 
(Rollason et al., 2009). Despite the fact that PAWS1 impacts on the the 
expression of these genes which are reported to be involved in the cellular 
migration, including NEDD9, PAWS1 re-expression did not significantly 
impact in PC3 cell lateral migration (Figure 3-28). Still, this assay was only 
analysing 2D cell migration on a stiff plastic surface. In order to further 
evaluate the impact of PAWS1 on PC3 cell migration, cells would have to be 
analysed in a 3D environment employing a more physiological environment. 
PDGFRA, a tyrosine receptor kinase, PDZRN3, an E3 RING ubiquitin 
ligase, LRP4, which has been linked to Wnt signalling and the two genes, 
NPY1R and BEX1, linked to the nervous system and brain have all been 
validated to be differentially regulated upon PAWS1 expression (Figure 3-24 
and Figure 3-25) (Foltz et al., 2006, Li et al., 2010, Silva et al., 2005). BEX1 
and BEX2 have been reported as potential tumour suppressor genes in 
glioblastoma (Foltz et al., 2006), whereas PDGFRA has been reported to be 
involved in many aspects of cellular homeostasis as well as development and 
glioblastoma (Ozawa et al., 2010, Williams, 1989). Whether PAWS1 
expression, which was observed to be absent in many glioma cell lines in the 
NCI-60 cancer cell line panel (Figure 3-13) can be linked to glioblastomas still 
remains to be investigated. 
Taken these observations together, it is likely that PAWS1 has many 
more functions, in part or completely, independently of BMP signalling. As the 
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PAWS1-dependent genes discussed above are only a small subset of the 
800 genes that are potentially regulated by PAWS1, it is likely that PAWS1 
exerts control over other aspects of cellular homeostasis (Appendix Table 1). 
Furthermore, I observed that BMP stimulation in PC3 cells led to significant 
changes in expression of only a limited number of genes (Appendix Tables 2 
and 3). On the other hand, moderate changes in gene expression resulting 
from BMP treatment might be sufficient to cause phenotypic changes in the 
cells. Therefore, these genes might not be considered as BMP target genes 
or are beyond the limitations of the RNA seq. to be analysed. This could be 
true for PAWS1-dependent target genes as well. 
CD2AP, which was identified as an interacting protein of PAWS1 with 
the highest score by mass fingerprinting (Appendix Table 4), was recently 
published to impact EGFR signalling together with another protein called 
CIN85 (Minegishi et al., 2013). CIN85 was also identified as an interacting 
protein of PAWS1 by mass fingerprinting ((Havrylov et al., 2009) and 
Appendix Table 4)). CD2AP and CIN85 have been reported to control the 
levels of HER2, a tyrosine kinase receptor, which could be important for 
tumours that overexpress HER2 (Minegishi et al., 2013). Moreover two other 
member of the FAM83 family, FAM83A and FAM83B, have also recently been 
linked to EGFR-tyrosine kinase inhibitor (EGFR-TKI) resistance (Cipriano et 
al., 2012, Lee et al., 2012). Whether PAWS1 plays a role EGFR signalling or 
EGFR-TKI resistance still has to be investigated but given the results 
mentioned above, it cannot be ruled out. 
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PAWS1 expression was observed in many mouse tissues potentially 
indicating a broad role for PAWS1 in different tissue types and contexts 
(Figure 3-12). However, PAWS1 protein expression was absent in mouse 
ovaries and testis, suggesting that PAWS1 expression is potentially not 
required for meiosis. PAWS1 expression appears to be absent in muscle 
tissues (Figure 3-12).  
3.3.5 Possible roles for PAWS1:CULLIN3 interaction 
The CULLIN E3 ligase complex consists of CULLIN3 (CUL3), the 
RING E3 ligase RBX1 and the BTB domain substrate specific adaptor 
proteins (Petroski and Deshaies, 2005, Pintard et al., 2004). CUL3 acts as a 
scaffold protein, whereby its C-terminus binds RBX1 and the BTB domain 
adapter proteins bind towards the N-terminus. In order to activate the 
CULLIN3 E3 ligase complex, it has to be conjugated with NEDD8 at the 
conserved lysine residue within CUL3 (Saha and Deshaies, 2008). This 
process is called neddylation and induces a conformational change, bringing 
the RBX1 E3 ligase in close proximity with its substrate bound to its BTB 
domain containing adaptor (Duda et al., 2008). 
CUL3 knock-out mice have been reported to be embryonically lethal 
(Singer et al., 1999). Furthermore, CULLIN3 E3 ligase complex has been 
reported to be involved in regulation of mitosis, in part by initiating the 
degradation of AURORA B (Sumara et al., 2007). AURORA B is a kinase that 
localises to centromeres during mitosis and regulates proper kinetochore 
assembly (Gorbsky, 2004). More recently AURORA A was also reported to be 
ubiqutylated by the CULLIN3 E3 ligase complex (Moghe et al., 2012). 
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Interestingly, AURORA A has been reported to be activated, rather than 
degraded, by ubiquitylation in this report (Moghe et al., 2012). AURORA A 
activation is important for entry into mitosis (Marumoto et al., 2005) whereby 
it activates PLK1 and, in turn, CDK1 (Macurek et al., 2008, Seki et al., 2008). 
Cyclin dependent kinases (CDKs) regulate the transition from one cell cycle 
stage to the next one (G1-S-G2-M). They in turn are activated by their 
corresponding cyclin proteins (Vermeulen et al., 2003a, Vermeulen et al., 
2003b). Interestingly one of the cylins, Cyclin A1 (CCNA1) was verified to be 
significantly down-regulated by PAWS1 expression, both in PC3 and HaCaT 
cells (Figure 3-26). Another protein, TPX2, was reported to bind and target 
AURORA A to the mitotic spindle and was down-regulated upon PAWS1 
expression in PC3 cells (Figure 3-25), (Kufer et al., 2002).  
Interestingly, in PAWS1 IPs I identified not only CUL3 but also many of 
the components of the CULLIN3 E3 ligase complex, including KLHL13 and 
15, COP9 and RBX1 (Appendix Table 4). Moreover, PAWS1 binds to CUL3, 
preferentially the neddylated (activated) form of CUL3, in HaCaT cell extracts 
(Figure 3-30). Interestingly, another member of the FAM83 family, FAM83D, 
also known as CHICA, has been reported to be associated with cell cycle 
progression, as it localises to the mitotic spindle (Santamaria et al., 2008). In 
order to test if PAWS1 is regulated during cell cycle, I synchronised HaCaT 
cells in the G1/S phase but neither CUL3 nor PAWS1 protein expression 
appears to be cell cycle regulated (Figure 3-31). This potentially implies that, 
at least in HaCaT cells, it is more likely that PAWS1 impacts on CUL3 rather 
than PAWS1 being a target for CUL3-mediated ubiquitylation and 
degradation. Evidence that PAWS1 might be regulated by post-translation 
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changes instead of its expression being altered comes from a large scale 
mass spectrometry analysis of mitotic phosphorylation sites, where Ser666 in 
PAWS1 was reported to by phosphorylated (Dephoure et al., 2008). The 
above discussed results suggest that PAWS1 could be implicated in cell 
cycle regulation and/or progression, albeit more research has to be done to 
directly link PAWS1 to the cell cycle. 
3.3.6 Biochemical roles for PAWS1 
One major drawback to studying PAWS1 as a regulator of BMP 
signalling is the lack of insight into its function. The amino-acid sequence 
analysis shows that the N-terminal domain of PAWS1 comprises a conserved 
domain of unknown function (DUF1669; Pfam PF07894) that displays 
similarities to known phospholipase D (PLD) active site motif (PLDc_2; Pfam 
PF13091) (Figure 3-1). PLD catalyses the hydrolysis of phosphatidylcholine 
into phosphatidic acid (PA) and choline. PA and its derivate diacylglycerol 
(DAG) are powerful second messenger molecules, involved in the activation 
of many signalling and metabolic pathways (Merida et al., 2008). When the 
key His (H) residue within the active-site PLD motif (HxKx4D) is mutated to 
Ala (A), the PLD activity is abolished (Gottlin et al., 1998, Xie et al., 1998). In 
PAWS1, Ala is present in place of the key His, suggesting that PAWS1 with 
its pseudo-PLD motif is unlikely to possess PLD activity. Nonetheless, it has 
not been confirmed experimentally whether PAWS1 possesses PLD activity. 
The DUF1669 is present within the entire FAM83 family (A-H), albeit only 
FAM83D displays the reported amino-acid sequence (HxKx4D) (Figure 3-1). 
A recent report showed that FAM83A, that has an Arg (R) instead of the His 
(H) has no PLD activity (Lee et al., 2012). Despite the likely lack of PLD 
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catalytic activity, PAWS1 could potentially interact with phospho-lipids and/or 
other PLDs or act as a scaffolding protein to control the signalling pathways 
downstream of PLDs. Identifying the precise molecular roles of PAWS1 will 
be critical to test how BMP stimulation and the association with SMAD1 can 
impact the biochemical properties of PAWS1. 
3.3.7 The impact of PAWS1 in embryogenesis 
Because PAWS1 interacts with SMAD1 and impacts the expression of 
a large number of genes, including some in BMP signalling, I assessed its 
role during Xenopus embryogenesis in collaboration with Dr. K. Dingwell 
(Prof. J. Smith’s laboratory at MRC NIMR, London). During Xenopus laevis 
embryogenesis the interplay between BMP and Wnt signalling has been well 
characterised (De Robertis and Kuroda, 2004). Activation of the Wnt pathway 
by microinjection of xWnt8 or ß-catenin RNA was shown to induce a 
secondary axis (Figure 3-32 (Du et al., 1995, Sokol et al., 1991, Molenaar et 
al., 1996)). In contrast, CHORDIN, an antagonist of BMP signalling is 
reported to induce a partial secondary axis (Sasai et al., 1994). xPAWS1 
mRNA microinjection in the ventral zone of the embryos induces a complete 
duplication of the axis, including cement glands, in the embryo (Figure 3-32). 
This suggested that PAWS1 could potentially impact BMP as well as other 
signalling networks, such as the Wnt signalling pathway during development. 
Nonetheless, this complete axis duplication phenotype indicates the 
morphogenic potential of PAWS1 in embryogenesis. The observations that 
expression of up to 800 genes is potentially regulated by PAWS1 in cells are 
consistent with the dramatic impact during embryogenesis. The precise 
molecular mechanisms by which PAWS1 causes axis duplication in X. laevis 
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embryogenesis are unknown and are still under investigation. Nonetheless, 
Dr. Dingwell was able to confirm the duplication of axis phenotype of 
xPAWS1 by using human PAWS1, suggesting that xPAWS1 is indeed the 
ortholog to human PAWS1. 
The evidence collected thus far implies that, unlike BMP-antagonists 
such as CHORDIN, PAWS1 does not inhibit canonical BMP-signalling. To 
assess the mechanisms by which PAWS1 causes axis duplication, I 
investigated its possible role in regulating the Wnt signalling. Initial evidence 
that PAWS1 could impact Wnt signalling stems from the observation that 
PAWS1 expression is linked to the regulation of LRP4 and LGR5 expression 
(Figure 3-25 and Appendix Table 1). LRP4, which has been discussed 
before, and LGR5 are components of the Wnt pathway in humans. LGR5 is a 
G protein-coupled receptor that mediates Wnt signalling (Carmon et al., 
2012). Furthermore, PAWS1 also interacts with CULLIN3, which has been 
implicated in the regulation of Wnt pathway during axis elongation (Angers et 
al., 2006). PAWS1 could potentially mediate a signalling crosstalk between 
BMP and Wnt signalling. One such mechanism could be by proteins such as 
PDZRN3. The expression of E3 RING ubiquitin ligase PDZRN3 is regulated 
by PAWS1 (Figure 3-25). Honda and colleagues reported that the BMP 
induced differentiation of C2C12 cells into osteoblasts is regulated by 
PDZRN3, which inhibits Wnt signalling (Honda et al., 2010). To test whether 
PAWS1 impacts on osteoblast differentitation in C2C12 cells, one could 
employ an alkaline phosphatase assay, which indirectly measures the 
osteoblast differentiation (Katagiri et al., 1994) upon PAWS1 expression. 
Rather unfortunately, the PC3 cells employed to study the role of PAWS1 in 
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this thesis have been reported to overexpress DICKKOPF, a Wnt antagonist 
(Kawano et al., 2006) and therefore were unsuitable for the analysis of Wnt 
pathway. Further investigations are needed to dissect the role of PAWS1 in 
Wnt signalling. 
Very recently, a report describing a mouse phenotype was linked to 
mis-expression of PAWS1 (Radden et al., 2013). Radden and colleagues 
demonstrated that a mutation in PAWS1 that leads to a substantially smaller 
version of PAWS1 in mice results a wooly (wly) phenotype (Radden et al., 
2013). However, no function of PAWS1 or concluding evidence that the mis-
expression of PAWS1 caused this phenotype was presented in this report 
(Radden et al., 2013). To further elucidate the physiological role PAWS1, 
conditional PAWS1 knockout (PAWS1 -/-) mice are being generated. These 
knock-out mice as well as possible knock-in mice where phospho-site 
mutations or mutations reported in cancer (Figure 3-2) would shed light on 
yet undiscovered functions and roles of PAWS1. 
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4 The specificities of small molecule inhibitors of the 
TGF-ß and BMP pathways 
4.1 Introduction 
Targeted disruption of specific TGF-ß signalling components provides 
potential therapeutic opportunities. Protein kinases have proven to be very 
promising drug discovery targets for intervention by small molecule inhibitors 
(Cohen, 2002, Dancey and Sausville, 2003). The availability of selective 
small molecule inhibitors of these protein kinases is potentially very useful for 
many therapeutic applications. The selective inhibitors are also efficient and 
cost-effective tools for inhibiting the target protein kinases in cells, tissues 
and whole organisms to study the physiological roles of these kinases. 
Over the past decade, BMP and TGF-ß type I receptor serine 
threonine protein kinases have been targeted, led primarily by 
pharmaceutical industry, for the development of small molecule inhibitors 
(Seoane, 2008). From these efforts, several inhibitors have been reported to 
selectively target TGF-ß or BMP type I receptors. SB-431542 (Callahan et al., 
2002, Sumara and Peter, 2007, Laping et al., 2002), SB-505124 (DaCosta 
Byfield et al., 2004), SB-525334 (Laping et al., 2002), LY-364947 (Peng et 
al., 2005, Sawyer et al., 2003), LY-2157299 (Bueno et al., 2008), A-83-01 
(Tojo et al., 2005), GW-6604 (de Gouville et al., 2005) and SD-208 (Uhl et al., 
2004) have all been reported as potent and selective inhibitors of TGF-ß 
activated ALKs (ALK4, 5 and 7) (Figure 4-1). The development of small 
molecule inhibitors of the BMP ALKs has lagged behind significantly 
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compared to the TGF-ß ALKs. Compound C, renamed Dorsomorphin (Yu et 
al., 2008b) and its derivative LDN-193189 (Cuny et al., 2008, Yu et al., 
2008a) have been reported as potent and selective inhibitors of the BMP 
ALKs 2, 3 and 6 (Figure 4-1). All these compounds are described as 
selective inhibitors of specific ALKs (either ALKs 1, 2, 3 and 6 or ALKs 4, 5 
and 7). However, comprehensive specificity tests against other protein 
kinases have only been reported for Compound C (Bain et al., 2007). In this 
chapter I present the specificities and potencies of the four most commonly 
used small molecule inhibitors of the type I TGF-ß receptor kinases (SB-
431542, SB-505124, LY-364947 and A-83-01) and type I BMP receptor 
kinases (Dorsomorphin, LDN-193189 and K02288) (Figure 4-1). These 
chemical inhibitors are profiled against a large panel of up to 123 protein 
kinases, which covers 23% of the human kinome. Identifying and 
characterizing small molecule inhibitors of the TGF-ß signalling pathway 
would be very beneficial for researchers as well as clinicians.  
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Figure 4-1 Chemical structures of the small molecule inhibitors of the TGF-ß 
(A–H) and BMP (I and K) pathways. 
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4.1.1 TGF-ß pathway specific inhibitors 
4.1.1.1 SB-431542 
SB-431542 (Figure 4-1) is a pyridine based small molecule inhibitor, 
which was originally engineered from a p38 mitogen-activated protein kinase 
(MAPK) imidazole inhibitor class library screen, as a potent ATP competitive 
inhibitor of ALK5. It inhibits ALK5 in vitro with an IC50 of 0.094 µM (Callahan 
et al., 2002, Laping et al., 2002). The first specificity test was performed by 
Inman and colleagues (Inman et al., 2002), who demonstrated that in 
addition to ALK5, it also inhibited ALK4 and ALK7 very potently in cells 
expressing constitutively active forms of the ALKs. Phosphorylation of 
SMAD2 was used as readout. It was also shown that SB-431542 did not 
inhibit BMP-induced phosphorylation of SMADs 1, 5 and 8. SB-431542 has 
been subsequently used by many researchers to dissect the TGF-ß pathway 
and is the most commonly used inhibitor used to block the TGF-ß pathway in 
cells and organisms. Although there have been two reports demonstrating 
the potency and specificity of SB-431542, a comprehensive characterisation 
of SB-431542 specificity has not been reported. 
4.1.1.2 SB-505124 
SB-505124 (Figure 4-1) evolved from the same programme that 
developed the closely related ATP competitive ALK5 inhibitor SB-431542 
(DaCosta Byfield et al., 2004). Like SB-431542, it was shown to inhibit ALK4, 
ALK5 and ALK7 (DaCosta Byfield et al., 2004). DaCosta Byfield and 
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colleagues showed that SB-505124 does not inhibit constitutively active 
ALK1, 2, 3 and 6, as measured by their ability to induce phosphorylation of 
SMADs 1, 5 and 8 in COS1 cells. Furthermore, it was demonstrated that 
concentrations of up to 100 µM SB-505124 were not cytotoxic in a cell based 
XTT viability assay. The effect of SB-505124 against a limited panel of non-
ALK kinases was also tested and at high concentration (10 µM) it was shown 
to inhibit p38 MAPKα (DaCosta Byfield et al., 2004). Nonetheless SB-505124 
has not been profiled against a comprehensive panel comprising a large 
number of kinases.  
4.1.1.3 LY-364947 
LY-364947 (Figure 4-1) is a pyrazole based small molecule, which was 
engineered from diheteroaryl-substituted pyrazole using a structure–activity 
relationship (Christensen et al.) development approach. Diheteroaryl-
substituted pyrazole was identified from a large cell based small molecule 
inhibitor screen to identify TGF-ß pathway inhibitors (Sawyer et al., 2003). 
LY-364947 was initially described as a cell permeable, ATP-competitive 
inhibitor of ALK5 (Peng et al., 2005, Sawyer et al., 2003). In vitro, it inhibited 
ALK5 with an IC50 of 0.058 μM. It was shown to inhibit TGF-ß induced 
phosphorylation of SMAD2 in cells ((Peng et al., 2005), Table 4-1A). None of 
these reports provided a comprehensive potency and specificity profiles for 
this compound. 
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4.1.1.4 A-83-01 
A-83-01 (Figure 4-1) was derived from LY-364947 and is therefore 
structurally related to it (Figure 4-1). It was initially developed as an inhibitor 
of ALK5 using a cell-based CAGA-Luciferase reporter assay but has also 
been shown to inhibit ALK4 and 7 (Tojo et al., 2005). A-83-01 inhibited TGF-ß 
induced CAGA-Luciferase reporter activity in Mv1Lu lung epithelial cells with 
an IC50 of 12 nM ((Tojo et al., 2005), Table 4-1A). However, a detailed kinetic 
analysis of A-83-01 potency and its ability to inhibit different ALKs or other 
kinases has not been reported. 
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A 
Assay SB4-31542 SB-505124 LY-364947 A-83-01 
TGF-ß induced p-SMAD2 ~0.5-1 µM1 ~0.25 µM4 0.135 µM5 N/A 
ALK4 in vitro kinase 
assay 
0.14 µM2 0.129 µM4 N/A N/A 
ALK5 in vitro kinase 
assay 
0.094 µM3 0.047 µM4 0.058 µM5 N/A 
CAGA-Luc assay in cells 0.25 µM4 0.1 µM4 N/A N/A 
CAGA-Luc with caALK4 0.75 µM1 N/A N/A 0.045 µM6 
CAGA-Luc with caALK5 0.5 µM1 N/A N/A 0.012 µM6 
CAGA-Luc with caALK7 1-2 µM1 N/A N/A 0.0075 µM6 
B 
Assay Dorsomorphin LDN-193189 
BMP induced P-SMAD1/5/8 0.47 µM7 0.005 µM8 
BRE-Luc with caALK2 0.20 µM7 0.005 µM9 
BRE-Luc with caALK3 0.50 µM7 0.03 µM9 
BRE-Luc with caALK6 5-10 µM7 0.15 µM9 
Table 4-1 Summary of the reported potencies of inhibitors of TGF-ß and BMP 
pathways 
(A) IC50 values for the inhibitors of the TGF-ß pathway for the indicated 
assays. Abbreviations: TGF-ß induced P-SMAD2, TGF-ß induced phosphorylation of 
SMAD2 in cells as detected by immunoblotting; CAGA-Luc in cells, CAGA-
Luciferase Reporter Activity dependent on TGF-ß signalling measured in a cell-
based assay; ca, constitutively active; N/A, not available. (B) IC50 values for the 
inhibitors of the BMP pathway for the indicated assays. Abbreviations: BMP induced 
P-SMAD1/5/8, BMP induced phosphorylation of SMADs1/5/8 in cells as detected by 
immunoblotting; ca, constitutively active. BRE-Luc, BMP-Responsive Luciferase 
reporter activity measured in a cell-based assay. 
1 (Sumara and Peter, 2007); 2 (Laping et al., 2002); 3 (Callahan et al., 2002); 
4(DaCosta Byfield et al., 2004): 5 (Peng et al., 2005); 6 (Tojo et al., 2005);  7(Yu et 
al., 2008b); 8 (Cuny et al., 2008); 9 (Yu et al., 2008a) 
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4.1.2 BMP pathway specific inhibitors 
4.1.2.1 Dorsomorphin/Compound C 
In vertebrates BMP signalling is important in defining the dorso-ventral 
(DV) axis. Inhibition of the BMP pathway results in dorsalised axis patterning 
in embryos (see section 3.1.2, (Nguyen et al., 1998)). A high throughput small 
molecule inhibitor screen in zebrafish embryos identified Compound C as an 
inhibitor of the BMP pathway, because it led to dorsalisation phenotype in 
zebrafish embryos (Yu et al., 2008b). Subsequently Compound C was 
renamed Dorsomorphin (Figure 4-1) and described as being a selective small 
molecule inhibitor of the BMP pathway (Yu et al., 2008b). Dorsomorphin was 
reported to inhibit the constitutively active ALK2, ALK3 and ALK6 in cells, as 
measured by the inhibition of BMP Responsive Element (BRE)-Luciferase 
reporter assay with IC50 values of 0.2 μM, 0.5 μM and 5 to 10 μM 
respectively ((Yu et al., 2008b), Table 4-1B). 
Compound C (Dorsomorphin) has previously been described as a 
selective small molecule inhibitor of the AMP activated protein kinase 
(AMPK) (Zhou et al., 2001). Although used extensively as an AMPK inhibitor, 
a comprehensive specificity study profiling Compound C against a panel of 
70 protein kinases showed that it inhibited a range of other kinases, including 
ERK8, MNK1, PHK, MELK, DYRK isoforms, HIPK2, Src and Lck with similar 
or greater potency than AMPK (Bain et al., 2007). This extremely useful 
specificity information of Compound C has not been mentioned by the reports 
describing Dorsomorphin as a specific inhibitor of the BMP pathway 
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(Boergermann et al., 2010, Hao et al., 2008, Hong and Yu, 2009, Yu et al., 
2008b). 
4.1.2.2 LDN-193189 
Using Dorsomorphin as a template, LDN-193189 was engineered 
primarily by replacing the 4-pyridine ring with 4-quinoline (Figure 4-1, (Cuny 
et al., 2008)). As a result the new compound (LDN-193189) had improved 
potency over Dorsomorphin as a BMP pathway inhibitor (Cuny et al., 2008). 
This was demonstrated in rat pulmonary artery smooth muscle cells 
(rPASMC), as LDN-193189 inhibited BMP-4-induced phosphorylation of 
SMADs1, 5 and 8 with an IC50 value of 5 nM. This is a 94-fold improvement 
when compared to the IC50 value of 470 nM for Dorsomorphin (Cuny et al., 
2008). LDN-193189 has been subsequently shown to inhibit the BRE-
Luciferase reporter activity driven by constitutively active ALK2, ALK3 and 
ALK6 with IC50 values of 5 nM, 30 nM and 150 nM respectively. On the other 
hand LDN-193189 inhibited ALK4, ALK5 and ALK7 with IC50 values greater 
than 500 nM (Yu et al., 2008a). Nonetheless there is no report available that 
describes the specificities and potencies of LDN-193189 against a 
comprehensive number of protein kinases 
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4.2 Results 
4.2.1 Specificities of small molecule inhibitors of the TGF-ß pathway 
4.2.1.1 Specificities and potencies of SB-431542 and SB-505124 
To investigate the ability of both SB-431542 and SB-505124 to inhibit 
the activity of a panel of over 105 protein kinases, both compounds were 
assayed at two different concentrations (0.1 and 1 µM) (Figure 4-2). At both 
concentrations, SB-431542 and SB-505124 inhibited ALK5 activity in vitro but 
did not inhibit ALK3 (Figure 4-2A and B, Figure 4-5A and B). At 1μM, SB-
431542 inhibited ALK5 but also RIPK2 and CK1δ by 77% and 70% 
respectively. Furthermore p38αMAPK was inhibited by 30% (Figure 4-2A). At 
lower concentration of 0.1μM, SB-431542 still inhibited RIPK2 and CK1δ by 
33% and 29% respectively (Figure 4-2A). Similarly at 1μM, SB-505124 
inhibited RIPK2 by about 72% and p38α MAPK by 49% but did not inhibit 
CK1δ (Figure 4-2B). At 0.1μM, SB-505124 inhibited RIPK2 by 18% but CK1δ 
and p38αMAPK were not inhibited (Figure 4-2B). Both concentrations of 
either of the two compounds did not significantly inhibit the activity of any 
other kinase used in the in vitro panel (Figure 4-2). Because SB-431542 
could inhibit CK1δ at 1 μM (Figure 4-2A), it was investigated if both SB-
431542 and SB-505124 could inhibit other CK1 isoforms in vitro. SB-431542 
inhibited CK1α, CK1δ and CK1ε isoforms with IC50 values of 1.34μM, 0.92μM 
and 0.38μM respectively but it did not inhibit CK1γ (Table 4-2). SB-505124 
inhibited CK1α, CK1δ and CK1ε isoforms with IC50s of 19.44μM, 3.38μM and 
1.60μM respectively and did not inhibit CK1γ (Table 4-2Table 4-2). 
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Furthermore, SB-431542 and SB-505124 inhibited RIPK2 with IC50 of 
0.41μM and 0.35μM respectively (Table 4-2). 
SB-431542 inhibits TGF-ß-induced phosphorylation of SMAD2 with an 
IC50 value of ~2.5 μM (Figure 4-6). The TGF-ß-induced phosphorylation of 
SMADs 1, 5 and 8 was only modestly affected at concentrations higher than 
1 μM and BMP-2-induced phosphorylation of SMADs 1, 5 and 8 was not 
inhibited by SB-431542 (Figure 4-6B).  
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Figure 4-2 The specificities of TGF-ß pathway inhibitors 
The specificity of (A) SB-431542, (B) SB-505124 at the indicated 
concentrations was profiled against a panel of up to 123 protein kinases. The results 
are presented as bars indicating percentage activity remaining for each kinase 
(averages of two duplicate determinations) in the presence of the indicated 
concentration of the inhibitor compared with a control lacking the inhibitor ± standard 
deviation. The results are ranked according to the percentage activity remaining 
when the assays were performed in the presence of the indicated inhibitors at 1 μM. 
Protein kinases referred to in results section 4.2.1.1 are indicated by red arrows. 
Abbreviations for the protein kinases can be found in the abbreviation list. 
A B 
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Kinase SB-431542 SB-505124 LY-364947 A-83-01 LDN-193189 
RIPK2 0.41 µM 0.35 µM 0.11 µM 0.10 µM 0.025 µM 
CK1α 1.34 µM 19.44 µM 2.27 µM 15.66 µM 3.61 µM 
CK1δ 0.92 µM 3.38 µM 0.22 µM 3.42 µM 0.92 µM 
CK1ε 0.38 µM 1.60 µM 1.34 µM 4.59 µM 14.24 µM 
CK1γ >100 µM >100 µM 43.97 µM 28.55 µM 98.92 µM 
GCK >100 µM >100 µM 7.91 µM 2.22 µM 0.08 µM 
Table 4-2 Potencies of small molecules developed as TGF-ß and BMP pathway 
inhibitors against some other kinases 
IC50 values were determined from multiple assays carried out at ten different 
inhibitor concentrations in vitro. 
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4.2.1.2 Specificities and potencies of LY-364947 and A-83-01 
When profiled against 123 protein kinases (Figure 4-3A), LY-364947 at 
a concentration of 1μM inhibited ALK5, RIPK2, VEGF-R, CK1δ and MINK1 
activity by greater than 50%. If the concentration is increased to 10 μM, LY-
364947, additionally inhibited the following kinases by more than 50%: 
p38αMAPK, PKD1, GCK, BRK, Lck, TAK1, YES1, FGF-R1 and p38ß MAPK. 
LY-364947 inhibited RIPK2 and CK1δ with IC50 of 0.11 μM and 0.22 μM 
respectively (Table 4-2). LY-364947 inhibited CK1α, CK1ε and CK1γ isoforms 
with IC50 values of 2.27 μM, 1.34 μM and 44 μM respectively (Table 4-2).  
A-83-01, which is structurally related to LY-364947 (Figure 4-1), was 
also used in an in vitro kinase assay against a panel of 107 kinases at 
concentrations of 1 μM and 0.1 μM (Figure 4-3B). At 1 μM, A-83-01 inhibited 
ALK5, VEG-FR, RIPK2, MINK1, p38α MAPK, PKD1 and FGF-R1 by greater 
than 50% (Figure 4-3B). At concentrations of 0.1μM, MINK1, p38α MAPK 
and FGF-R1 were inhibited by more than 30% while ALK5, VEG-FR, RIPK2 
were still inhibited by more than 50% (Figure 4-3B). A-83-01 was able to only 
moderately inhibit the activity of CK1 isoforms. The IC50 values of CK1α, 
CK1δ, CK1ε and CK1γ were 15.66 μM, 3.42 μM, 4.59 μM and 29 μM 
respectively (Table 4-2). 
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Figure 4-3 The specificities of TGF-ß pathway inhibitors 
The specificity of (A) LY-364947, (B) A-83-01 at the indicated concentrations 
was profiled against a panel of up to 123 protein kinases. The results are presented 
as bars indicating percentage activity remaining for each kinase (averages of two 
duplicate determinations) in the presence of the indicated concentration of the 
inhibitor compared with a control lacking the inhibitor ± standard deviation. The 
results are ranked according to the percentage activity remaining when the assays 
were performed in the presence of the indicated inhibitors at 1 μM. Protein kinases 
referred to in results section 4.2.1.2 are indicated by red arrows. Abbreviations for 
the protein kinases can be found in the abbreviation list. 
  
B A 
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4.2.2 Specificities of small molecule inhibitors of the BMP pathway 
4.2.2.1 Specificity of Dorsomorphin (Compound C) as a BMP pathway 
inhibitor 
The specificity and the potency of Dorsomorphin was profiled at three 
different concentrations (10, 1 and 0.1 µM) against a panel of 119 protein 
kinases (Figure 4-4A). At a concentration of 10 μM, Dorsomorphin inhibited 
the activities of 64 out of the 119 kinases by greater than 50%. At 
concentrations of 1 μM, Dorsomorphin inhibited the activities of 34 out of 119 
kinases more potently than it inhibited AMPK and by more than 50% (Figure 
4-4A). Even at concentrations of 0.1 μM, it inhibited VEGF-R, ERK8, GCK, 
CLK2, DYRK1A, PHK, ABL, NUAK1, PRK2 and YES1 by more than 50% 
(Figure 4-4A). Dorsomorphin inhibited ALK3 in vitro with an IC50 value of 
about 1 μM while ALK5 was not inhibited (Figure 4-5C).   
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Figure 4-4 The specificities of BMP pathway inhibitors 
(A) Dorsomorphin and (B) LDN-193189 were assayed against a panel of up 
to 121 kinases at the indicated concentrations. The results are presented as bars 
indicating percentage activity remaining for each kinase (averages of two duplicate 
determinations) in the presence of the indicated concentration of the inhibitor 
compared with a control lacking the inhibitor ± standard deviation. The results are 
ranked according to the percentage activity remaining when the assays were 
performed in the presence of the indicated inhibitors at 1 μM. Protein kinases 
referred to in Results section 4.2.2 are indicated by red arrows. 
B A 
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Figure 4-5 Inhibition of ALK3 and ALK5 by inhibitors of the TGF-ß and BMP 
pathways 
(A) Kinase assay with ALK3 as described in section 2.2.12, in the presence 
or absence of the indicated concentrations of TGF-ß pathway inhibitors SB-431542, 
SB-505124, LY-364947 and A-83-01. The assay samples were resolved by SDS-
PAGE, and the gels were Coomassie-stained, dried and analysed by 32P 
autoradiography. For percentage activity remaining determinations, Coomassie 
stained bands corresponding to substrate proteins were excised, 32P-incorporation 
measured and the resulting radioactivity (cpm) used as a percentage of control. (B) 
Same as (A) but using ALK5 instead of ALK3. (C) As above, except that ALK3 and 
ALK5 were assayed in the presence or absence of the indicated concentrations of 
Dorsomorphin.  
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4.2.2.2 Specificity of LDN-193189 as a BMP pathway inhibitor 
LDN-193189 was derived from Dorsomorphin in order to improve 
potency against the BMP pathway (Cuny et al., 2008). In HaCaT cells, LDN-
193189 inhibits BMP-2-induced phosphorylation of SMADs 1, 5 and 8 with an 
IC50 value of ~0.005 μM (Figure 4-6A). The TGF-ß (50 pM) induced 
phosphorylation of SMAD2 was only modestly affected at concentrations 
higher than 3 μM, although TGF-ß induced phosphorylation of SMADs 1, 5 
and 8 was inhibited at a dose of around 0.3 μM LDN-193189 (Figure 4-6B). 
Subsequently, I investigated the inhibitory effect of LDN-193189 against the 
activity of various ALKs using in vitro kinase assays (Figure 4-7). LDN-
193189 inhibited the ability of ALK2 to phosphorylate GST-SMAD1 in vitro 
with an IC50 value of 45 nM, while ALK2 autophosphorylation was inhibited 
with an IC50 of 30 nM (Figure 4-7A). LDN-193189 inhibited the ability of ALK3 
to phosphorylate SMAD1 under these conditions with an IC50 value of 100 
nM, although even at 3 μM, ALK3 activity could not be completely inhibited 
(Figure 4-7B). BMPRII is essential for the activity of ALK3 in vitro but its auto-
phosphorylation was not affected by LDN-193189 (Figure 4-7B). LDN-
193189 inhibited the activity of ALK4 and ALK5, although with higher IC50 
values of 0.3 μM and 0.5 μM respectively (Figure 4-7C and D).  
Because the off target effects of LDN-193189 towards other protein 
kinases have not been described previously, the specificity and potency of 
LDN-193189 at three different concentrations was assayed against a panel of 
121 protein kinases (Figure 4-4B). From the resulting data, it is evident that 
the specificity and potency profile for LDN-193189 was similar to that of 
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Dorsomorphin (compare Figure 4-4A and B). At a concentration of 10 μM, 
LDN-193189 inhibited 44 out of the 121 kinases by more than 50% (Figure 
4-4B). At 1 μM, LDN-193189 still inhibited 24 out of the total 121 protein 
kinases by more than 50%. Even at 0.1 μM, LDN-193189 inhibited RIPK2, 
FGF-R1, NUAK1, CAMKKß, MINK1, GCK, VEG-FR and BRK by greater than 
50% (Figure 4-4B).  
When tested in vitro, LDN-193189 inhibits RIPK2 and GCK with IC50 
values of 0.025 μM and 0.08 μM respectively. These values are comparable 
to those calculated for inhibition of ALK2 and ALK3 by LDN-193189 using in 
vitro kinase assays (Table 4-2, Figure 4-7A and B).  
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Figure 4-6 Inhibition of TGF-ß and BMP pathways by LDN-193189 and SB-
431542 
(A) Serum-starved HaCaT cells were treated with the indicated 
concentrations of LDN-193189 for 2 h and then treated with BMP-2 (25 ng/ml) for 1 
h prior to lysis. Extracts were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes, which were analysed by immunoblotting using the 
indicated antibodies. (B) Same as A but cells were treated with TGF-ß (50 pM) for 1 
h prior to lysis. (C) Same as A, but indicated concentrations of SB-431542 were 
used for 3 h prior to lysis. (D) Same as C, but cells were treated with TGF-ß (50 pM) 
1 h prior to lysis. 
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Figure 4-7 LDN-193189 inhibits ALK2 and ALK3 in vitro 
(A) Kinase assay with ALK2 as described in section 2.2.12, in the absence or 
presence of the indicated concentrations of LDN-193189. The assay samples were 
resolved by SDS-PAGE, and the gels were Coomassie-stained, dried and analysed 
by 32P autoradiography. For IC50 determinations, Coomassie stained bands 
corresponding to substrate proteins were excised, 32P-incorporation measured and 
the resulting radioactivity (cpm) plotted against concentrations of LDN-193189 used. 
(B) Same as A, except that ALK3 was used. (C) Same as A, except that ALK4 was 
used. (D) Same as A, except that ALK5 was used.  
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4.2.3 Inhibition of RIPK2 by LDN-193189 in RAW macrophage cells 
As shown before, RIPK2, a member of the receptor interacting protein 
(RIP) family of protein kinases, was inhibited potently in vitro by LDN-193189 
(Table 4-2). To test whether LDN-193189 can inhibit RIPK2 in cells at 
concentrations sufficient to inhibit BMP signalling (Figure 4-6A), RAW 
macrophage cells were used. These cells were treated with the 
peptidoglycan-related agonist D-glutamyl-meso-diaminopimelic acid (meso-
DAP), which leads to the phosphorylation of ERK1/2 (Figure 4-8). This 
phosphorylation was inhibited when cells were treated with 0.1 μM or 10μM 
LDN-193189 (Figure 4-8). 
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Figure 4-8 Inhibition of the NOD-RIPK2 pathway by LDN-193189 
RAW 264.7 cells were treated with indicated concentrations of LDN-193189 
for 2 h prior to treatment of cells with 15 μM Meso-DAP for 1 h before lysis. Extracts 
were resolved by SDS-PAGE and analysed by immunoblotting using the indicated 
antibodies. 
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4.3 Discussion 
In this study, I have established the in vitro specificities of some of the 
most commonly used small molecule inhibitors of the TGF-ß and BMP 
pathways against a panel of up to 123 protein kinases. This represents 
almost a quarter of the human kinome. The results obtained indicate many 
potential off-target effects for these small molecule inhibitors, when they are 
used to assess the physiological roles of TGF-ß and BMP pathways by 
inhibition of the type I receptors (ALKs). Therefore, any potential impact on 
the activity of the TGF-ß and BMP pathways observed by using any of these 
small molecule inhibitors should be interpreted with caution. If any of these 
inhibitors are used to inhibit the TGF-ß and BMP pathways, either in cell 
culture-based assays or whole animal studies, it is recommended that the 
minimum effective concentrations against the intended targets are used. It is 
also recommended that this minimal effective concentration is determined for 
each assay individually, in order to minimise the potential unwanted off-target 
effects. As mentioned above, the specificity of the small molecule inhibitors 
was only profiled against 23% of all human kinases. Hence, these inhibitors 
could potentially inhibit other kinases that could not be included in this study. 
Nonetheless, this study does provide vital information for researchers when 
deciding on which inhibitor to use for any particular assay. 
4.3.1 Inhibitors of the TGF-ß pathway 
Active TGF-ß signalling has been implicated in numerous diseases 
(see section 1.6), including the development of fibrotic sclerosis of multiple 
organs like heart, kidney, lungs, liver and skin (Border and Noble, 1994, 
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Bottinger and Bitzer, 2002, Gu et al., 2007). TGF-ß signalling is also strongly 
associated with cancer progression and metastasis (see section 1.6; 
(Massague, 2008, Padua and Massague, 2009)). As a result, TGF-ß 
signalling components, have been targeted for the development of small 
molecule kinase inhibitors (mainly targeting ALK5), ligand binding antibodies 
or antisense oligonucleotides by major pharmaceutical industries (Callahan 
et al., 2002, Sawyer et al., 2003, Seoane, 2008). Several TGF-ß pathway 
inhibitors have entered pre-clinical and clinical trials to treat fibrosis and 
advanced metastatic cancers (Seoane, 2008). The outcome of these trails 
are mixed (Seoane, 2008). One possible explanation is that these inhibitors 
block TGF-ß signalling globally and therefore unwanted side effects occur. 
Another likely explanation is that all compounds used could also impact other 
pathways and thereby create unwanted off-target effects. Therefore it is 
important to use chemical inhibitors that are highly specific to a specific target 
in order to minimise unwanted off-target effects that could have undesired 
consequences for the whole organism. 
While both SB-431542 and SB-505124 are relatively selective 
inhibitors of ALKs 4, 5 and 7, SB-505124 is the more potent inhibitor of ALK4, 
5 and 7 and inhibits CK1 isoforms less potently than SB-431542 ((DaCosta 
Byfield et al., 2004), Table 4-1A, Table 4-2). Furthermore, in cell-based 
assays, SB-505124 was reported to be less cytotoxic than SB-431542 
(DaCosta Byfield et al., 2004). Both, SB-431542 and SB-505124 inhibit 
RIPK2 with similar IC50 values (Table 4-2) and both have also been reported 
to inhibit p38α MAPK at high concentrations with IC50 values above 10 μM 
(DaCosta Byfield et al., 2004, Sumara and Peter, 2007). SB-525334, which is 
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structurally very closely related to SB-505124 (Figure 4-1), has been reported 
to be around 3-fold more potent in inhibiting ALK5 and around 2-fold more 
potant in inhibiting ALK4 compared to SB-505124 (Grygielko et al., 2005). 
However, as it has not been used as extensively as other ALK5 inhibitors, it 
was not included in this study. Although A-83-01 showed to be the most 
potent ALK5 inhibitor in vitro (Figure 4-5B), at concentrations sufficient to 
inhibit ALK5, it also inhibited RIPK2, MINK1, VEGF-R, p38α MAPK, PKD1 
and FGF-R1 potently. LY-364947, a less potent inhibitor of ALK5 compared 
to A-83-01, also inhibited RIPK2, MINK1, VEGF-R and CK1 isoforms potently 
(Figure 4-3A and B).  
Based on the discussions above on specificities and potencies of the 
four small molecule inhibitors of the TGF-ß pathway used in this study, the 
use of SB-505124 over SB-431542, at or below 1μM, as an inhibitor of ALKs 
4, 5 and 7 in cell-based assays is recommended. If LY-364947 or A-83-01 is 
used as a TGF-ß pathway inhibitor, the potential off-target effects have to be 
considered with caution. 
To date, there are no small molecule inhibitors of the TGF-ß pathway 
that can selectively inhibit ALK4, 5 or 7. All five discussed inhibitors in this 
study show no significant selectivity between these ALKs. On the other hand, 
knockout mouse models of ALK4, ALK5 or ALK7 display unique phenotypes 
(Itoh et al., 2009, Jornvall et al., 2004). Whereas knocking out ALK4 and 
ALK5 is embryonically lethal and the mice die at around E9.5 and E10.5 
respectively (Gu et al., 1998, Jornvall et al., 2004), ALK7 knockout mice are 
viable and fertile (Jornvall et al., 2004). This emphasises the need for ALK-
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specific inhibitors to further dissect the roles of individual ALKs in cells. 
Targeting selective ALKs might also be beneficial for treating specific 
diseases, where individual ALKs might be responsible for driving a particular 
disease state. 
4.3.2 Inhibitors of the BMP pathway 
BMP signalling plays critical roles during embryogenesis and in 
controlling the fate of various progenitor cell populations including embryonic 
stem cells and hematopoietic stem cells. BMP signalling is also important in 
skeletogenesis (Chen et al., 2004, De Robertis and Kuroda, 2004, Li and 
Cao, 2006, Varga and Wrana, 2005). While the efforts of the pharmaceutical 
companies have focussed on developing small molecule inhibitors of the 
TGF-ß pathway, the development of small molecule inhibitors of the BMP 
pathway has largely lagged behind. The selective small molecule inhibitors of 
the BMP pathway would be useful in dissecting and understanding the 
physiological roles of BMP signalling in different cellular contexts. ALKs 2, 3 
and 6 are ubiquitously expressed and mediate BMP signals in most cells and 
tissues. ALK1 is unique in that it is mainly reported to be expressed in 
endothelial cells and has been reported to phosphorylate SMAD1 in 
response to BMP and TGF-ß ligands (Oh et al., 2000, Wrighton et al., 2009). 
Aberrant BMP signalling has been reported to play a role in heterotopic 
ossification, where ALK6 is mutated to a constitutively active form (Yu et al., 
2008a). Similarly overexpression of certain BMP ligands and activation of 
downstream signalling has been reported in some cancers (Blanco Calvo et 
al., 2009). Having a potent and specific small molecule inhibitor of BMP 
activated ALKs could therefore be of clinical benefit against these diseases.  
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Dorsomorphin, and its derivative LDN-193189 were reported as 
selective and potent inhibitors of BMP signalling (Cuny et al., 2008, Yu et al., 
2008a, Yu et al., 2008b). Subsequently, both compounds have been widely 
used in vitro, in cell-based assays and also in whole organisms to study the 
BMP pathway and its physiological roles. In this study the specificities of 
Dorsomorphin and LDN-193189 have been profiled against a panel of up to 
121 protein kinases in vitro (Figure 4-4A and B). When compared to the best 
TGF-ß pathway inhibitors, Dorsomorphin and LDN-193189, are rather non-
specific inhibitors of the BMP pathway as they inhibit a number of other 
protein kinases potently (Figure 4-4). Some of the off-target effects of using 
Dorsomorphin at concentrations sufficient to inhibit BMP signalling have been 
demonstrated before and in this study and it is likely that many more exist 
((Bain et al., 2007, Cannon et al., 2010), Figure 4-4A). Therefore, using 
Dorsomorphin as a small molecule inhibitor for the BMP pathway should be 
avoided. 
LDN-193189 on the other hand is a very potent inhibitor of BMP 
signalling, inhibiting BMP-induced phosphorylation of Smad1 in cells with an 
IC50 of 5 nM ((Cuny et al., 2008, Yu et al., 2008a), Figure 4-6A). ALK2 and 
ALK3 were inhibited in vitro by LDN-193189 with IC50 values of 30–45 nM 
and 100 nM respectively (Figure 4-7A and B). Interestingly, these IC50 values 
are substantially higher when compared to those obtained from inhibiting the 
BMP pathway in cells (Figure 4-6A). A possible explanation would be that 
LDN-193189 binds very efficiently, maybe allosterically, to the BMP-activated 
ALKs in cells. However, the crystal structures of LDN-193189 in complex with 
the kinase domain of ALK1 revealed that LDN-193189 binds to the ATP-
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binding pocket of the ALK1 kinase domain 
(http://www.thesgc.org/structures/structure_description/3MY0/). It is also 
possible that the inhibitory effects of LDN-193189 to block BMP signalling 
very potently could be only partly dependent on the direct effects of LDN-
193189 on ALKs and partly also on the off-target effects on other kinases. 
These kinases could impact on both the activation and activity of ALKs or the 
access of ALKs to their substrates or a combination of these possibilities. 
This is not unlikely because LDN-193189 inhibited a large number of other 
kinases very potently in vitro (Figure 4-4B). While LDN-193189 shows much 
improved potencies against BMP ALKs 2 and 3 compared to Dorsomorphin, 
its potency against many other kinases did not change to a large extent 
(Figure 4-4). The usage of LDN-193189 as an inhibitor of the BMP pathway 
in cells or whole organisms should be considered with caution, knowing its 
ability to inhibit other kinases, notably RIPK2, FGF-R1, NUAK1, CAMKKß, 
MINK1, GCK, VEG-FR and BRK and possibly many more. RIPK2 for 
example is implicated in NOD1 and NOD2 signalling and activates MAP 
Kinases (Figure 4-8), NFκB signalling, as well as the mediation of 
inflammatory responses. In cells, NOD1 and NOD2 can sense peptidoglycan-
related molecules from bacteria that have entered the cell and evaded 
immune recognition via Toll-like receptors at the cell membrane (Inohara et 
al., 2005). Therefore inhibiting RIPK2 in whole organisms could lead to 
unwanted side effects by, for example, affecting the immune system. 
Nonetheless due to its potency as a BMP pathway inhibitor, LDN-
193189 provides a very good platform to design derivatives that could 
enhance its selectivity for BMP-activated ALKs. Evidently, Dorsomorphin is 
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not a good candidate for a selective inhibitor of the BMP pathway. In 
zebrafish, Dorsomorphin, when used at sufficient concentrations to block 
BMP signalling, it strongly inhibited intersegmental vessel formation by 
inhibiting VEGF-R2 (Cannon et al., 2010). This is only one example, 
demonstrating the potential off-target effects when using a non-specific 
inhibitor. DMH1, a Dorsomorphin analogue was reported as being very 
specific to BMP signalling and displaying no off-target effects against VEG-
FR (Hao, J 2009). However, there is no comprehensive study of DMH1 
against a substantial panel of kinases that Dorsomorphin and LDN-193189 
inhibit potently to prove its specificity. Very recently a study described 
K02288 (Figure 4-1) as being a specific and potent small molecule inhibitor of 
BMP signalling (Sanvitale et al., 2013). K02288 was designed as an inhibitor 
of ALK2 but also possess activity against ALK1, ALK6 and to a lesser extend 
ALK3. The potencies compared to LDN-193189 against ALK1 and ALK2 are 
similar, whereas LDN-193189 inhibits ALK3 more potently and K02288 
inhibits ALK6 more potently. K02288 inhibition of BMP-mediated SMAD1/5/8 
phosphorylation was reported to be 10-fold lower compared to LDN-193189 
(Sanvitale et al., 2013). Although the specificity was shown to be improved 
compared to LDN-193189 when the compounds were assayed against 200 
human kinases, RIPK2, NUAK1, CAMKKß, GCK and GCKR, all inhibited by 
LDN-193189, were not tested. Testing specificity against these kinases may 
yet prove K02288 a more selective inhibitor of the BMP pathway.  
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